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Background: Atopic eczema (AE) is a chronic, itchy, inflammatory skin condition that affects the quality of life
of children and their families. The role of specialist clothing in the management of AE is poorly understood.
Objectives: To assess the effectiveness and cost-effectiveness of silk garments for the management of AE
in children with moderate to severe disease.
Design: Parallel-group, observer-blind, randomised controlled trial of 6 months’ duration, followed by a
2-month observational period. A nested qualitative study evaluated the beliefs of trial participants,
health-care professionals and health-care commissioners about the use of silk garments for AE.
Setting: Secondary care and the community in five UK centres.
Participants: Children aged 1–15 years with moderate or severe AE.
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Interventions: Participants were randomised (1 : 1 using online randomisation) to standard care or standard
care plus 100% silk garments made from antimicrobially protected knitted sericin-free silk [DermaSilkTM
(AlPreTec Srl, San Donà di Piave, Italy) or DreamSkinTM (DreamSkin Health Ltd, Hatfield, UK)]. Three sets of
garments were supplied per participant, to be worn for up to 6 months (day and night). At 6 months the
standard care group received the garments to use for the remaining 2-month observational period.
Main outcome measures: Primary outcome – AE severity using the Eczema Area and Severity Index (EASI)
assessed at 2, 4 and 6 months, by nurses blinded to treatment allocation. EASI scores were log-transformed
for analysis. Secondary outcomes – patient-reported eczema symptoms (Patient Oriented Eczema Measure);
global assessment of severity (Investigator Global Assessment); quality of life of the child (Atopic Dermatitis
Quality of Life, Child Health Utility – 9 Dimensions), family (Dermatitis Family Impact Questionnaire) and
main carer (EuroQoL-5 Dimensions-3 Levels); use of standard eczema treatments (e.g. emollients, topical
corticosteroids); and cost-effectiveness. The acceptability and durability of the clothing, and adherence to
wearing the garments, were assessed by parental/carer self-report. Safety outcomes – number of skin
infections and hospitalisations for AE.
Results: A total of 300 children were randomised (26 November 2013 to 5 May 2015): 42% female,
79% white, mean age 5 years. The primary analysis included 282 out of 300 (94%) children (n = 141 in each
group). Garments were worn for at least 50% of the time by 82% of participants. Geometric mean EASI
scores at baseline, 2, 4 and 6 months were 8.4, 6.6, 6.0, 5.4 for standard care and 9.2, 6.4, 5.8, 5.4 for
silk clothing, respectively. There was no evidence of difference between the groups in EASI score averaged
over all follow-up visits adjusted for baseline EASI score, age and centre (ratio of geometric means 0.95,
95% confidence interval 0.85 to 1.07; p = 0.43). This confidence interval is equivalent to a difference of
–1.5 to 0.5 in the original EASI scale units. Skin infections occurred in 39 out of 141 (28%) and 36 out of
142 (25%) participants for standard care and silk clothing groups, respectively. The incremental cost per
QALY of silk garments for children with moderate to severe eczema was £56,811 from a NHS perspective
in the base case. Sensitivity analyses supported the finding that silk garments do not appear to be
cost-effective within currently accepted thresholds.
Limitations: Knowledge of treatment allocation may have affected behaviour and outcome reporting for
some of the patient-reported outcomes.
Conclusions: The addition of silk garments to standard AE care is unlikely to improve AE severity, or to be
cost-effective compared with standard care alone, for children with moderate or severe AE. This trial adds
to the evidence base to guide clinical decision-making.
Future work: Non-pharmacological interventions for the management of AE remain a research priority
among patients.
Trial registration: Current Controlled Trials ISRCTN77261365.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 21, No. 16.
See the NIHR Journals Library website for further project information.
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Plain English summary
Eczema is a common childhood skin condition that impacts on quality of life as a result of symptomssuch as itchiness, sore skin and impaired sleep. Patients are often keen to find non-drug treatments
for eczema.
Some small studies had suggested that specialist silk clothing might help to improve the symptoms of
eczema, but larger, well-designed studies are needed to be sure of these results.
The CLOTHing for the relief of Eczema Symptoms (CLOTHES) Trial tested whether or not silk clothing could
reduce the severity of eczema in children aged > 6 months. A total of 300 children, aged 1–15 years, with
moderate to severe eczema, took part. A computer was used to decide whether the children received silk
clothing plus usual eczema care (moisturisers and topical corticosteroids) or usual care alone. Children in
the clothing group were asked to wear silk tops and leggings as often as possible, day and night, for
6 months. Weekly questionnaires and visits to the nurse at 2, 4 and 6 months were used to assess the
impact of the clothing.
Three hundred children took part in the study. Most of the children taking part were aged < 6 years, and
three-quarters had previously seen a hospital doctor about their eczema. The silk garments were worn for
at least half of the time by 82% of the trial participants. We found no difference between the two groups
for nurse-assessed eczema severity, use of topical corticosteroid creams, number of skin infections or
quality of life. Wearing the clothing did not reduce the number of visits to the doctor for their eczema,
or the use of eczema medications.
Overall, the trial suggested that specialist silk clothing is not a useful treatment for eczema in children
and does not represent good value for money.
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Scientific summary
Background
Atopic eczema (AE) is a common childhood skin condition that causes itch, soreness and sleep loss. The
treatment of AE typically includes the regular use of emollients and topical corticosteroids. Although effective,
these treatments can be time-consuming and messy to apply, and patients often worry about side effects.
Many patients are keen to explore non-pharmacological interventions for the management of AE, and
the use of silk garments has been advocated as an effective treatment. Such garments are available on
prescription or for private purchase, but the evidence base for their use is limited. As a result, the National
Institute for Health Research Health Technology Assessment programme commissioned the CLOTHing for
the relief of Eczema Symptoms (CLOTHES) Trial.
Objectives
Primary objective
l To assess whether or not the addition of silk therapeutic garments to standard care reduces AE severity
in children with moderate to severe disease over a period of 6 months.
Secondary objectives
l To estimate the within-trial cost-effectiveness of silk therapeutic garments from a NHS and a
family perspective.
l To explore parent/guardian and child views on and experiences of using silk garments, and factors that
might influence the use of these garments in everyday life.
l To examine prescribers’ and commissioners’ views on the use of silk garments for the management of AE.
Methods
Study design
A multicentre, parallel-group, observer-blind, pragmatic randomised controlled trial (RCT) of 6 months’
duration, followed by a 2-month observational period. Children were randomised (1 : 1) to receive silk
garments plus standard care or standard care alone. The primary outcome was assessed by research nurses
blinded to the treatment allocation at 2, 4 and 6 months.
The trial included a nested qualitative evaluation, a health economic analysis and a subgroup analysis
based on the presence or absence of loss-of-function mutations in the gene encoding filaggrin (FLG).
Recruitment
The trial took place in five UK centres. Participants were identified through secondary and primary care,
and in response to local advertising.
Eligibility criteria
Children with AE, aged 1–15 years, were enrolled. All had a score of ≥ 9 on the Nottingham Eczema
Severity Score, denoting moderate to severe disease over the last 12 months. Participants had at least one
area of active AE on a part of the body that would be covered by the garments.
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Children were excluded if they had taken systemic medication (e.g. ciclosporin, oral corticosteroids) or had
received light therapy for AE in the preceding 3 months, used wet/dry wraps more than five times in the
last month, started a new medication or treatment regimen that may affect AE in the last month, were
currently using silk garments for their AE and were unwilling to stop during the trial, and were currently
taking part in another clinical trial. Only one child was enrolled per family.
Interventions
For the intervention group, two brands of silk garments were used [DermaSilkTM (AlPreTec Srl, San Donà di
Piave, Italy) and DreamSkinTM (DreamSkin Health Ltd, Hatfield, UK)], as these were the two brands available
on prescription at the time of trial design. Both brands were made with antimicrobially protected, knitted,
sericin-free 100% silk.
Participants received three sets of garments (long-sleeved vest and leggings, or body suits and leggings,
depending on the age of the child), and were instructed to wear the garments as often as possible during
the day and at night. Garments were replaced, as required, during the 6-month RCT (if they were worn
out, were lost or no longer fitted).
All participants continued with their standard AE care including regular emollient use and topical
corticosteroids (or calcineurin inhibitors) for controlling inflammation. The participants were asked not to
change their standard AE treatment for the duration of the trial unless medically warranted. If a research
nurse suspected that the AE had become infected, participants contacted their normal medical team for
confirmation of diagnosis and subsequent treatment.
Outcomes
Primary outcome
Atopic eczema severity was assessed by research nurses at baseline, 2, 4 and 6 months using the Eczema
Area and Severity Index (EASI). Baseline EASI was used as a covariate in the analysis model.
Secondary outcomes
l Global assessment of AE by research nurses (Investigator Global Assessment) and by participants
(Participant Global Assessment) at baseline, 2, 4 and 6 months.
l Participant-reported AE symptoms (Patient Oriented Eczema Measure) assessed weekly.
l Three-Item Severity scale at baseline, 2, 4 and 6 months, assessed by the research nurses.
l Use of AE treatments: proportion of days on which topical steroids, topical calcineurin inhibitors,
emollients and wet/dry wrapping were used.
l Health-related quality of life at baseline and 6 months from the perspectives of the family (Dermatitis
Family Impact), the main carer (EuroQoL-5 Dimensions-3 Levels) and the child (Atopic Dermatitis Quality
of life preference-based index; Child Health Utility – 9 Dimensions in those aged ≥ 5 years).
l Durability of the garments and acceptability of use (at 6 months), and adherence (weekly).
l Within-trial cost-effectiveness from a NHS perspective.
Safety outcomes
Skin infections requiring antibiotic or antiviral treatment and serious adverse events related to AE.
Sample size
Three hundred participants provided 90% power, at the 5% significance level (two-tailed), to detect a
difference of around 3 points between the groups in mean EASI scores. Sample size was based on a
repeated-measures analysis of covariance, standard deviation (SD) 13, correlation between EASI scores
at different time points of 0.6 and loss to follow-up of 10%.
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Randomisation and blinding
Randomisation was stratified by recruiting hospital and by participants’ age: < 2 years, 2–5 years or > 5 years.
A computer-generated pseudo-random code with random permuted blocks of randomly varying size (2, 4 or 6)
was created by the Nottingham Clinical Trials Unit.
The sequence of treatment allocations remained concealed until the database was locked at the end of the
study, when it was revealed to data analysts.
Participants in the intervention group were further randomised to one of the two silk garment brands.
Branding labels and packaging were removed from the garments prior to distribution.
FLG genotype analysis
Saliva samples were collected for deoxyribonucleic acid extraction. Those of white European ethnicity were
tested for the four most prevalent FLG loss-of-function mutations in this population: R501X, 2282del4,
R2447X and S3247X.
Statistical methods
The main approach to analysis was modified intention to treat, that is, analysis according to randomised
group regardless of adherence to allocation and including only participants who provided outcome data
at follow-up. All regression models included the randomisation stratification variables of recruiting site
and age as covariates, and also included baseline scores (if measured). Adjusted differences in means are
presented for continuous outcomes, and adjusted risk differences and relative risks for binary outcomes.
The primary analysis used a multilevel model with observations at the 2-, 4- and 6-month follow-ups, nested
within participants, and included participants in whom EASI was assessed at least once at follow-up. The
EASI scores were right skewed at all follow-up time points. The score was log-transformed for analysis and
the effect of the trial garments is presented as a ratio of geometric means. This ratio was back-transformed
to the original EASI scale to facilitate the interpretation of findings.
Sensitivity analyses for the primary outcome were performed (1) to include adjustment for variables
that had an observed imbalance at baseline, (2) using multiple imputation for missing outcomes and
(3) to explore the impact of adherence in wearing the garments by estimating the complier average
causal effect at 6 months using instrumental variable regression methods.
A planned subgroup analysis based on presence or absence of loss-of-function mutations in FLG was
conducted for the primary outcome by adding an interaction term between allocated treatment and
FLG genotype to the primary analysis model.
Participants were classified as being broadly adherent if they wore the trial garments for at least 50% of
the days or 50% of the nights.
Health economics
Within-trial economic analysis compared the costs and quality-adjusted life-years (QALYs) from the
perspective of the UK NHS. QALYs were estimated using linear interpolation and area-under-the-curve
analysis, adjusting for baseline values, age and study centre.
A regression-based approach was used for the statistical analysis. The level of uncertainty associated with
the decision over which option was most cost-effective was explored using non-parametric bootstrapping
to construct the cost-effectiveness acceptability curve.
Qualitative study
A nested qualitative study examined parent and child experiences of using silk garments within the trial, and
barriers and motivators to prescribing silk garments from the perspectives of prescribers and commissioners.
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Ten face-to-face or telephone interviews with child participants and three focus group discussions
(two with children aged 7–8 years and one with children aged 5–6 years) were conducted.
Semistructured telephone interviews and focus groups were conducted with 33 parents/guardians of
children in the trial (four focus groups and 22 telephone interviews).
Telephone interviews were conducted with 21 health-care professionals including dermatology specialist
nurses (n = 9), dermatologists (n = 4), general practitioners (n = 3), pharmacists (n = 3) and health-care
commissioners (n = 2).
The results were analysed thematically using the five-stage Framework Analysis process for the adult
studies, and using the three methods of holistic, selective and detailed data analysis for data derived from
child participants.
Results
Three hundred children were randomised between 26 November 2013 and 5 May 2015 (151 to standard
care and 149 to intervention), with 282 (94%) included in the primary analysis (141 in each group).
The participants had a mean age of 5 years; 42% were female and 79% were of white ethnicity. Demographics
and AE characteristics were well balanced at baseline, apart from a slight imbalance in sex, baseline EASI,
parent-reported history of asthma and food allergy. These were adjusted for in the sensitivity analysis.
Adherence was high: 82% of participants wore the garments for at least 50% of the time (median of
81% of nights and 34% of days). Acceptability assessed at 6 months suggested that 70% were satisfied
or very satisfied with the garments and 74% of the children were either happy or very happy to wear
them. Specific concerns were raised about poor durability and fit of the garments.
Research nurses remained blinded to treatment allocation for 96% of participants.
For the primary outcome of AE severity, there was no difference between the groups in the nurse-assessed
EASI scores. Geometric mean EASI scores at baseline and at 2, 4 and 6 months were 8.4, 6.6, 6.0, 5.4,
respectively, in the standard care group and 9.2, 6.4, 5.8, 5.4, respectively, in the intervention group.
For EASI scores averaged over the 2-, 4- and 6-month follow-up visits, the ratio of geometric means was
0.95 [95% confidence interval (CI) 0.85 to 1.07; p = 0.43]. This CI is equivalent to a difference between
the intervention and the standard care groups over the study period ranging from a decrease of
approximately 1.5 points on the EASI scale (indicating less severe AE in the intervention group) to an
increase of 0.5 points (indicating more severe AE in the intervention group).
For the secondary outcomes, there were no between-group differences in nurse-assessed AE severity,
quality of life or medication use. Some small differences were observed for two of the participant-reported
secondary outcomes, most probably as a result of response bias and the collection of multiple outcomes.
The rate of skin infections was similar in the two groups, occurring in 39 out of 141 (28%) participants in the
standard care group and in 36 out of 142 (25%) participants in the intervention group. Two participants in the
standard care group and four participants in the silk garments group were hospitalised for AE during the study.
All sensitivity analyses for the primary outcome (adjusting for additional baseline factors, imputing missing
values and exploring the impact of adherence in wearing the garments) were supportive of the primary
analysis. There was no differential effect of the clothing on EASI eczema severity according to FLG subgroup
(p-value for interaction effect 0.47).
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The mean cost of silk garments, including initial and replacement garments, was £318.52 (SD £136.60)
per participant in the base case. Sixty-one (45.5%) participants required at least one replacement garment
over the 6-month period.
Combined with wider health resource use, the adjusted mean difference in cost per participant was
£364.94 (95% CI £217.47 to £512.42; p < 0.001). This difference reflects the cost of the intervention;
wider NHS costs were not significantly different between the groups.
The adjusted mean difference in QALY per participant was 0.0064 (95% CI –0.0004 to 0.0133).
The adjusted incremental cost per QALY was £56,811, suggesting that silk garments for AE are not
cost-effective within currently accepted thresholds.
In the qualitative component of the CLOTHES trial, parents and children provided valuable insights that
correlated closely with the quantitative trial results. On the whole, clinicians and commissioners had limited
knowledge and experience and were reluctant to prescribe garments that they perceived as being costly
and lacking in robust evidence of effectiveness.
Conclusion
Implications for health care
This trial found no evidence of clinical or economic benefit of using silk garments compared with standard
care in children with moderate to severe AE.
There were no differences between the treatment groups for any of the blinded outcomes. Furthermore,
the 95% CIs around the primary efficacy estimates were narrow, suggesting that a clinically important
treatment effect is unlikely to have been missed.
At the time of commissioning this research (2011), £840,272 was spent on prescriptions for silk garments
per annum in the UK (all indications). By 2015, this amount had more than doubled to more than £2M per
annum, suggesting considerable uptake of silk garments in recent years.
This is the first large, independent trial to have evaluated silk garments for the management of AE and
the nested economic evaluation suggests that use of these garments is unlikely to be cost-effective for
health providers.
The CLOTHES trial was an adequately powered RCT, with high follow-up rates and good adherence to the
trial interventions. The study has strong external validity as it was pragmatic in design to reflect normal
practice and participants were broadly reflective of the types of patients who are likely to be prescribed silk
garments for their AE. The trial placed special emphasis on objective outcome measures in order to
minimise response bias.
These trial results provide health commissioners with a better evidence base on which to make informed
decisions about silk garments for AE. Whether or not the small benefits identified in some of the
secondary outcomes are sufficient to justify purchasing these garments is something for individual parents
to consider on a case-by-case basis.
Recommendations for research
The use of non-pharmacological interventions for the management of AE remains a priority area for
research, particularly among patients.
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Other non-pharmacological interventions that have been prioritised by patients and health-care
professionals in a UK priority-setting partnership are:
1. role of food allergy testing in the management of AE
2. psychological treatments for itching/scratching
3. best ways to wash
4. best natural products to use on the skin
5. avoidance of irritants and allergens in the environment
6. role of diet (exclusion diets and nutritional supplements)
7. role of education programmes and multidisciplinary care.
Methodological challenges remain in comparing trials of the same interventions as a result of the different
study designs and outcome measures used. Efforts to support global initiatives to improve trial design,
such as the Harmonising Outcome Measures for Eczema initiative, should be encouraged and their
recommendations adopted into future AE trials.
Trial registration
This trial is registered as ISRCTN77261365.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Background
Atopic eczema (AE) (also known as atopic dermatitis or eczema) is a chronic, itchy, inflammatory skin
condition that is common throughout the world.1 Childhood AE has a substantial impact on the quality of
life of both children and their families.2–4 Standard treatment options for AE focus on topical medications:
emollients, with the addition of topical corticosteroids and topical calcineurin inhibitors, tailored according
to the severity of the AE.5 Although most cases of AE can be successfully treated with topical medications,
many parents express inconvenience and/or concern in using these preparations and are keen to identify
new ways of managing the symptoms of AE using non-pharmacological approaches.6
Clothing may play a role in either soothing or exacerbating AE symptoms and patients are commonly advised
to avoid wool because of its tendency to worsen itch and to use cotton or fine-weave materials next to the
skin.7 Specialist clothing is now available on prescription in the UK in a variety of forms, including sericin-free
silk, viscose and silver-impregnated fabrics.8 The therapeutic silk garments included in this study are available
on prescription in the UK, at a cost ranging from £66 to £155 per set of top and leggings (2014/15 prices).8
These garments are claimed to be beneficial for the management of AE, as they can help to regulate the
humidity and temperature of the surface of the skin, are smooth in texture and may reduce skin damage
from scratching. Some products have antimicrobial properties that may help to reduce the bacterial load on
the skin, which may be important in AE.9 However, the evidence from randomised controlled trials (RCTs)
supporting the use of silk garments is limited.10,11
To identify RCTs published prior to the CLOTHES trial, we searched the Global Resource of Eczema Trials
database.12 At the time of starting the CLOTHES trial, 14 small RCTs assessing the effects of therapeutic
clothing had been published: three RCTs investigated silk clothing [DermaSilkTM (AlPreTec Srl, San Donà di
Piave, Italy)];13–15 two investigated silver-coated textiles;16,17 three investigated cellulose seaweed fibres with
silver;18–20 one investigated cellulose;21 one investigated an anion textile;22 two investigated types of ethylene
vinyl alcohol fibre;23,24 one investigated borage oil-coated garments;25 and one investigated cotton and synthetic
fibres.26 Since the start of the trial, an additional study on chitosan-coated textiles has been published.27
The three previously published silk clothing RCTs are summarised in Table 1 (for further details of all trials
of therapeutic clothing for AE, see Appendix 1).
In view of the limited evidence for silk garments in AE, the UK National Institute for Health Research (NIHR)
Health Technology Assessment (HTA) programme issued a funding call in 2011 and, subsequently,
commissioned the CLOTHing for the relief of Eczema Symptoms (CLOTHES) Trial.
Objectives
Primary objective
l To assess whether or not the addition of silk therapeutic garments to standard AE care reduces AE
severity in children with moderate to severe disease over a period of 6 months.
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Secondary objectives
l To estimate the within-trial cost-effectiveness of silk therapeutic garments from a NHS and wider
(family and employer) perspective.
l To explore parent/guardian and child views on and experiences of using silk garments and factors that
might influence the use of these garments in everyday life.
l To examine prescribers’ and commissioners’ views on the use of silk garments for the management
of AE.
Role of the funder
The study was funded by the NIHR HTA programme. Espère Healthcare Ltd (UK and Ireland distributor for
DermaSilk) and DreamSkinTM Health Ltd (Hatfield, UK) donated the garments. The NIHR had input into
trial design through peer review of the funding proposal and the garment companies provided advice in
defining how the intervention should be used. Neither of the clothing companies had a role in data
collection, analysis or interpretation or writing of the report. However, both had sight of the report prior to
publication and had the opportunity to comment. The corresponding author had full access to all the data
and had final responsibility for the decision to submit.
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Chapter 2 Methods
Extracts of text, figures and tables throughout this report have been published in Thomas KS, Bradshaw LE,Sach TH, Batchelor JM, Lawton S, Harrison EF, et al. Silk garments plus standard care for treating
eczema in children: a randomised controlled observer-blind pragmatic trial (CLOTHES TRIAL). PLOS Med
2017; in press. https://doi.org/10.1371/journal.pmed.1002280.28 This is an Open Access article distributed
under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Trial design
The CLOTHES trial was a multicentre, parallel-group, observer-blind, pragmatic RCT of 6 months’ duration,
followed by a 2-month observational period (Figure 1). Children aged 1–15 years with moderate to severe
Expression of interest
Baseline visit: consent,
screening and randomisation
Outcome assessments
(clinic visit at 2 months)
Standard care
(n = 150)
Standard care + silk garments
(n = 150)
DreamSkin
(n = 75)
DermaSilk
(n = 75)
Outcome assessments
(clinic visit at 4 months)
Outcome assessments
(clinic visit at 6 months)
Questionnaire
8 months
Optional focus groups and
individual interviews with a subset
of children and parents/guardians
Standard care group provided
with trial garments at 6 months
FIGURE 1 CLOTHES trial flow chart.
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AE were randomised (1 : 1) to receive either silk garments plus standard AE care or standard AE care alone.
The primary outcome was assessed by research nurses blinded to the treatment allocation at baseline,
2, 4 and 6 months.
Participants randomised to silk garments were further randomised to receive one of the two brands of
garments used in the trial (DermaSilk or DreamSkin). Two products were used in the trial in order to
improve the generalisability of the trial findings and to avoid commercial advantage to one particular
company.
Participants allocated to the standard care group were given the silk garments after the primary outcome
had been recorded at 6 months and used the garments for the remaining 2-month observational period.
This was done in order to minimise loss to follow-up and potential contamination in the standard
care group.
The trial included a nested qualitative evaluation, health economic analysis and subgroup analysis based on
presence or absence of loss-of-function mutations in the gene encoding filaggrin (FLG). This was performed
because loss-of-function mutations in FLG are known to increase the risk of eczema and it is possible that
they affect response to silk clothing.
During the first 6 months of trial recruitment, an internal pilot was conducted to assess ability to recruit,
adherence to the intervention and retention in the trial.
The study was approved by Health Research Authority East Midlands – Nottingham 1 Research Ethics
Committee (reference number 13/EM/0255) and the local research and development department for each
participating centre prior to recruitment commencing at that site. The trial was registered on Current
Controlled Trials prior to start of recruitment (ISRCTN77261365 11 October 2013).
Recruiting centres
Recruitment took place in five UK centres: Nottingham University Hospitals NHS Trust, Royal Free London
NHS Foundation Trust, Cambridge University Hospitals NHS Foundation Trust, Portsmouth Hospitals NHS
Trust and Isle of Wight NHS Trust.
Participants were identified through secondary and primary care, or by self-referral in response to adverts
placed in local media, in the community and online. Potential participants were identified when they
attended a secondary care clinic or by responding to invitation letters and patient information sheets that
were sent to parents of children identified from secondary care clinic lists. A parent information sheet and
three separate age-appropriate child information sheets (for children aged 0–5, 6–10 and 11–15 years)
were used in the study (see Appendices 2–5).
A number of press releases were issued at the start of the trial. Posters and flyers were displayed in
recruiting centres and research nurses also took an active role in advertising the trial in the community by
placing posters and flyers in local schools, shops and community centres. The trial was promoted online
by the National Eczema Society and the Nottingham Support Group for Carers of Children with Eczema
and adverts were also posted in relevant web forums using ethics-approved text. If parents were
interested, either they contacted the recruiting centres directly or they enquired at the trial co-ordinating
centre and their details were passed on to the relevant recruiting centre.
General practice surgeries and other hospitals local to the recruiting centres were used as patient
identification centres by displaying trial posters and flyers.
METHODS
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Participants
Children were considered for entry into the trial if the following inclusion criteria were met:
l they were aged 1–15 years at baseline
l they had a diagnosis of AE according to the UK Working Party’s diagnostic criteria29 and a score of ≥ 9 on
the Nottingham Eczema Severity Score,30 denoting moderate or severe AE over the preceding 12 months
l they had at least one area of active AE on a part of the body that would be covered by the silk garments
l they were resident within travelling distance of a recruiting centre.
In addition, children were not entered into the trial if any of the following exclusions applied:
l they had taken systemic medication (e.g. ciclosporin, oral corticosteroids) or received light therapy for
AE in the preceding 3 months
l they had used wet/dry wraps at least five times in the last month
l they had started a new medication or treatment regimen that may affect AE in the last month
l they were currently using silk garments for their AE and were unwilling to stop during the trial
l they were currently taking part in another clinical trial
l they had expressed a wish not to take part in the trial.
Only one child was enrolled per family; if more than one child in a family was eligible, the decision as to
which child would be involved was made by the parents and children concerned.
Informed consent
Written informed consent was obtained from the parent/guardian of each participant at the baseline visit,
prior to any trial procedures being carried out. In addition, assent was provided by the children if they
wanted to. Consent to take part in the genetic study (FLG genotyping), and for samples to be stored and
used for potential future research, was included as optional.
Interventions
Silk garments
The silk garments used in the study are licensed as a medical device with a Conformité Européenne (CE) mark
for use in AE, denoting that they comply with European Union legislation and safety requirements. They are
100% silk garments made from antimicrobially protected, knitted, sericin-free silk. Sericin is removed from the
silk fibres during manufacturing because it is a protein that coats the outside of the fibres and has the potential
to cause allergic reactions.
Two products were chosen for inclusion in the trial (DermaSilk and DreamSkin), as these were the two brands
available on prescription in the UK at the time of trial design. Distribution of the intervention to participants
was handled from the co-ordinating centre, where a stock of garments across a range of sizes in both brands
was maintained. Participants received three sets of garments (long-sleeved vest and leggings or long-sleeved
body suits and leggings, depending on the age of the child) and were instructed to wear the garments as often
as possible during the day and at night, either as underwear or as pyjamas (Figure 2). Three sets were provided
to allow for the washing and rotation of garments. The child’s height at randomisation was used to determine
the correct size of garments, which were posted out to participants as soon as possible after randomisation.
On receipt of the garments, participants were instructed to try on one set to check that they fitted correctly and
then confirm this with the co-ordinating centre. Standardised care instructions were provided on a paper insert
included in the garment package (Box 1) and instructions were also replicated in the participant diary.
Garments were replaced as required during the 6-month RCT (if they were worn out, were lost or no longer
fitted the child). If replacement garments were required, the participants returned the worn garments to
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BOX 1 Care instructions for garments
Washing instructions for trial clothing
How do I use the garments?
Please wear the garments as often as possible, both during the day and at night (either as underwear or
as pyjamas).
Moisturising creams should be applied thinly to the skin (just enough for the skin to glisten) and should be
applied a few minutes before putting on the clothing to allow the creams to be absorbed into the skin.
How do I care for the garments?
You will be given three sets of garments during the trial. This will allow one set to be in use, one in the wash
and one spare. We recommend that you use all three sets within 1 week, rotating frequently.
To machine wash: wash at up to 40 °C using your usual mild non-biological detergent. The fibres of the
garment are quite delicate and washing the garment inside a pillowcase on a delicate cycle will protect it
during the wash. If possible, lay the garment flat to dry.
To hand wash: place in hand-hot water containing your usual mild non-biological detergent and agitate
by hand for a few minutes. Rinse well with plenty of warm, clean water and squeeze dry. Do not wring.
If possible, lay the garment flat to dry.
Other important points
Please do not use bleach. Make sure there are no bleaching agents in your detergent [such as Vanish
(Reckitt Benckiser, Slough, UK)].
Please do not use fabric softeners.
Please do not tumble dry.
Any reduction in garment length is likely to be a result of a tightening of the knit. A cool steam iron can be
used to restore the shape of a garment that appears to have shrunk.
FIGURE 2 Garments being worn.
METHODS
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the co-ordinating centre with a completed garment request form and new garments were sent out.
After the 6-month RCT period was over, garments were not replaced.
Standard care
All participants continued with their standard AE care in line with National Institute for Health and Care
Excellence (NICE) guidance,5 including regular emollient use, avoidance of irritants and topical corticosteroids
(or calcineurin inhibitors) for controlling inflammation. Participants were asked not to change their standard
AE treatment for the duration of the trial unless medically warranted.
Participants who frequently used wet- or dry-wrap dressings for their AE were excluded, but occasional use
of wet or dry wraps was monitored but not prohibited.
If a research nurse suspected that the AE had become infected, participants were advised to contact their
normal medical team for confirmation of diagnosis and subsequent treatment.
Outcomes
Details of derivations for outcomes can be found in the statistical analysis plan (see Appendix 6).
Primary outcome
The primary outcome of AE severity measured using the objective Eczema Area and Severity Index (EASI)31
was assessed at baseline and at 2, 4 and 6 months. Baseline EASI score was used as a covariate in the
analysis model. EASI score was assessed by trained research nurses who were blinded to treatment allocation.
EASI score was chosen as the primary outcome as it is a validated scale recommended as the core outcome
instrument for AE signs.32 EASI involves an evaluation of four AE signs [erythema (redness), excoriation
(scratching), oedema/papulation (swelling and fluid in the skin) and lichenification (thickening of the skin)]
and an assessment of percentage area affected by eczema in four body regions (head and neck, upper limbs,
trunk and lower limbs). EASI score ranges from 0 to 72, with higher scores representing more severe disease.
All research nurses received training in the use of EASI (using standardised training photographs and
assessment of patients with AE by two independent assessors until concordance was reached). Resources
were provided to assist in assessing the signs and body surface area (see Appendix 7).
Participants were assessed by the same research nurse at all time points in order to minimise interobserver
variability.
Secondary outcomes
l Global assessment of AE by research nurses [Investigator Global Assessment (IGA)] and by participants
[Patient Global Assessment (PGA)] at baseline and at 2, 4 and 6 months, using a six-point scale
(clear, almost clear, mild, moderate, severe and very severe).
l Self-reported AE symptoms using the recommended core outcome instrument,33 the Patient Oriented
Eczema Measure (POEM), which captures frequency of itch, sleep loss, bleeding, weeping/oozing,
cracking, flaking and dryness.34 It has a range from 0 to 28, with higher scores representing more
severe disease. POEM scores were collected weekly using an online questionnaire for the first 6 months
and once again at 8 months. Obtaining self-reported eczema severity every week for 6 months was
used to capture long-term control of flares as well as self-reported eczema symptoms.
l Three-Item Severity (TIS) scale35 at baseline and at 2, 4 and 6 months, assessed by research nurses at a
single representative body site (defined as the most bothersome patch of AE that was covered by the
garments). The selected representative body site did not have to be the same at each visit. The TIS
measures three clinical signs (erythema, oedema/papulation and excoriation) and the total score ranges
from 0 to 9, with higher scores representing more severe disease. Given the importance of an objective
measure to capture eczema severity in this observer-blind trial, it was felt that a second validated
eczema severity scale was warranted.
DOI: 10.3310/hta21160 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 16
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Thomas et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
9
l Use of AE treatments: number of days of use of topical steroids, topical calcineurin inhibitors, emollients
and wet/dry wrapping, assessed weekly throughout the trial. At each visit, research nurses assessed
change in AE treatment regimen and categorised as no change, neutral change, reduction or escalation.
l Health-related quality of life at baseline and at 6 months from the perspectives of the family [Dermatitis
Family Impact (DFI)],36 the main carer [EuroQoL-5 Dimensions-3 Levels (EQ-5D-3L)]37 and the child
[Atopic Dermatitis Quality of Life (ADQoL) preference-based index38 and Child Health Utility-9 Dimensions
(CHU-9D)39 in those aged ≥ 5 years].
l Durability of the garments, adherence and acceptability of use (as assessed by children and parents/carers).
Adherence was collected weekly, and information on durability and acceptability was captured at 6 and
8 months in the participant questionnaires. Sticker charts were provided for children to record how many
days/nights the garments had been worn for the intervention group and how many days/nights they had
been in the study for the standard care group (see Appendix 8). These were intended to help keep children
engaged in the study and to assist in completing the adherence data in the weekly questionnaires.
l Health resource use for treatment of AE throughout the trial: health-care visits, inpatient stays, medications,
tests, personal items for AE and time off work or school.
Safety outcomes
Skin infections requiring antibiotic or antiviral treatment self-reported by parents and serious adverse
events related to AE (hospitalisation as a result of AE) were recorded.
Tertiary outcomes
Although it was assumed that the different brands of garments were similar, the effects of receiving
different brands of garments were also explored. Another additional exploratory analysis was conducted
based on AE severity scores in areas covered by the garments (body and limbs) compared with areas
uncovered by the garments (head and neck). All tertiary analyses were considered exploratory.
Data collection
Trial data generated by all centres were entered by research nurses directly into a web-based MACRO
database (MACRO 4 version 3800, Elsevier, London, UK), maintained by the Nottingham Clinical Trials Unit
(CTU). Access to the trial database was controlled by user logins and research nurses could enter/edit data
for their site only. Paper worksheets were provided for research nurses to record data during the clinic visit
(see Appendix 9) and were transcribed after the visit. Participant questionnaires completed at clinic visits
were transcribed by the research nurses into the trial database. Data entry was checked against the paper
record for 100% of the primary outcome and for a 10% sample of all data.
Participants were provided with a diary booklet in which they were encouraged to record all health-care visits
for eczema, eczema prescriptions, purchases for AE and time off work/school because of AE (see Appendix 10).
The diary was reviewed by the research nurse at each clinic appointment and used as an aide memoir to
complete the relevant sections of the trial database.
Missing and/or ambiguous data were queried with research nurses and resolved whenever possible.
Weekly questionnaires were completed by the participant online or in paper format (see Appendix 11) and
sent to the Nottingham CTU for data entry on the bespoke in-house system. The preference for paper or
online questionnaires was recorded at baseline. Participants completing online questionnaires were emailed
a unique web link to the questionnaire each week on the day completion was due. A further reminder
e-mail was sent at the beginning of day 3 if the questionnaire had not been completed. Links remained
active until the end of day 3, after which time the week’s entry was classed as missing. Participants who
failed to complete the weekly questionnaire for ≥ 3 weeks in a row were contacted by the Nottingham CTU
and encouraged to complete the questionnaires.
For the week 24 (6-month) (see Appendix 12) and week 32 (8-month) (see Appendix 13) questionnaires, online
submission remained open for 14 and 7 days, respectively, in order to ensure maximum data completion at the
METHODS
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primary end point and end of trial. For these time points, non-responders were contacted by telephone and a
paper copy of the questionnaire was sent by post if required.
Sample size
Three hundred participants provided 90% power, at the 5% significance level (two-tailed), to detect a
difference of around 3 points between the groups in mean EASI scores. Although this between-group
difference is approximately half the published minimum clinically important difference for EASI that was
suggested from one study in adults,40 we wanted to be sure that a clinically important difference to patients
was not missed as a result of our focus on an objective outcome for the primary outcome. Sample size was
based on repeated measures analysis of covariance, assuming a standard deviation (SD) of 13, a correlation
between EASI scores at different time points of 0.6 and loss to follow-up of 10%.
Stopping rules and discontinuation
An internal pilot RCT was conducted over the first 6 months of trial recruitment to ensure delivery of the
trial to time and target. Pre-defined stop/go criteria were assessed by the Trial Steering Group at 6 months
as outlined in Table 2. Target recruitment for the RCT phase was ≥ 75 participants.
Adherence to wearing the clothing was defined as a trigger for concern if participants reported using the
clothing < 50% of the time.
Randomisation and blinding
Randomisation was stratified by recruiting hospital and by participant’s age: < 2, 2–5 or > 5 years. A
computer-generated pseudo-random code with random permuted blocks of randomly varying size (2, 4 or 6)
was created by the Nottingham CTU, in accordance with their standard operating procedure, and held
on a secure University of Nottingham server. Research staff at sites were not aware of the block sizes.
Participants were further randomised to one of the two silk garment brands (DermaSilk or DreamSkin)
using a computer-generated pseudo-random code with random permuted blocks of randomly varying size,
stratified by allocated group.
Research nurses accessed the randomisation website by means of a remote, internet-based randomisation
system developed and maintained by the Nottingham CTU. Access was controlled by unique user logins.
The sequence of treatment allocations was concealed until interventions had all been assigned and
recruitment and data collection were complete. Study statisticians were blinded to treatment allocations
until the database was locked.
TABLE 2 Stop/go criteria for the pilot RCT phase
Criteria to be assessed at 6 months
of recruitment Proposed action
≥ 90% of target recruitment and retention Continue with main trial as planned
70–89% of target recruitment and retention Continue with main trial, implement strategies for improvement
50–69% of target recruitment and retention Urgent measures required, discuss plans with Trial Steering
Committee and NIHR HTA
< 50% of target recruitment and retention Stop trial unless good reason for delay and rectifiable solution can be
readily implemented
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After each allocation, the randomisation system notified staff at the Nottingham CTU, who then sent a letter
confirming the treatment allocation to the participant (along with the silk garments as necessary). Staff at the
Nottingham CTU removed branding labels from the garments and repackaged them in plain trial packaging
before sending so that participants were not aware of which brand of garments they had received.
Although it was not possible to blind participants to their treatment allocation, efforts were made to
minimise expectation bias by emphasising in the trial documents that the evidence supporting the use of
silk garments for AE was limited and that it was not yet known if such garments offered any benefit over
standard care. Participant-facing study documents also avoided the use of value-laden terms such as
‘specialist’ or ‘therapeutic’ garments.
In order to preserve blinding of the research nurses, participants were reminded in the study literature and
in their clinic appointment letters/texts not to wear the garments when they attended the clinic nor to
mention the garments when talking to the research nurses. Additionally, children were sent cards, both to
thank them for their participation and remind them not to disclose to the research nurse whether or not
they had been given the garments. All questions relating to the acceptability and use of the garments
were completed by either postal or online questionnaires, and telephone and e-mail contact with
participants was made by staff from the Nottingham CTU whenever possible. If the research nurses
became unblinded, this was recorded. Full details of blinding arrangements are summarised in Table 3.
FLG genotype analysis
If participants gave written informed consent to collect a saliva sample, these samples were collected using
SalivaGeneTM Collection Module II (Stratec Biomedical Systems, Birkenfeld, Germany), or SalivaGeneTM
Buccal Swab (Stratec Biomedical Systems, Birkenfeld, Germany) if children were unable to spit into the
container. After collection, samples were packaged by research nurses and posted to the University of
Dundee, UK, where deoxyribonucleic acid (DNA) extraction was performed.
Samples were tested for the six most prevalent FLG loss-of-function mutations in the white European
population as previously reported: R501X, 2282del4, R2447X, S3247X, 3702delG and 3673delC.41 Only
participants of white European ethnicity were included in the FLG genotype subgroup analysis because FLG
mutations are known to be ethnically specific. Individuals in whom the four most prevalent mutations
(R501X, 2282del4, R2447X and S3247X) were successfully genotyped were categorised as FLG wild type
(none of the prevalent mutations was identified; these individuals constituted the control cohort), FLG
heterozygotes (carrying one FLG null mutation) or FLG homozygotes or compound heterozygotes
(individuals carrying two FLG null mutations).
TABLE 3 Summary of blinding arrangements
Role in trial
Blinding
status Comments
Participants Not blinded Not possible to blind participants, efforts made to minimise
expectation bias
Research nurses and principal
investigators
Blinded Participants were reminded in their clinic appointment letters not
to wear the clothing when attending the clinic or to mention the
clothing in any way when talking to the research nurses
Trial staff at the Nottingham CTU Not blinded Acted as the main point of contact for participants wishing to
contact the research team, packaged and posted the clothing to
the participants according to the randomisation schedule, and
provided general advice
Statistician Blinded Statistician finalised the statistical analysis plan prior to revealing
the treatment codes
METHODS
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Statistical methods
Analyses are detailed in the statistical analysis plan (see Appendix 6), which was finalised prior to database
lock and release of treatment allocation codes for analysis. All analyses were carried out using Stata 13.1
(StataCorp LP, College Station, TX, USA). The main approach to analysis was modified intention to treat,
that is, analysis according to randomised group regardless of adherence to allocation and including only
participants who provided outcome data at follow-up. Estimates of the intervention effect are presented
with 95% confidence intervals (CIs) and p-values.
All outcomes collected at the 2-monthly clinic visits were summarised by time point and treatment group.
All outcomes collected from the weekly questionnaires were summarised by week and treatment group.
Correlation matrices between outcomes at the 2-monthly clinic visits are given in Appendix 14 (see Table 53)
and between POEM scores at 8, 16 and 24 weeks are given in Appendix 15 (see Table 55). All regression
models included the randomisation stratification variables of recruiting site and age as covariates and also
included baseline scores (if measured). Adjusted differences in means for the intervention group compared
with the standard care group are presented for continuous outcomes, and adjusted risk differences and
relative risks for binary outcomes.
Preliminary analyses
Descriptive statistics of demographic and clinical measures were used to examine balance between the
randomised arms at baseline.
Primary outcome
The primary analysis used a multilevel model with observations at 2, 4 and 6 months, nested within participants,
and included participants in whom EASI was assessed at least once at follow-up. The model assumed that
missing EASI scores were missing at random given the observed data. The model used a random intercept
and slope at the participant level, with an unstructured covariance matrix for these random effects. Diagnostic
plots to check the normality of the residuals from the fixed part of the model, homogeneity of the variance of
the residuals and the normality of the random effects when the model was initially fitted indicated that the
assumptions for the multilevel model were not met. The score was therefore log-transformed for analysis and
the effect of the trial garments is presented as a ratio of geometric means.42,43 This ratio was back-transformed
to the original EASI scale to facilitate interpretation of findings.
The effect of trial garments on AE severity changing over the study period was explored by including an
interaction term between group and time point in the model. There was no evidence of a differential effect
over time, so a single treatment effect has been reported that averages the treatment effect over all time points.
Sensitivity analyses for the primary outcome were performed:
l To adjust for variables that had an observed imbalance between the groups at baseline.
l Using multiple imputation (by chained equations) for missing outcome data.
l To explore the impact of adherence in wearing the garments on the primary outcome by estimating
the complier average causal effect (CACE) at 6 months using instrumental variable regression methods.
This analysis aims to provide an unbiased estimate of the treatment effect among compliers, defined as
participants who would comply with their allocation regardless of the treatment arm to which they
were randomised. Estimates are presented for two measures of compliance:
i. binary compliance, defined as participants who wore the trial garments for at least 50% of the days
or 50% of the nights
ii. continuous compliance, defined as each additional 10% of time that the garments were worn. This
was calculated by summing the number of days and nights that the trial garments were reported to
be worn, then dividing by the total number of days and nights in questionnaires completed about
garment wear.
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A planned subgroup analysis based on the presence or absence of loss-of-function mutations in FLG was
conducted by adding an interaction term between allocated treatment and FLG genotype (none, one or
two FLG null mutations) to the primary analysis model.
Secondary outcomes
The global assessment scores (IGA and PGA) were dichotomised into ‘clear, almost clear or mild AE’ versus
‘moderate, severe or very severe AE’, and analysed using generalised estimating equations to allow
estimation of risk difference and risk ratio. The TIS score was analysed using the multilevel model
framework as outlined above for the primary outcome (not transformed). For the global assessment scores
and the TIS score, the effect of the trial garments changing over the study period (2-, 4- and 6-month
visits) was explored by including an interaction term between group and time point in the models. There
was no evidence of a differential effect over time for any outcomes, so a single treatment effect per
outcome has been reported that averages the treatment effect over all time points.
For each participant from the weekly questionnaire data, the mean of their weekly POEM scores between
week 1 and week 24 and the percentage of days that topical treatments were used were calculated.
The participant mean POEM scores and percentage of days that topical steroids were used were analysed
using a linear model weighted according to the number of weekly questionnaires completed.
Quality-of-life outcomes at 6 months were analysed using linear models. Changes to treatment regimen
were based on whether or not a participant had reported any treatment escalation over the 6-month RCT
period and analysed using a generalised linear model. Skin infections were analysed using negative
binomial regression.
Adherence to wearing the trial garments was summarised using the percentage of days and nights that
the study garments were worn. Participants were classified as adherent if they wore the trial garments for
at least 50% of the days or 50% of the nights. This was done for participants who completed at least half
(12/24) of the weekly questionnaires. Sensitivity analyses explored adherence for all participants by making
different assumptions about garment wear during periods in which the questionnaire was not completed.
Adherence to wearing the trial garments was explored descriptively according to age group and baseline
eczema severity.
Serious adverse events, durability and acceptability of use of the garments and information from the
follow-up questionnaire at 8 months were summarised descriptively.
Tertiary outcomes
The primary analysis assumed that the effect of the different brands of garments was similar, but the
impact of garment brand on AE severity was explored in a tertiary analysis. AE severity according to brand
was explored by adding a term for garment brand to the primary analysis model for the EASI described
above. AE symptoms according to brand were explored by comparing POEM scores after 2 months of
garment wear (baseline and 2 months for the intervention group and 6 and 8 months for the standard
care group).
During the study there was a supply problem with one of the garment suppliers (DreamSkin), which meant
that the randomised schedule was not followed during this time and participants received the alternative
brand (DermaSilk). Any participants randomised to the intervention group during a time period that
DreamSkin garments of the required size were out of stock were not included in the tertiary analysis by
brand of garments. Similarly, any participants in the standard care group who completed their 6-month
visit during a period when DreamSkin garments of the required size were out of stock were not included.
Adherence and acceptability of the garments at 6 and 8 months were summarised descriptively by
allocated group and allocated garment brand.
METHODS
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Additional analyses
On completion of the pre-planned analyses, and following concerns that the baseline EASI scores appeared
lower than might be expected for children with moderate to severe eczema, an additional post hoc analysis
was conducted to explore the interaction between baseline severity and treatment group. This was
conducted by adding an interaction term between allocated group and baseline EASI score (log-transformed
and continuous) to the primary analysis model.
Summary of changes to the protocol
The full protocol and statistical analysis plan are available on the CLOTHES website (www.nottingham.ac.uk/
CLOTHES). Changes to the protocol initiated after the start of recruitment included an increase in the
number of FLG genotype mutations to be included in the genetic analysis (two additional mutations were
added: 3702delG and 3673delC) and addition of details of the nested qualitative evaluation.
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Chapter 3 Results: clinical findings
Recruitment and follow-up
Recruitment to the study took place between 26 November 2013 and 5 May 2015 (Figure 3). During this
time, 922 children were assessed for eligibility and 300 were subsequently randomised (Figure 4).
Eighty-nine children were randomised within the first 6 months of recruitment, meeting the target of
75 participants as specified for the internal pilot phase.
Attendance at follow-up visits was ≥ 90% for all clinic visits. In both groups, 129 (85%) attended all three
follow-up visits. The same nurse performed the outcome assessments for all study visits for all but
four participants.
The primary analysis included 141 participants in each group (participants were included if the primary
outcome was assessed at least once after baseline) (see Figure 4).
In the case of the weekly online questionnaires (24 questionnaires over 6 months), 127 out of 151 (84%)
participants in the standard care group and 126 out of 149 (85%) participants in the intervention group
completed 12 or more. The median number completed was 22 (25th to 75th centile, 17 to 24) in both
groups. The number of participants completing the questionnaire each week was very similar in the
standard care and intervention groups (Figure 5).
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Enrolment
2 months
4 months
6 months
Number assessed for eligibility
(n = 922)
Randomised
(n = 300)
Not randomised
(n = 622)
• Not meeting eligibility criteria, n = 326
• Parent not willing to give informed consent, n = 97
• Undecided/did not get back in touch, n = 187
• Other, n = 7
• Did not attend baseline appointment, n = 5
Allocated to intervention
(n = 149)
Included in primary analysis
(n = 141) 
Included in sensitivity analysis using
multiple imputation for missing values
(n = 149)
• Sent silk garments, n = 149
   • DermaSilk, n = 75
   • DreamSkin, n = 74
Follow-up for primary EASI 
outcome measure at 2 months
• Completed, n = 139
• Not obtained, n = 10
   • Discontinued from study, n = 7
   • Visit not attended, n = 3
Follow-up for primary EASI 
outcome measure at 4 months
• Completed, n = 135
• Not obtained, n = 14
   • Discontinued from study, n = 10
   • Visit not attended, n = 3
   • Visit completed, EASI not fully 
      assessed, n = 1
Follow-up for primary EASI 
outcome measure at 6 months
• Completed, n = 133
• Not obtained, n = 16
   • Discontinued from study, n = 15
   • Visit completed, EASI not fully 
      assessed, n = 1
Allocated to standard care
(n = 151)
Included in primary analysis
(n = 141) 
Included in sensitivity analysis using
multiple imputation for missing values
(n = 151)
• Sent silk garments in error, n = 1
Follow-up for primary EASI 
outcome measure at 2 months
• Completed, n = 137
• Not obtained, n = 14
   • Discontinued from study, n = 10
   • Visit not attended, n = 4
Follow-up for primary EASI 
outcome measure at 4 months
• Completed, n = 133
• Not obtained, n = 18
   • Discontinued from study, n = 10
   • Visit not attended, n = 8
   • Visit completed, EASI not fully 
      assessed, n = 0
Follow-up for primary EASI 
outcome measure at 6 months
• Completed, n = 139
• Not obtained, n = 12
   • Discontinued from study, n = 12
   • Visit completed, EASI not fully 
      assessed, n = 0
FIGURE 4 Participant flow through the study.
RESULTS: CLINICAL FINDINGS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
18
Baseline data
Participants
The mean age of participants was 5 years (SD 3.6); 58% were male and 79% were of white ethnicity
(Table 4). The majority (72%) had previously been treated in secondary care for their AE, 72% had
moderate or severe AE (based on IGA scores at baseline) (Table 5) and 37% were reported to use a potent
or very potent steroid as their main steroid (Table 6).
The demographic and AE characteristics were well balanced at baseline, although there were slightly more
boys in the intervention group than in the standard care group, and parent-reported history of asthma and
food allergy was higher in the standard care group than in the intervention group (see Table 4). The mean
EASI score was slightly higher in the intervention group than in the standard care group, as more children
had a baseline EASI score of > 30 (intervention, 14 participants; standard care, 4 participants; Figure 6);
however, the median and interquartile ranges were similar between the groups (see Table 5). Other AE
severity measures were similar between the two groups apart from the PGA scores [a greater proportion
of participants in the standard care group rated their AE as moderate, severe or very severe than the
intervention group (75% vs. 66%) (see Table 5)]. Health-related quality of life in the two groups was
similar at baseline (Table 7).
FLG genotype
Table 8 shows the FLG genotyping results for participants of white ethnicity. Samples from 219
participants were tested for the six most prevalent FLG loss-of-function mutations in the white European
population: R501X, 2282del4, R2447X, S3247X, 3702delG and 3673delC. Genotyping methods for the
four most prevalent genotypes (R501X, 2282del4, R2447X and S3247X) were largely successful (n = 217
were included in the analysis), but the genotyping methods used for 3703delG and 3673delC were
unsuccessful for 24 participants (11% of samples tested) owing to the suboptimal quality and quantity of
DNA obtained from paediatric saliva samples.
In total, 217 participants of white European ethnicity were categorised as FLG wild type (individuals in
whom none of the prevalent mutations was identified), FLG heterozygotes (carrying one FLG null mutation)
and FLG homozygotes or compound heterozygotes (individuals carrying two FLG null mutations) for the
four most prevalent mutations (R501X, 2282del4, R2447X and S3247X). Of these, 74 participants had at
least one mutation.
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FIGURE 5 Percentage questionnaire completion by week and group.
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TABLE 4 Baseline characteristics
Characteristic Standard care (N= 151) Intervention (N= 149) Total (N= 300)
Age (years)
Mean (SD) 5 (3.6) 5.1 (3.7) 5.1 (3.6)
Median (25th, 75th centile) 4 (2, 8) 4 (2, 7) 4 (2, 7.5)
Minimum, maximum 1, 14 1, 15 1, 15
1–4, n (%) 86 (57) 77 (52) 163 (54)
5–11, n (%) 57 (38) 62 (42) 119 (40)
12–15, n (%) 8 (5) 10 (7) 18 (6)
Sex, n (%)
Male 82 (54) 92 (62) 174 (58)
Female 69 (46) 57 (38) 126 (42)
Ethnicity, n (%)
White 123 (81) 114 (77) 237 (79)
Indian 5 (3) 2 (1) 7 (2)
Pakistani 3 (2) 3 (2) 6 (2)
Bangladeshi 0 2 (1) 2 (1)
Black Caribbean 1 (1) 2 (1) 3 (1)
Black African 3 (2) 4 (3) 7 (2)
Black (other) 2 (1) 0 2 (1)
Chinese 1 (1) 3 (2) 4 (1)
Other Asian (non-Chinese) 0 4 (3) 4 (1)
Mixed race 12 (8) 13 (9) 25 (8)
Other 1 (1) 2 (1) 3 (1)
History of atopy, n (%)
Asthma 57 (38) 46 (31) 103 (34)
Allergic rhinitis 60 (40) 56 (38) 116 (39)
Food allergy 80 (53) 68 (46) 148 (49)
Anaphylaxis 23 (15) 23 (15) 46 (15)
Type of AE, n (%)
Discoid 19 (13) 17 (11) 36 (12)
Flexural 144 (95) 147 (99) 291 (97)
Location of AE, n (%)
Head and neck 115 (76) 120 (81) 235 (78)
Hands and wrists 116 (77) 108 (72) 224 (75)
Feet and ankles 100 (66) 96 (64) 196 (65)
Limbs 151 (100) 149 (100) 300 (100)
Trunk 128 (85) 122 (82) 250 (83)
Previous medical care, n (%)
No previous treatment – – –
GP only 41 (27) 40 (27) 81 (27)
GP and in secondary care 110 (73) 109 (73) 219 (73)
GP, general practitioner.
Categories for history of AE, type of AE and location of AE are not mutually exclusive.
RESULTS: CLINICAL FINDINGS
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TABLE 5 Atopic eczema severity assessments at baseline
Severity assessment Standard care (N= 151) Intervention (N= 149) Total (N= 300)
EASIa
Mean (SD) 9.6 (7.8) 11.4 (10.6) 10.5 (9.3)
Median (25th, 75th centile) 7.3 (4.2, 12) 7 (4.1, 15.4) 7.2 (4.1, 13.7)
Min., max. 1.1, 41.1 1, 47 1, 47
TISb
Mean (SD) 4.9 (1.8) 4.9 (1.8) 4.9 (1.8)
Median (25th, 75th centile) 5 (4, 6) 5 (3, 6) 5 (4, 6)
Min., max. 1, 9 1, 9 1, 9
Nottingham Eczema Severity Scorec
Mean (SD) 13.1 (1.6) 13.2 (1.7) 13.1 (1.6)
Median (25th, 75th centile) 13 (12, 14) 13 (12, 15) 13 (12, 14)
Min., max. 9, 15 9, 15 9, 15
Moderate AE (9–11), n (%) 28 (19) 30 (20) 58 (19)
Severe AE (12–15), n (%) 123 (81) 119 (80) 242 (81)
IGA, n (%)
Almost clear 4 (3) 2 (1) 6 (2)
Mild 39 (26) 39 (26) 78 (26)
Moderate 77 (51) 67 (45) 144 (48)
Severe 30 (20) 36 (24) 66 (22)
Very severe 1 (1) 5 (3) 6 (2)
PGA, n (%)
Almost clear 5 (3) 6 (4) 11 (4)
Mild 33 (22) 45 (30) 78 (26)
Moderate 83 (55) 67 (45) 150 (50)
Severe 27 (18) 25 (17) 52 (17)
Very severe 3 (2) 6 (4) 9 (3)
PGA completed by, n (%)
Parent/guardian 129 (85) 125 (84) 254 (85)
Child 22 (15) 24 (16) 46 (15)
POEMd
Mean (SD) 16.6 (4.8) 17.3 (5.8) 17 (5.4)
Median (25th, 75th centile) 16 (13, 20) 17 (13, 21) 17 (13, 20)
Min., max. 4, 28 4, 28 4, 28
POEM completed by, n (%)
Parent/guardian 128 (85) 122 (82) 250 (83)
Child 23 (15) 27 (18) 50 (17)
Max., maximum; min., minimum.
a Scores range between 0 and 72, with higher scores indicating more severe AE (assesses AE on the day).
b Scores range between 0 and 9, with higher scores indicating more severe AE (assesses AE on the day).
c Scores range between 0 and 15, with higher scores indicating more severe AE (assesses AE over the previous 12 months).
d Scores range between 0 and 28, with higher scores indicating more severe AE (assesses AE in the last week).
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TABLE 6 Medication used for AE in the month prior to randomisation
Medication usage
Standard care (N= 151),
n (%)
Intervention (N= 149),
n (%)
Total (N= 300),
n (%)
Used emollient within the last month 150 (99) 146 (98) 296 (99)
Consistency of main emollient
Light 13 (9) 6 (4) 19 (6)
Creamy 53 (35) 57 (38) 110 (37)
Greasy 20 (13) 21 (14) 41 (14)
Very greasy 64 (42) 62 (42) 126 (42)
Topical steroid used within the last
month
136 (90) 130 (87) 266 (89)
Potency of main steroid
Mild 40 (26) 34 (23) 74 (25)
Moderate 43 (28) 40 (27) 83 (28)
Potent 51 (34) 53 (36) 104 (35)
Very potent 2 (1) 3 (2) 5 (2)
Calcineurin inhibitors used within
the last month
14 (9) 15 (10) 29 (10)
Strength of main calcineurin inhibitor
Mild 9 (6) 8 (5) 17 (6)
Moderate 4 (3) 4 (3) 8 (3)
Strong 1 (1) 3 (2) 4 (1)
Use of wet/dry wraps in the past month
No 138 (91) 135 (91) 273 (91)
Yes 13 (9) 14 (9) 27 (9)
RESULTS: CLINICAL FINDINGS
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TABLE 7 Quality-of-life measures at baseline
Quality-of-life measure Standard care (N= 151) Intervention (N= 149) Total (N= 300)
DFIa
Mean (SD) 12.0 (6.3) 12.4 (6.6) 12.2 (6.4)
Median (25th, 75th centile) 11 (7, 15) 12 (7, 16) 11 (7, 16)
Min., max. 0, 29 0, 30 0, 30
Health state from EQ-5D-3L for parentb,c
Mean (SD) 79.5 (17.5) 77.3 (18.2) 78.4 (17.9)
Median (25th, 75th centile) 80 (72, 90) 80 (70, 90) 80 (70, 90)
Min., max. 8, 100 8, 100 8, 100
Utility from EQ-5D-3L for parentb,d
Mean (SD) 0.8983 (0.1612) 0.9018 (0.1710) 0.9 (0.1658)
Median (25th, 75th centile) 1 (0.812, 1) 1 (0.812, 1) 1 (0.812, 1)
Min., max. –0.016, 1 0.101, 1 –0.016, 1
n 151 147 298
CHU-9Db,e
Mean (SD) 0.8292 (0.1263) 0.8386 (0.1115) 0.8341 (0.1184)
Median (25th, 75th centile) 0.849 (0.7853, 0.9058) 0.8561 (0.7524, 0.92) 0.8503 (0.7637, 0.9189)
Min., max. 0.4661, 1 0.5584, 1 0.4661, 1
n 64 70 134
Completed by (n)
Parent/guardian 17 23 40
Child 47 47 94
ADQoLf
Mean (SD) 0.6952 (0.13) 0.6883 (0.1409) 0.6918 (0.1354)
Median (25th, 75th centile) 0.744 (0.648, 0.768) 0.744 (0.634, 0.768) 0.744 (0.648, 0.768)
Min., max. 0.356, 0.841 0.356, 0.841 0.356, 0.841
n 151 149 300
Completed by [n (%)]
Parent/guardian 104 (69) 102 (68) 206 (69)
Child 47 (31) 47 (32) 94 (31)
Max., maximum; min., minimum.
a Assesses the impact of the child’s skin condition on family life over the previous week and ranges between 0 and 30,
with higher scores indicating greater impact of the child’s skin condition on family life.
b Questions are asked about feelings/abilities on the day of the baseline clinic visit.
c Score ranges between 0 and 100, with higher scores indicating better health on the day.
d Score ranges between –0.56 and 1, with higher scores indicating better quality of life.
e Only completed for children aged ≥ 5 years (65 children in standard care and 72 in the intervention group were aged
≥ 5 years at baseline). Utility scores range between 0.32 and 1, with higher scores indicating better quality of life.
f Scores range between 0.36 and 0.84, with higher scores indicating better health states.
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Adherence to intervention
All participants in the intervention group were sent the silk garments, on average, 1 day after
randomisation. One participant allocated to the standard care group was sent the silk garments in error,
but was included in the analysis according to randomised allocation (see Figure 4).
Adherence in wearing the garments was high: 102 out of 124 (82%) participants wore the clothes for
≥ 50% of the time (see Table 9). The garments were worn more often at night than during the day
(median 81% of nights and 34% days) (Table 9 and Figure 7). The mean number of times that the
garments were worn remained fairly constant throughout the study period (see Figure 7). Adherence to
wearing the garments was not associated with age or eczema severity at baseline (correlation coefficients
0.003 to 0.20; Table 10). Sensitivity analyses for adherence according to questionnaire completion are
shown in Table 9.
Contamination
Only six participants in the standard care group reported wearing silk clothing during the 6-month
study period.
TABLE 8 Genetic study participation for participants of white ethnicity
Genotype status
Standard care (N= 123),
n (%)
Intervention (N= 114),
n (%)
Total (N= 237),
n (%)
Informed consent provided for genetic study
No 6 (5) 5 (4) 11 (5)
Yes 117 (95) 109 (96) 226 (95)
If yes, saliva sample collected
Noa 1 (1) 5 (4) 6 (3)
Yes 116 (94) 104 (91) 220 (93)
Result obtainable on FLG mutation from sampleb
No 1 (1) 1 (1) 2 (1)
Yes 115 (93) 102 (89) 217 (92)
Sample not received by Dundee 0 (0) 1 (1) 1 (0.4)
Result not obtainable for each mutation tested
R501X 0 0 0
2282del4 1 0 1
R2447X 1 1 2
S3247X 1 0 1
3702delG 9 15 24
3673delC 9 15 24
FLG genotype (using mutations R501X, 2282del4, R2447X and S3247X)
No mutations 72 (59) 71 (62) 143 (60)
One FLG null mutation 31 (25) 20 (18) 51 (22)
Two FLG null mutations 12 (10) 11 (10) 23 (10)
Not known 8 (7) 12 (11) 20 (8)
a Reasons saliva sample not collected despite informed consent having been given: child too distressed, child declined,
parents changed their minds, participant did not attend any follow-up visits, and consent withdrawn from RCT for
two participants.
b Based on the mutations R501X, 2282del4, R2447X and S3247X. The rare mutations 3702delG and 3673delC were not
used for the purposes of the subgroup analysis.
RESULTS: CLINICAL FINDINGS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
24
TABLE 9 Adherence with trial garments in the intervention groupa
Adherence
Main analysis
(participants with
≥ 12 questionnaires
completed) (N= 124)
Sensitivity
analysis 1b,c
(N= 149)
Sensitivity
analysis 2b,d
(N= 149)
Proportion of nights that garments were worn for at least
some of the night, median (25th, 75th centile)
80.7 (56.8, 95.9) 74.4 (52.1, 94.8) 61.5 (32.9, 87)
Percentage of days that clothing was worn for at least
some of the day, median (25th, 75th centile)
34.1 (9.8, 75.9) 28.6 (3.7, 74.3) 19.3 (2.5, 63.4)
Adherence to wearing trial garments, n (%)
Adherente 102 (82) 117 (79) 87 (58)
Worn for at least 50% of days and 50% of nights 50 (40) 54 (36) 45 (30)
Worn for at least 50% of days only – 1 (1) –
Worn for at least 50% of nights only 52 (42) 62 (42) 42 (28)
Not adherent (wore clothing for < 50% of the time) 22 (18) 32 (21) 62 (42)
a Adherence to wearing trial garments summarised from week 2 onwards.
b Both sensitivity analyses include all participants in the interventon group regardless of the number of questionnaires
completed and assumes that participants never wore the garments if they did not complete any questionnaires about
how often they wore the garments (five participants).
c Sensitivity analysis 1: assuming garments worn for the same proportion of time when the questionnaire was not
completed as when the questionnaires were returned.
d Sensitivity analysis 2: assuming garments not worn when the questionnaire was not completed.
e Participants were defined as adherent with trial garments if they were worn for at least 50% of the days or at least 50%
of the nights.
Notes
Bold signifies the total numbers for adherent and non-adherent rows (with further breakdown of adherence).
Note that two participants completed 12 or more questionnaires, but completed information about the clothing wear on
fewer than 12 questionnaires.
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FIGURE 7 Mean number of days/nights trial garments worn each week.
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Durability of the garments
Information about the number of garments and replacement garments sent out by the co-ordinating
centre during the trial is presented in Chapter 4. This section presents information reported by parents on
the 6-month questionnaire about the condition of the trial garments. Just over half of parents reported
that at least one garment (top or leggings) could no longer be worn (Table 11). Children aged 4 years
or under were more likely than older children to require replacement garments, as they outgrew the
garments over the 6-month study period. Just over one-third of responders at 6 months reported that
garments could no longer be worn as they had worn out or torn.
Acceptability of use of silk clothing
At 6 months, 85 out of 121 (70%) participants reported being satisfied or very satisfied with the garments
(95% CI 61% to 78%) and 89 out of 121 (74%) participants were either happy or very happy to wear the
garments (95% CI 64% to 81%).
Blinding
Blinding appeared to be successful. Research nurses remained blinded to treatment allocation for 289 out
of 300 (96%) participants. Unblinding occurred for three participants in the standard care group and eight
participants in the intervention group. This unblinding was first reported at 2 months for one participant in
the standard care group and seven participants in the intervention group and at the 4-month visit for all
other participants.
Unblinding mainly occurred as a result of the child or parents saying that they had or had not received the
garments. Unblinding occurred for two participants because they wore the garments to the assessment visit.
TABLE 10 Spearman correlation coefficients between percentage of days/nights that clothing worn with age and
baseline eczema severity
Variable
Percentage of days that clothing was
worn for at least some of the day
(n= 124)
Percentage of nights that clothing was
worn for at least some of the night
(n= 124)
Age 0.003 0.20
Baseline EASI score –0.03 0.03
Baseline POEM score 0.08 0.13
Spearman correlation coefficients range between –1 (perfect negative correlation) and 1 (perfect postive correlation).
Correlation coefficient of 0 indicates no correlation.
TABLE 11 Parent-reported condition of trial garments at 6 months
Condition of garments at 6 months
Age (years)
1–4
(N= 63)
5–11
(N= 51)
12–15
(N= 7)
Intervention
(N= 121)
At least one garment no longer able to be worn at 6 months, n/N (%) 41/61 (67) 18/46 (39) 1/5 (20) 60/112 (54)
Reasons that garments can no longer be worn, n
Too small 22 6 0 28
Worn out/torn 26 14 1 41
Lost 3 2 0 5
Other 6 2 0 8
RESULTS: CLINICAL FINDINGS
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Primary outcome: Eczema Area and Severity Index
Primary analysis
Mean AE severity based on EASI scores improved in both groups during the 6-month follow-up period;
however, there was no clinically important difference between the groups in the nurse-assessed EASI
scores (Table 12 and Figure 8). Averaged over the 2-, 4- and 6-month follow-up visits, the ratio of
geometric mean EASI scores was 0.95 (95% CI 0.85 to 1.07; p = 0.43). This CI is equivalent to a difference
of approximately 1.5-point improvement to 0.5 points worse for the intervention group, compared with
the standard care group in the original EASI scale units.
TABLE 12 Primary outcome: EASI scores
Allocated group Baseline 2 months 4 months 6 months
Adjusted ratio of
geometric means
(95% CI); p-value
Standard care
n 151 137 133 139
Median 7.3 5.3 4.3 4.2
25th, 75th centile 4.2, 12 2.5, 10.5 2.1, 10 2, 9.2
Geometric mean 8.4 6.6 6.0 5.4
Intervention
n 149 139 135 133 0.95 (0.85 to 1.07); 0.43a
Median 7 4.9 4.1 4
25th, 75th centile 4.1, 15.4 2.2, 9.9 2.2, 9.4 1.9, 7.9
Geometric mean 9.2 6.4 5.8 5.4
a This CI is approximately equivalent to a difference of –1.5 to 0.5 in the original EASI scale units.
EASI score was log-transformed and analysed using a multilevel model adjusting for baseline EASI score and the
stratification variables age and site as covariates. A total of 282 participants were included in the analysis model (n = 141
each group).
EASI scores range between 0 and 72, with higher scores indicating more severe AE.
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FIGURE 8 Primary outcome: geometric mean EASI scores with 95% CIs.
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Arithmetic means of the EASI scores and log-transformed EASI scores for each group and time point are
given in Appendix 14 (see Table 52).
Sensitivity analyses for the primary outcome
Sex, history of food allergy and history of asthma were added as covariates into the analysis model
because of baseline imbalance. This estimate of the ratio of the geometric mean was the same as for the
primary analysis (0.95, 95% CI 0.85 to 1.07).
Multiple imputation of missing EASI data, assuming that scores were missing at random, gave a very
similar result to the primary analysis (Table 13). When it was assumed that missing scores were
systematically worse in the standard care group, the 95% CI for the geometric mean was equivalent to
scores of 2 points lower to 0.1 points higher for the intervention group than for the standard care group.
Further exploratory analysis of the EASI scores for areas covered by the garments (body and limbs) and
areas uncovered by the garments (head and neck) can be found in Appendix 16.
Causal effect of adherence with wearing trial garments on primary outcome
The CACE was estimated using the EASI scores at 6 months for participants who completed 12 or more
questionnaires (standard care, n = 127; intervention, n = 124). Table 14 presents the CACE estimate based
on a binary definition of adherence of wearing the trial garments for at least 50% of the days or 50% of
the nights and the CACE estimate for each additional 10% of the time the garments were worn. The
intention-to-treat estimate for participants included in the CACE analysis is also presented using the EASI
scores at 6 months for comparison (analysis according to randomised group).
The intention-to-treat and CACE estimate based on wearing the garments for at least 50% of the days or
50% of the nights are similar (see Table 14) as a result of 82% of intervention participants satisfying this
definition (see Table 9). The ratio of geometric means for all comparisons is greater than 1, favouring
the standard care group. The CACE estimate for each additional 10% of time that garments were worn
suggests that eczema severity (EASI scores) did not improve with greater amounts of garment wear.
A further summary table using all data at 6 months is shown in Appendix 17.
TABLE 13 Sensitivity analysis for the primary outcome using multiple imputation for missing data
Sensitivity assumptions
Adjusted ratio of geometric
means (95% CI)
Assuming that missing EASI scores are MAR 0.93 (0.83 to 1.05)
Assuming missing EASI scores are missing not at random
Favouring intervention group
Assuming that missing EASI scores are 3 points higher (worse) than under MAR in the
standard care group and assuming MAR in intervention group
0.89 (0.80 to 1.01)
Favouring standard care group
Assuming that missing EASI scores are 3 points higher than under MAR in the
intervention group and assuming MAR in standard care group
0.97 (0.86 to 1.09)
MAR, missing at random.
Multiple imputation using chained equations. The imptuation model included age, site, sex, POEM scores at the clinic visits,
whether or not there had been a treatment escalation during the study and mean POEM score from the weekly
questionnaires (as well as number of questionnaires included). A total of 20 data sets were imputed and estimates from the
multilevel model of the log-transformed EASI score adjusting for baseline EASI score and the stratification variables age and
site as covariates were combined using Rubin’s rules. A total of 300 participants were included.
RESULTS: CLINICAL FINDINGS
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Subgroup analysis for primary outcome according to FLG status
Eczema Area and Severity Index scores according to group and FLG status (none, one or two FLG null
mutations) for participants of white ethnicity are shown in Table 15 and Figure 9. Participants with FLG
gene mutations were no more likely to benefit from the silk clothing than participants without a mutation
(p-value for interaction effect 0.47).
Post hoc subgroup analysis for primary outcome according to baseline
eczema severity
Eczema Area and Severity Index scores according to group and baseline eczema severity (almost clear or
mild EASI scores and moderate or severe EASI scores)44 are shown in Table 16. There was no evidence that
the clothing was more or less effective depending on the severity of eczema at baseline.
TABLE 14 Causal effect of adherence in wearing trial garments on eczema severity (EASI)
Estimate n
Adjusted ratio of geometric
means (95% CI)
ITT at 6 monthsa 243 1.026 (0.87 to 1.21)
CACE: binary – garments worn for at least 50% of days or 50% of the nightsb 243 1.031 (0.85 to 1.25)
CACE: each additional 10% of time garments wornb,c 243 1.004 (0.977 to 1.032)
ITT, intention to treat.
a Analysed using linear regression with log-transformed EASI score at 6 months as the outcome variable, and adjusted for
randomisation stratification variables and baseline EASI score.
b Analysed using instrumental variable regression.
c Percentage of time worn calculated as (total number of days and nights clothing worn × 100)/(total number of
questionnaires completed × 14).
Analysis includes participants with EASI assessed at 6-month follow-up and completing 12 or more questionnaires.
TABLE 15 Subgroup analysis for primary EASI outcome of eczema severity according to FLG genotype
(none, one or two FLG null mutations) for participants of white European ethnicity
Subgroup and allocated group Baseline 2 months 4 months 6 months
Adjusted
subgroup-
specific ratio
of geometric
means
(95% CI)a
Adjusted
interaction
effectb
(95% CI)a
FLG wild type: no mutations (+/+)
Standard care
n 72 67 65 69
Median (25th, 75th centile) 6.2
(3.9, 10.7)
4.5
(2.4, 9.0)
3.2
(2.1, 9.9)
3.3
(1.8, 6.8)
Geometric mean 7.7 6.1 5.5 4.8
Intervention
n 71 67 67 67
Median (25th, 75th centile) 5.4
(3.3, 13.8)
4.3
(2.1, 10.3)
3.8
(2.2, 8.4)
4.0
(2.3, 9.9)
Geometric mean 8.1 6.4 5.7 6.1
Analysis 1.04
(0.89 to 1.21)
continued
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TABLE 15 Subgroup analysis for primary EASI outcome of eczema severity according to FLG genotype
(none, one or two FLG null mutations) for participants of white European ethnicity (continued )
Subgroup and allocated group Baseline 2 months 4 months 6 months
Adjusted
subgroup-
specific ratio
of geometric
means
(95% CI)a
Adjusted
interaction
effectb
(95% CI)a
One FLG null mutation (+/–)
Standard care
n 31 28 27 29
Median (25th, 75th centile) 8.0
(3.8, 12.0)
5.3
(2.9, 11.4)
4.6
(2.7, 8.6)
4.4
(1.6, 10.7)
Geometric mean 8.5 7.1 6.5 5.4
Intervention
n 20 19 19 19
Median (25th, 75th centile) 8.7
(5.0, 15.7)
6.1
(3.0, 8.4)
4.4
(2.2, 9.5)
4.0
(1.9, 8.0)
Geometric mean 10.1 6.9 5.5 5.2
Analysis 0.87
(0.67 to 1.14)
0.84
(0.61 to 1.15)
Two FLG null mutations (–/–)
Standard care
n 12 11 12 12
Median (25th, 75th centile) 17.9
(7.7, 23.4)
10.7
(3.8, 23.6)
10.8
(3.6, 16.1)
9.9
(4.1, 14.3)
Geometric mean 13.7 10.3 9.3 9.9
Intervention
n 11 11 9 9
Median (25th, 75th centile) 12.4
(8.6, 16.6)
6.6
(5.4, 16.8)
9.3
(5.3, 23.4)
7.4
(2.6, 16.5)
Geometric mean 13.0 8.9 10.2 7.8
Analysis 0.89
(0.60 to 1.30)
0.85
(0.56 to 1.29)
a Ratio of geometric means and the interaction effect adjusted for baseline EASI score and the stratification variables age
and site as covariates.
b Ratio of geometric means for intervention vs. standard care in individuals with one of two FLG null mutations compared
with ratio of geometric means for intervention vs. standard care for FLG wild-type genotype. A total of 209 participants
were included in the analysis model (110 participants in standard care and 99 participants in the intervention); p-value
for interaction effect = 0.47.
We also compared the FLG wildtype genotype with the combined group having one or two FLG null mutations in a further
exploratory analysis: the interaction effect for any mutation compared with no mutation was 0.85 (95% CI 0.65 to 1.11;
p= 0.24).
RESULTS: CLINICAL FINDINGS
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FIGURE 9 Geometric mean EASI scores by group and FLG status. FLG +/+ denotes no mutations; FLG +/– denotes
one FLG null mutation; and FLG –/– denotes two FLG null mutations.
TABLE 16 Subgroup analysis for primary EASI outcome of eczema severity scores according to EASI eczema severity
at baseline
Subgroup and allocated
group Baseline 2 months 4 months 6 months
Adjusted
subgroup-specific
ratio of geometric
means (95% CI)
Almost clear/mild baseline EASI scores (1 to 7)
Standard care
n 73 66 65 68
Median (25th, 75th centile) 4 (2.6, 5.5) 2.9 (1.8, 4.8) 2.7 (1.5, 4) 2.3 (1.4, 4.3)
Geometric mean 4.8 4.2 3.7 3.5
Intervention
n 75 72 72 70 0.95 (0.81 to 1.12)
Median (25th, 75th centile) 4.1 (2.8, 5.5) 2.8 (1.6, 4.3) 2.7 (1.6, 4.3) 2.5 (1.2, 4.2)
Geometric mean 4.9 3.8 3.7 3.7
Moderate/severe baseline EASI scores (7.1–50)
Standard care
n 78 71 68 71
Median (25th, 75th centile) 12 (8.8, 18.8) 9.2 (5.2, 15.8) 9.4 (4.7, 16.4) 7.7 (4.1, 12.3)
Geometric mean 14.2 10.0 9.5 8.2
Intervention
n 74 67 63 63 0.95 (0.81 to 1.12)
Median (25th, 75th centile) 15.4 (10, 23.1) 9.6 (5.6, 19.6) 8 (4, 17.3) 6.9 (3.9, 13.8)
Geometric mean 17.3 11.3 9.5 8.3
Note
Ratio of geometric means and the interaction effect adjusted for baseline EASI score and the stratification variables age and
site as covariates.
A total of 282 participants were included in the analysis model (n = 141 each group).
Coefficient from multilevel model from interaction term between baseline EASI (log-transformed and continuous) and
treatment group: 0.0827 (95% CI –0.0801 to 0.2454); back-transformed 1.086 (95% CI 0.923 to 1.278; p = 0.32).
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Secondary outcomes
Global assessment of atopic eczema
The proportion of participants with a nurse-assessed IGA of AE of moderate severity or worse decreased in
both groups during the follow-up period, but there was no difference between the two groups: relative
risk 0.98 (95% CI 0.82 to 1.12; p = 0.63; Table 17).
In contrast, for the participant-rated IGA, fewer participants rated their AE as moderately severe or worse in
the intervention group than standard care: relative risk 0.83 (95% CI 0.70 to 0.98; p = 0.03; see Table 17).
Self-reported atopic eczema symptoms using the Patient Oriented Eczema Measure
Mean weekly POEM scores by group are shown in Figure 10. The mean of the participants’ mean weekly
POEM scores over the 6-month study was 2.8 points lower in the intervention group than in the standard
care group (95% CI –3.9 to –1.8; p < 0.001; Table 18). There was a more obvious separation of the
groups in the first 3 months of the trial than in the final 3 months.
Three-Item Severity scale
The mean TIS scores improved in both groups during the follow-up period. No between-group differences
were observed: difference in means 0.09 (95% CI –0.22 to 0.40; p = 0.57; Table 19).
Use of atopic eczema treatments
The percentage of days during the study that emollients, topical corticosteroids, calcineurin inhibitors and
wet/dry wraps were used is shown in Table 20.
The mean percentage of topical corticosteroid use was slightly less in the intervention group than the
standard care group, equivalent to using topical corticosteroids on 6 days fewer over the 24 weeks
(95% CI equivalent to using steroids for between 16 days fewer and 4 days more). The mean frequency of
usage was similar in the two groups for the other topical treatments. Details of the amount of topical
corticosteroid prescribed over the 6-month trial are summarised in Chapter 4, Table 30.
The potency of participants’ main topical corticosteroid was similar in the two groups at 6 months
(Figure 11).
TABLE 17 Global assessment of moderate, severe or very severe AE
Outcome and
allocated group
Baseline,
n/N (%)
2 months,
n/N (%)
4 months,
n/N (%)
6 months,
n/N (%)
Adjusted risk
difference
(95% CI);
p-value
Adjusted
relative risk
(95% CI);
p-value
IGA
Standard care 108/151 (72) 72/137 (53) 63/133 (47) 56/139 (40) –0.1%
(–9.3% to 6.3%);
0.70
0.98
(0.82 to 1.12);
0.63Intervention 108/149 (72) 71/139 (51) 60/136 (44) 58/134 (43)
PGA
Standard care 113/151 (75) 82/137 (60) 72/133 (54) 60/139 (43) –10.1%
(–18.3% to –2.0%);
0.01
0.83
(0.70 to 0.98);
0.03Intervention 98/149 (66) 62/139 (45) 56/135 (41) 51/134 (38)
Note
A total of 283 participants were included in the analysis models for both IGA and PGA (standard care, n= 141;
intervention, n= 142).
Risk difference and relative risk for IGA adjusted for age and baseline IGA of moderate, severe or very severe eczema
(binary). The model for IGA did not converge when recruiting site was included.
Risk difference and relative risk for PGA adjusted for stratification variables site and age and baseline PGA of moderate,
severe or very severe eczema.
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FIGURE 10 Mean weekly patient reported symptoms (POEM scores) with 95% CI. Baseline POEM scores (16.6 standard
care; 17.3 intervention): data not shown on graph as scores were collected in clinic rather than by online questionnaire.
TABLE 18 Participant mean of weekly POEM scores
POEM scores
Standard care
(n= 147), mean (SD)
Intervention
(n= 145), mean (SD)
Adjusted difference in
means (95% CI); p-value
POEM score at baseline clinic visit 16.6 (4.8) 17.3 (5.8)
Participant mean of weekly POEM score
during the 6-month RCT
14.2 (5.5) 11.6 (5.6) –2.8 (–3.9 to –1.8);
< 0.001
Note
Shows data for participants who completed at least one questionnaire.
Summary statistics and analysis reported are weighted according to the number of questionnaires completed. POEM scores
range between 0 and 28, with higher scores indicating more severe AE. Difference in means adjusted for baseline POEM
score (collected in clinic) and stratification variables, age and site.
Summary statistics for the POEM for each group and week are given in Appendix 15 (see Table 54).
TABLE 19 Three-Item Severity scale scores
Allocated group Baseline 2 months 4 months 6 months
Adjusted difference in
means (95% CI); p-value
Standard care
n 151 137 133 139
Mean (SD) 4.9 (1.8) 4 (1.9) 4.1 (2.2) 3.7 (1.9)
Intervention
n 149 139 136 134 0.09 (–0.22 to 0.40); 0.57
Mean (SD) 4.9 (1.8) 4.1 (2) 4.1 (2.1) 3.7 (2)
Note
A total of 283 participants were included in the analysis model (standard care, n= 141; intervention, n= 142). Difference in
means adjusted for baseline TIS score and the stratification variables age and site as covariates. TIS scores range between 0
and 9, with higher scores indicating more severe AE.
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Changes in AE treatments during the trial are shown in Table 21. There were no differences between
the groups in the percentage of participants who escalated their AE treatment between baseline and
6 months, although participants in the standard care group were more likely to have escalated treatment
within the first 2 months of the study.
Health-related quality of life
Health-related quality-of-life outcomes for the DFI, EQ-5D-3L, ADQoL and CHU-9D are shown in Table 22.
There were no differences between any of these quality-of-life outcomes between the two groups. The
difference in means were all close to 0 and favoured the intervention group for DFI, EQ-5D-3L and ADQoL,
and favoured the standard care group for CHU-9D.
TABLE 20 Frequency of AE treatments
Frequency of medication use
Standard care (n= 147),
mean (SD)
Intervention (n= 145),
mean (SD)
Adjusted difference in
means (95% CI); p-value
Percentage of days topical steroids
used
44.1 (28.2) 39.3 (27.8) –3.7 (–9.6 to 2.3); 0.23
Percentage of days emollients used 88.4 (20.1) 86.0 (22.1)
Percentage of days calcineurin
inhibitors used
5.8 (15.9) 5.7 (16.3)
Percentage of days wet/dry wraps
used
5.2 (17.1) 3.1 (12.5)
Note
Shows data for participants who completed at least one questionnaire.
Summary statistics and analyses reported are weighted according to the number of questionnaires completed.
Difference in means for percentage of days topical steroids used adjusted for topical steroid use at baseline (yes/no)
and stratification variables age and site.
Between-group analysis not performed for percentage of day’s emollient used as assumptions for model not met as most
participants were using these most of the time. Similarly, assumptions were not met for the analysis for the percentage of
day’s calcineurin inhibitors used and wet/dry wraps used because of the large number of participants that were not using
these treatments.
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FIGURE 11 Potency of main steroid at baseline and follow-up.
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Safety outcomes
The number of participants reporting a skin infection was similar in the two groups (Table 23).
Four participants in the intervention group and two in the standard care group had a hospital inpatient
stay because of AE. The two hospital inpatient stays required by one participant in the intervention group
were classified as potentially related to trial treatment by the medical monitor.
Open follow-up period
The questionnaire at 8 months was completed by 111 participants (74%) in the standard care group and
116 participants (78%) in the intervention group.
The frequency with which the clothing was worn during the open follow-up period (when all participants
received the garments) is shown in Table 24. Just under half of the responders reported that the garments
were worn for all or most of the time for the days and/or nights between 6 and 8 months.
TABLE 21 Atopic eczema treatment changes between clinic visits
Change in medication use
Standard
care (N= 151),
n (%)
Intervention
(N= 149),
n (%)
Adjusted risk difference
(95% CI); p-value
Adjusted relative risk
(95% CI); p-value
Between baseline and 2 months
Treatment escalation 34 (25) 15 (11)
Neutral change 18 (13) 13 (9)
No change 81 (59) 105 (76)
Treatment reduction 4 (3) 6 (4)
n 137 139
Between 2 and 4 months
Treatment escalation 16 (12) 16 (12)
Neutral change 17 (13) 8 (6)
No change 96 (72) 107 (79)
Treatment reduction 4 (3) 5 (4)
n 133 136
Between 4 and 6 months
Treatment escalation 16 (12) 16 (12)
Neutral change 10 (7) 15 (11)
No change 105 (76) 93 (69)
Treatment reduction 8 (6) 10 (7)
n 139 134
Any treatment escalation
between baseline and
6 monthsa
50 (36) 42 (30) –5.3% (–16.3% to 5.7%);
0.34
0.87 (0.62 to 1.22);
0.43
a Based on 140 participants in the standard care group and 138 in the intervention group. Participants who missed visits
were included if they had an escalation at any of the visits they attended or if they attended the 6-month visit and there
was neutral or no change, or a reduction in treatment. Risk difference and relative risk adjusted for stratification
variables age and site.
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Overall, 135 out of 227 participants (59%, 95% CI 53% to 66%) were satisfied or very satisfied with the
clothing at 8 months, and 139 out of 227 participants (61%, 95% CI 54% to 68%) were happy or very
happy to wear the clothing.
Opinions of trial clothing at 8 months are shown in Table 24. Just over one-third of respondents thought
that their/their child’s AE had improved as a result of wearing the trial garments, with a similar proportion
responding that they were not sure. Just under half of respondents would ask their general practitioner
(GP) to prescribe the garments. Only 14 responders had asked their GP to prescribe the clothing and six
responders reported purchasing silk clothing during the trial.
TABLE 22 Quality-of-life outcomes
Quality-of-life outcome and
allocated group Baseline 6 months
Adjusted difference in means
(95% CI); p-value
DFI
Standard care –0.8 (–2.1 to 0.4); 0.18
n 151 138
Mean (SD) 12.0 (6.3) 8.6 (6.8)
Intervention
n 149 133
Mean (SD) 12.4 (6.6) 7.6 (6.1)
ADQoL
Standard care 0.0260 (–0.0018 to 0.0539); 0.07
n 151 139
Mean (SD) 0.6952 (0.1300) 0.7292 (0.1308)
Intervention
n 149 134
Mean (SD) 0.6883 (0.1409) 0.7515 (0.1273)
CHU-9D (aged ≥ 5 years only)
Standard care –0.0243 (–0.0584 to 0.0098); 0.16
n 64 67
Mean (SD) 0.8292 (0.1263) 0.8828 (0.1059)
Intervention
n 70 65
Mean (SD) 0.8386 (0.1115) 0.8677 (0.1114)
EQ-5D-3L index for parents health-related quality of life
Standard care 0.0115 (–0.0185 to 0.0415); 0.45
n 151 138
Mean (SD) 0.8983 (0.1612) 0.9107 (0.1529)
Intervention
n 147 134
Mean (SD) 0.9018 (0.1710) 0.9184 (0.1564)
Note
Ranges for quality-of-life-life scores: DFI (0–30, with higher scores indicating greater impact of the child’s skin condition on
family life); ADQoL (0.356–0.841, with higher scores indicating better quality of life); CHU-9D (0.33–1, with higher scores
indicating better quality of life); EQ-5D-3L (–0.594 to 1, with higher scores indicating better quality of life).
Difference in means adjusted for stratification variables age and site, and baseline score.
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Change in POEM scores and topical treatment usage between 6 and 8 months is shown in Table 25 for
the standard care group and in Table 26 for the intervention group. POEM scores decreased slightly in the
standard care group (who had been sent the silk garments at 6 months) between 6 and 8 months. POEM
scores were similar at 8 months to the scores at 6 months for the intervention group. Topical treatment
usage at 8 months was similar to that at 6 months in both groups.
Tertiary outcomes
Brand of garments
Figure 12 shows the numbers of participants randomised to the two brands of clothing. Garments were
required during a DreamSkin out-of-stock period for 19 participants randomised to the intervention
group (eight randomised to DermaSilk and 11 to DreamSkin) and 26 participants at 6 months who were
allocated to the standard care group (nine randomised to DermaSilk and 17 to DreamSkin). These
participants are not included in the analysis according to brand of clothing.
The EASI scores during the 6-month RCT were similar according to garment brand (Figure 13). There was
no differential effect of the garments according to brand (ratio of geometric means for DermaSilk vs.
DreamSkin was 0.98, 95% CI 0.83 to 1.16). Adherence, satisfaction and the child being happy to wear
the clothing were all similar at 6 months regardless of brand (Table 27). Further comparisons of the brands
using data from the 8-month questionnaires can be found in Appendix 18.
TABLE 23 Safety outcomes: skin infections and inpatient stays because of AE
Safety outcomes
Standard care
(n= 141)
Intervention
(n= 142)
Adjusted relative risk
(95% CI); p-value
Any skin infection during 6-month RCT, n (%)a,b 39 (28) 36 (25) 0.89 (0.54 to 1.47); 0.66
Number of skin infections per participant
Median (25th, 75th centile) 1 (1, 2) 1 (1, 2)
Min., max. 1, 5 1, 8
n 39 36
Number of inpatient stays per participant because
of AE, n (%)a,c
0 139 (99) 138 (97)
1 1 (1) 2 (1)
2 1 (1) 2 (1)
≥ 3 0 0
Total number of nights in hospital because of AE
Mean (SD) 2.5 (2.1) 2.8 (1.7)
Median (25th, 75th centile) 2.5 (1, 4) 2.5 (1.5, 4)
Min., max. 1, 4 1, 5
n 2 4
Max., maximum; min., minimum.
a Percentages for any skin infection and inpatient stay use the number of participants attending at least one follow-up visit
as the denominator.
b Skin infections are reported by the parent/main carer and are defined as any skin infections that required treatment with
antivirals or antibiotics. Relative risk adjusted for stratification variables age and site.
c Inpatient hospital stays for AE (for any reason) are reported by the parent/main carer.
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TABLE 24 Frequency of wear and opinion of trial clothing at 8 months
Qualitative feedback
Standard care
(N= 111), n (%)
Intervention
(N= 116), n (%)
Total
(N= 227), n (%)
Frequency clothing worn during the follow-up period (6–8 months)
Never 8 (7) 17 (15) 25 (11)
Rarely 20 (18) 18 (16) 38 (17)
Some of the time 26 (23) 27 (23) 53 (23)
All/most of the time (days only) 3 (3) 2 (2) 5 (2)
All/most of the time (nights only) 42 (38) 25 (22) 67 (30)
All/most of the time (days and nights) 7 (6) 24 (21) 31 (14)
Not answered 5 (5) 3 (3) 8 (4)
Feel that AE improved because of trial clothing
Yesa 25 (23) 57 (49) 82 (36)
No 28 (25) 27 (23) 55 (24)
Not sure 49 (44) 28 (24) 77 (34)
Not answered 9 (8) 4 (3) 13 (6)
Would ask GP to prescribe clothing
Yesb 48 (43) 61 (53) 109 (48)
No 32 (29) 31 (27) 63 (28)
Not sure 22 (20) 20 (17) 42 (19)
Not answered 9 (8) 4 (3) 13 (6)
Have asked GP to prescribe clothing
Yes 5 (5) 9 (8) 14 (6)
No 94 (85) 103 (89) 197 (87)
Not answered 12 (11) 4 (3) 16 (7)
GP prescribed clothing
Yes 3 5 8
No 2 4 6
Reason GP did not prescribe clothingc
Too expensive 1 4 5
No evidence of efficacy 1 4 5
Not available in postcode 1 – 1
Bought silk clothing for AE during the study
Yes 3 3 6
GP, general practitioner.
a 95% CI 29% to 43%.
b 95% CI 41% to 55%.
c Reasons not mutually exclusive.
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TABLE 25 Patient Oriented Eczema Measure and topical treatment usage at 6 and 8 months in the standard
care group
Outcomes
6 months
8 months
(N= 111)
Change from
6 months
(N= 105) 95% CI
All participants
(N= 121)
Completed
questionnaire at
8 months (N= 105)
POEM
Mean (SD) 13.2 (6.7) 13.2 (6.5) 11.8 (7.4) –1.6 (6.5) –2.8 to –0.4
n 120 104 111 104
Number of days emollients used in previous week
Mean (SD) 6 (1.9) 5.9 (1.9) 6 (2) 0 (1.7) –0.4 to 0.3
n 119 104 111 104
Number of days topical corticosteroids used in previous week
Mean (SD) 2.9 (2.6) 2.9 (2.6) 3 (2.6) 0 (2.1) –0.4 to 0.4
n 118 103 110 103
Topical calcineurin inhibitors
used in previous week, n/N (%)
10/117 (9) 8/103 (8) 7/109 (6)
Topical wet/dry wraps used in
previous week, n/N (%)
10/117 (9) 9/102 (9) 8/108 (7)
TABLE 26 Patient Oriented Eczema Measure and topical treatment usage at 6 and 8 months in the intervention group
Outcomes
6 months
8 months
(N= 116)
Change from
6 months
(N= 112) 95% CI
All participants
(N= 121)
Completed
questionnaire at
8 months (N= 112)
POEM
Mean (SD) 11.3 (7.2) 11.5 (7.2) 11.1 (6.8) –0.4 (4.6) –1.2 to 0.5
n 121 112 114 110
Number of days emollients used in previous week
Mean (SD) 6.2 (1.9) 6.3 (1.6) 6.2 (1.8) 0 (1.7) –0.4 to 0.3
n 120 111 111 106
Number of days topical corticosteroids used in previous week
Mean (SD) 3 (2.5) 3 (2.6) 2.8 (2.4) –0.2 (2.4) –0.7 to 0.2
n 120 111 112 107
Topical calcineurin inhibitors
used in previous week, n/N (%)
14/119 (12) 13/110 (12) 12/108 (11)
Topical wet/dry wraps used in
previous week, n/N (%)
7/119 (6) 7/110 (6) 8/108 (7)
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FIGURE 13 Geometric mean EASI scores by brand of garment.
TABLE 27 Adherence and acceptability by brand of clothing
Feedback on clothing DermaSilk DreamSkin
Adherencea
≥ 12 weekly questionnaires completed on clothing wear (n) 56 54
Percentage of nights that clothing was worn for at least some of the night,
median (25th, 75th centile)
80.7 (60.8, 93.9) 73.4 (50.7, 95.7)
Percentage of days that clothing was worn for at least some of the day, median
(25th, 75th centile)
29.8 (8.7, 74.8) 31.6 (6.8, 70.2)
Adherence to wearing trial clothing, n (%)
Not adherent 9 (16) 12 (22)
Adherentb 47 (84) 42 (78)
Worn for at least 50% of days and nights 21 (38) 18 (33)
Worn for at least 50% of days only – –
Worn for at least 50% of nights only 26 (46) 24 (44)
Acceptabilityc
6-month questionnaire completed (n) 54 52
Satisfied/very satisfied with the clothing overall, n (%) 41 (76) 32 (62)
Child happy/very happy to wear clothing, n (%) 43 (80) 35 (67)
a Adherence to wearing trial clothing summarised from week 2 onwards, and summarised provided that at least 12 of the
weekly questionnaires were completed from week 2 (i.e. half).
b Participants were defined as adherent with trial garments if they were worn for at least 50% of the days or at least 50%
of the nights.
c Percentage use of the number of participants with the 6-month questionnaire completed as the denominator.
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Chapter 4 Health economic evaluation
Introduction
Childhood eczema has been shown to have an impact on health-related quality of life similar to that of other
common childhood conditions, such as asthma and diabetes.3 Eczema also has a substantial cost impact on
society and the individual families affected; for example, the total annual UK cost of eczema in children aged
≤ 5 years is estimated to be £70.6M (or £120.19 per child) (inflated from 1996 to 2015 price year),45 of
which 64% was accounted for by NHS health-care costs.46 A further UK study looking at patients of all ages
estimated the total annual cost of eczema for the UK to be in the order of £726.7M, of which £195.3M
was incurred by the NHS, £464.1M by the patients and £67.2M by society in terms of lost working days
(inflated from 1995 to 2015 price year;45 original price year not reported but most likely to be 1995).47
Core eczema treatment involves the regular use of emollients and topical corticosteroid creams. Children
with more severe eczema may also need to occasionally use topical antibiotics, oral antibiotics, wet wraps,
oral antihistamines, systemic immunosuppressive agents (such as ciclosporin or methotrexate) and special
dietary products.5
Silk therapeutic garments have been available as a prescription on the NHS since 2008. In that year the net
cost of silk garments in the UK was £168.779 for 5507 items.48–51 Since this time, the cost of prescribing silk
garments has risen to ≥ £2M for 81,797 prescription items (for all indications) (Figure 14). Silk garments are
also available for private purchase by any individual who has the means and willingness to pay for them.
At the time this research was commissioned, there were only two companies supplying silk garments to the
UK NHS (DermaSilk and DreamSkin). In 2012, a third company (SkinniesTM, Dermacea Ltd, Stourbridge, UK)
had products prescribed via the NHS. In 2015, the net ingredient cost (per quantity) of a set of silk garments
to the NHS varied from £66.02 for a DreamSkin bodysuit and leggings for a child aged 12–18 months to
£155.47 for a DermaSilk top and bottom set (size: adult, small). As the qualitative work (see Chapter 5)
undertaken alongside the trial reveals, commissioners thought that the garments were expensive and were
uncertain about how many garments would need to be prescribed owing to a lack of knowledge about the
quality and lifespan of the garments. For such items to be cost-effective for the NHS, they need to have
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FIGURE 14 Net cost of silk garments prescribed in the UK (2008–15).
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clinical benefit that is either sufficiently large to justify the cost of the garments [i.e. have an incremental
cost-effectiveness ratio (ICER) that is below the cost-effectiveness threshold] and/or lead to cost savings to
the NHS via potential reduced consultations with health professionals or reduced prescriptions of other
medications for eczema.
Prior to this trial, there was no scientific evidence about the cost-effectiveness of silk garments for the
treatment of moderate to severe eczema. As a result, the national health-care system in the UK has been
prescribing something for which there is not a strong evidence base demonstrating either clinical effectiveness
or cost-effectiveness. One of the aims of the economic component of this trial was to assess if silk garments
for eczema represent value for money for the NHS and, thus, whether or not the NHS should be funding
this intervention.
This chapter presents the economic evaluation, which was conducted alongside the trial as planned in the
original research in order to estimate the mean incremental cost and mean quality-adjusted life-year (QALY)
change (per patient) with silk garments and standard care, compared with standard care without silk
garments.
Methods
Aims and perspective
The aim of the economic evaluation was to estimate the within-trial cost-effectiveness of silk therapeutic
clothing plus standard care compared with standard care alone from a NHS perspective in the base case,
and from a NHS and wider (family and employer) perspective in secondary analyses. Personal Social
Services costs were not explicitly asked about, as the clinical team felt that these were unlikely to be
relevant to those with childhood eczema.
Two forms of economic evaluation were used, cost–utility analysis and cost-effectiveness analysis, in order
to enable comparisons with non-eczema interventions and other eczema interventions, respectively.
The economic evaluation adhered to published and well-accepted guidelines for the economic evaluation
of health-care interventions, as appropriate.52–54
Resource use: identification, measurement and valuation
The range of resource use and costs captured was in keeping with the chosen perspective. Three categories
of resource use were identified as important to capture. These were intervention resource use, other health
resource use and wider family/employer costs. All resources were costed at 2014/15 price year levels in UK
pounds sterling.
Intervention resource use (silk garments)
Intervention resource use was measured during the trial using an inventory that recorded number, type and
size of garments issued to and returned by participants. At baseline each participant was issued with the
equivalent of three sets of pyjamas (tops and leggings) or leggings and a bodysuit for younger children.
Garments were removed from their original packaging and repackaged in trial packaging. The inventory in
some cases recorded tops and bottoms as individual items when in reality we expect that they had actually
come from a single pyjama set, which would be cheaper than the two items separately. In valuing the
resources, the base case thereby assumed that all those issued between the ages of 3 and 12 years
(the age range within which a pyjama set is available) were from a pyjama set as this is what is most likely
to be prescribed in routine care.
Some garments were returned to be exchanged for a different size. Where one of these sets had been tried
on for size, these could not re-enter stock and had to be disposed of (as would be the case if the NHS
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prescribed them and they did not fit); these items were included in the cost. However, if items were
returned unused such that they could be sent to another participant, this was recorded and these items
were not included in the cost, to avoid double counting. Some participants needed replacement garments
during the 6-month trial period because of a child’s growth or wear and tear. The issuing of such garments
was recorded in the inventory and included in the intervention cost. In valuing the silk garments, the cost
was not annuitised to take account of a lifespan longer than 6 months as data collected within the trial
suggest that a lifespan of 6 months for the garments is a reasonable assumption to make.
In the base case, the silk garments were valued using the net ingredient cost per quantity from the Prescription
Cost Analysis 2015 published by the Health and Social Care information Centre.55 However, this is not the only
method available for costing prescriptions. In the sensitivity analysis, an alternative approach based on the NHS
Business Services Authority actual cost formula (obtained from the NHS Business Services Authority website)
was used.56 The actual cost is based on the net ingredient cost minus the national average discount percentage
(where the average discount was 7.43% based on March 2015 data) plus payment for consumables,
containers and a professional fee (although in the case of silk garments, payments for consumables and
containers are not incurred).57
In the trial the silk garments were posted to participants, but this does not reflect how the garments are
distributed in the NHS, where patients would collect their prescription from a pharmacy. As a result we did
not include the cost of posting silk garments in the trial.
Other health resource use
Health resource use beyond the intervention cost was recorded by the participant or a parent on the weekly
diary card and recorded by the research nurse at each of the study visits (baseline, 2, 4 and 6 months). To aid
memory, an online questionnaire prompted participants to complete their diary if a health-care professional
was visited, or a prescription issued, for eczema in the last week. Participants were asked to record only
those resources consumed as a result of the child’s eczema; all items reported by parents were included. This
included health-care visits to primary care professionals (number of appointments to GP and practice nurse),
secondary care visits (number of outpatient visits, nights in inpatient care, and accident and emergency) and
prescriptions [including topical corticosteroids, topical calcineurin inhibitors, emollients (including bath
emollients), wet/dry wraps, antibiotics/antivirals for skin infections and other eczema-related prescriptions].
These resource items were valued using published national sources of unit costs in UK pounds sterling for the
2014/15 price year.55,58,59 The individual items of resource use and their unit cost can be seen in Table 28.
Primary care resource use items were valued using the published Personal Social Services Research Unit health
and social care unit costs.58 The unit cost for GPs assumed that the per patient contact lasted 12 minutes for
a face-to-face appointment and 7 minutes for a telephone consultation, including direct care staff cost
and qualification cost. The practice nurse visit assumed a face-to-face contact lasted 16 minutes. NHS
homeopathic appointments were assumed to have taken place in primary care. Consultations with a
pharmacist were assumed to have lasted 20 minutes and the unit cost of a community pharmacist was
assumed to have been the same as that of a hospital pharmacist. The cost of a nutritionist or dietitian
appointment was taken from the NHS reference costs59 for community health services dietitian.
Unit costs for secondary care resource use items were largely sourced from the NHS reference costs for
2015.59 Short inpatient stays (one night) were assumed to be for skin disorders without interventions, with a
Complications and Comorbidities (CC) score of 0–1; medium stays (three nights) were assumed to be for
skin disorders without interventions, with a CC score of 2–5; and longer stays (four nights) were assumed
to be for skin disorders without interventions, with a CC score of 6–9. Patch tests were assumed to
be standard patch tests for children aged ≤ 12 years. Accident and emergency visits were assumed to be
non-admitted, with category 2 investigation and category 3 treatment. The unit cost per consultation with a
consultant eczema nurse was assumed to be the same as for ‘other specialist nursing, child, face to face’
(currency code N29CF) under community health services.59
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TABLE 28 Unit costs in 2014/15 UK pounds sterling
Resource item Unit cost (£) Source
Intervention: silk therapeutic garments
Base case: prescription cost analysis approach (per set) 66.02–155.49 HSCIC55
Sensitivity analysis: tariff approach (per set) 62.83–145.02 NHSBSA57
Primary health care
GP (per surgery consultation) 37.00 PSSRU58
GP (per telephone consultation) 22.00 PSSRU58
GP (per consultation out of hours) 68.91 PSSRU58
Practice nurse (per consultation) 12.14 PSSRU58
Community eczema nurse (per consultation) 38.00 PSSRU58
Community nurse (per consultation) 38.00 PSSRU58
Pharmacist (per contact) 14.67 PSSRU58
Health visitor (per contact) 54.00 PSSRU58
Nutritionist (per telephone contact) 82.66 DH59
Homeopathic visit 57.00 a
Blood test (per test) 9.07 DH59
Influenza vaccination (per vaccine and nurse time) 30.14 HSCIC55/PSSRU58
Secondary health care
A&E (per visit) 93.00 PSSRU58
Outpatient first visit (dermatology, per consultation) 128.40 DH59
Consultant eczema nurse (per consultation) 161.03 DH59
Eczema nurse (per telephone contact) 42.57 DH59
Paediatric assessment 299.51 DH59
Inpatient stay for skin disorder without intervention (one night) 1185.48 DH59
Inpatient stay for skin disorder without intervention (three nights) 1756.10 DH59
Inpatient stay for skin disorder without intervention (four nights) 2267.63 DH59
Patch test (per test) 91.81 DH59
Medications
Various Various HSCIC55
Wider family/employer costs
Gross mean hourly wage for all employee jobs in UK 15.27 Annual Survey of
Hours and Earnings60
Out-of-pocket costs Various As reported by
parents
A&E, accident and emergency; DH, Department of Health; HSCIC, Health and Social Care Information Centre;
PSSRU, Personal Social Services Research Unit.
a Estimate based on the range of values provided on: www.nhs.uk/Conditions/Homeopathy/Pages/Introduction.aspx.
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Wider family/employer costs
The resource items recorded in this category reflect a more societal perspective. They include the additional
out-of-pocket costs incurred by the family and productivity costs to employers of time taken off work as a
result of parents’ caring for their child with eczema.
Out-of-pocket costs incurred by the family
In our previous NIHR HTA-funded eczema trial,61 only 33% of families taking part in the trial reported any
out-of-pocket costs incurred as a result of their child’s eczema. The rate of reporting seemed low and,
therefore, to try and improve reporting of such costs, in this trial we undertook to further develop the
question eliciting this information. We informed this development by using the out-of-pocket data we did
manage to collect in the Softened Water Eczema Trial (SWET). We categorised the types of out-of-pocket
costs reported and developed a table of examples to help families understand the types of things that may
be relevant. The range of items included over-the-counter purchases, special clothing, laundry and bedding,
special foods, equipment and travel costs for appointments.
The information provided and the wording of the question eliciting this information can be seen in
Appendix 10. Respondents were asked to place a monetary value on the additional cost incurred as a
result of eczema. For instance, if they bought a more expensive washing detergent because it was ‘skin
kind’, they were asked to state the amount over and above that which they would have paid for a normal
washing detergent.
Productivity costs
In addition, families were asked to record time off work and school as a result of eczema. Parents’ time off
work was valued using the mean gross hourly wage rate for all employee jobs in the UK, as reported in
the Annual Survey of Hours and Earnings in 2015, because we did not ask respondents to report their
personal earnings.60 This approach is known as the ‘human capital approach’ and assumes that a person’s
productivity is equal to their wage rate to place a maximum cost on their time off work. This is not the only
available approach to costing lost productivity and research has shown that different approaches can lead
to different estimates that may impact on the conclusion reached about cost-effectiveness;62 we therefore
also report the actual time lost. Time taken off school as a result of eczema is reported in hours and minutes
and is not valued in monetary terms because of the lack of evidence about the cost of lost schooling.
Measurement of outcomes and quality-adjusted life-years
The main economic analysis is the cost–utility analysis, whereby effectiveness is measured in terms of
QALYs for the child. This will be presented as the base case because it enables decision-makers to compare
the value for money afforded by this intervention with that for other conditions. It also enables us to
clearly differentiate the results of the cost–utility analysis based on the ADQoL from the other cost–utility
analyses based on the CHU-9D and the parental EQ-5D-3L.
In the base-case analysis, utility was measured in all children using the disease-specific ADQoL.38 The
ADQoL consists of four binary choice questions,38 in answer to which respondents were asked to indicate
whether they agreed more with the statement on the left or on the right:
1. you cannot join in some activities with other children/you are not limited in joining in activities with
other children
2. you are very moody/you are not very moody
3. you cannot be comforted/you are quite settled
4. you sleep badly most nights/generally, you sleep very well.
The ADQoL was completed by parental proxy for children aged < 7 years and by self-report in those aged
≥ 7 years. The developer of the ADQoL used standard gamble methods to estimate utility values for the
16 health states described by the instrument. This involved asking adult participants to imagine that they
were 10 years old and would be in the health state described for the rest of their life. The utility values
generated ranged from 0.356 to 0.841.38
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The primary measure of effectiveness for the cost-effectiveness analysis was the difference in the proportions
achieving treatment success at 6 months – defined as those with at least a 50% improvement compared
with baseline on the primary outcome measure, EASI.31 Secondary analysis was conducted using continuous
data from the DFI, where scores range from 0 (no impact on family life, best score) to 30 (maximum impact
on family score, worst score).36
In addition, the main carer was asked to record their own utility using the EQ-5D-3L in order to see if
the intervention impacted on parental quality of life (e.g. through sleep loss). The EQ-5D-3L is a generic
preference-based health-related quality-of-life instrument with five dimensions, each of which has three
levels.37 The UK tariff was valued using time trade-off methods with a sample of the general adult population.
Utility values on the EQ-5D-3L range from –0.594 to 1.63 As there is no guidance to the best method for
analysing adult utility data in combination with data on the child’s utility,64 we present a cost per QALY for
the child as the base case and a cost per QALY per carer in secondary analyses, such that we do not combine
the two sets of utility in a single analysis. It should be noted that the cost per QALY analysis for the main carer
excludes any QALYs gained by the child with eczema and also probably underestimates the impact on the
wider family in cases where a child with eczema lives with more than one adult, and in cases where they
have siblings.
All utility instruments were measured at baseline and 6 months, and used to estimate QALYs for the trial
period by using linear interpolation and area under the curve with and without baseline adjustment,65
and adjustment by centre and age. The total area under the curve (without baseline adjustment) was
measured as:
(utility_baseline + utility_ follow-up)/2 × 0:5 (1)
to reflect the 6-month time frame. The primary cost–utility analysis reports the incremental cost per QALY
based on the ADQoL because children of all ages, or their main carer, were asked to complete this
instrument. Secondary analyses will report the cost per QALY based on the main carer’s EQ-5D-3L values
separately. Previous work has not explored the ability of the EQ-5D-3L to detect impacts on carers’ quality
of life for this condition.
Statistical analysis and analysis of uncertainty
Neither costs nor benefits were discounted,53 reflecting the 6-month time horizon of the analysis.
A complete-case analysis approach was undertaken, with participants included only if they had complete
cost and effect data at each time point.
In line with the statistical analyses, the primary analysis was conducted using the principles of intention to
treat: all participants with data at baseline and follow-up were included, regardless of adherence to the
allocated intervention. If > 10% of participants had missing data, then imputation of missing values was to
be conducted as a sensitivity analysis.
The economic evaluation is a ‘within-trial analysis’. This means that costs and benefits were only evaluated
for the trial follow-up period (6 months). Costs and outcomes in both arms of the study were estimated
using the methods described in Measurement of outcomes and quality-adjusted life-years. This information
on costs and benefits was used to conduct a complete-case incremental economic analysis comparing
the silk garments in addition to standard care with standard care alone. This was completed for both the
cost-effectiveness and cost–utility analyses. Conclusions are based on the estimated results. ICERs were
calculated using accepted methodology.52,53
The statistical analysis estimated both the unadjusted and adjusted estimates, where the latter controlled for
any differences in baseline characteristics (i.e. the cost regression adjusted for baseline costs, age and
recruiting centre, whereas the QALY regression adjusted for baseline utility, age and recruiting centre).
All adjusted analyses used a regression-based approach (seemingly unrelated regression equations)66 to
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estimate incremental costs and QALYs with the exception of the cost-effectiveness analysis for EASI. As EASI
was analysed as a binary variable (coded 1 for treatment success and 0 otherwise), generalised linear models,
assuming costs and effects were independent, were employed. The cost regression used the Poisson family
and identify link function, whereas the effects regression used the binomial family and identify link function.
As cost data were skewed, we used non-parametric bootstrapping to estimate adjusted mean (95% CI)
incremental cost and mean (95% CI) incremental QALY estimates. Bootstrapping was also used to estimate
cost-effectiveness acceptability curves;67,68 these show the probability that each of the intervention groups is
the most cost-effective option at different monetary valuations of the outcome variable. A range of ceiling
ratio (or willingness to pay per QALY) values were tested, including the £20,000 and £30,000 per QALY
thresholds used by NICE in cost–utility calculations.69
Sensitivity analysis tests the robustness of results in the face of any uncertainties.53 It also improves the
generalisability of results by indicating what could happen with different values of a parameter. Two areas
of uncertainty were considered worth exploring. The first was the cost of the silk therapeutic garments,
because 46% of total costs from a NHS perspective were accounted for by the cost of the silk garments in
the study. Instead of using the Health and Social Care Information Centre Prescription Cost Analysis net
ingredient cost per item, we reran the analysis using unit costs for silk garments based on the NHS
Business Services Authority actual cost formula to estimate the actual cost to the NHS:56
actual cost = (net ingredient cost less the discount) + payment for consumables
+ out-of-pocket expenses:
(2)
In particular, this approach takes account of the average discount enjoyed by the NHS when purchasing
prescription items. As payment for consumables and out-of-pocket expenses is not relevant for silk garments,
we did not include these but did include the 90p fee pharmacists receive for dispensing. We did not do this
for all prescription items as medication costs were not significantly different between the two treatment arms.
Second, as there is uncertainty about how best to capture utility in children, we included a second generic
preference-based instrument, the CHU-9D,39 at baseline and 6 months in order to compare the results with
those gained using the disease-specific ADQoL.38 The generic health-related quality-of-life instrument,
CHU-9D,39 was used only in children aged ≥ 5 years at baseline. The CHU-9D consists of nine dimensions
(worry, sadness, pain, tired, annoyed, school work/homework, sleep, daily routine, ability to join in activities)
using a recall period of today or last night, dependent on the question; each dimension has five levels.39
The wording of the dimensions and levels resulted from qualitative work with children and young people.
It can be self-completed by children and young people aged 7–17 years with a proxy version for parents to
complete for children aged < 7 years. At the time the CLOTHES trial was designed, the CHU-9D had not
been used with the under-fives and so we did not use it with those aged < 5 years. Additional guidance
now exists to help parental proxies complete the CHU-9D for this age range (personal communication
with K Stevens, University of Sheffield, 2014). The CHU-9D was valued by the UK general adult population
using standard gamble methods and utility using this instrument can range between 0.33 and 1.39 In this
study, the CHU-9D was self-completed by children and young people aged ≥ 7 years and parental proxy
completed for 5- and 6-year-olds. QALYs for the trial period based on the CHU-9D were estimated using
the same methods described for estimating QALYs based on the ADQoL and main carer EQ-5D-3L
(see Measurement of outcomes and quality-adjusted life-years).
Some of the subgroup and sensitivity analyses included in the original health economic analysis plan
(see Appendix 19) were not conducted for the following reasons:
l imputation of missing values, as missing values were < 10%
l per-protocol analysis adjusting for adherence; sensitivity analyses in Chapter 3, Causal effect of
adherence with wearing trial garments on primary outcome showed no evidence of a causal effect of
adherence with wearing trial garments on the primary outcome.
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l subgroup analysis based on impairment in skin barrier function (FLG genotype), as subgroup analysis of
the primary outcome suggested no differential effect
l resource use data collected in the observational period (6–8 months) were not included, as there was
no overall effect at 6 months.
All statistical analysis was undertaken in Stata 14.
Results
The base-case cost–utility analysis included all participants with complete resource use and ADQoL data at
baseline and 6 months (n = 273: 134 in the silk garment plus standard care arm and 139 in standard care
alone arm). Of the total 300 study participants, 27 (9%) were not included in the base-case economic
evaluation because they had discontinued the study or had data missing. In the base case, 58.2% of
participants were male and 80.2% were white, and the average age was 5 years.
Baseline health-care costs for eczema over the preceding 4 weeks were £35.60 (SD £69.46) per participant
in the silk garment arm and £34.82 (SD £69.14) in the standard care arm (mean difference £0.78, 95% CI
–£15.74 to £17.30).
Baseline utility of the child participants (as measured using the ADQoL) was a mean of 0.6879 (SD 0.1418)
per participant in the silk garment arm and 0.6959 (0.1288) per participant in the standard care arm
(mean difference –0.0081, 95% CI –0.0404 to 0.0241) (Table 29).
Resource use and costs
Intervention resource use and costs
In the 6-month period, the mean number of sets of garments (tops and leggings) per participant was 4.15
(minimum 3, maximum 9.5). Sixty-one (45.5%) intervention participants received replacement garments
over the 6 months [each participant received, on average, 1.1 extra sets (minimum 0, maximum 6.5)].
The associated mean cost of silk garments, including initial and replacement garments, was £318.52
(SD £136.60; minimum–maximum £198.06–£1167.15) per participant in the base case (see Table 31).
Other health resource use and costs
Resource use and costs for all resource items are given in Tables 30 and 31. When intervention use was
combined with other health resource use, the adjusted mean incremental cost per participant was £364.94
(95% CI £217.47 to £512.42) for those who received silk garments compared with those who did not in
the base case (see Table 31). The difference in total costs between groups reflects the cost of the
intervention; other NHS costs were not significantly different between groups (£48.57 higher per
participant, on average, in the intervention group, 95% CI –£105.92 to £203.05).
Productivity costs
On average, parents/carers took off 3.00 (SD 7.90) hours from paid employment in the silk garment arm
and 1.79 (SD 5.10) hours in the standard care arm (mean difference 1.21 hours, 95% CI –0.37 to 2.79
hours) as a result of taking care of their child with eczema. Employing a human capital approach, and
using a national published gross mean hourly wage rate for men and women of £15.27, resulted in mean
estimates of lost productivity of £45.78 (SD £120.61) in the silk garment arm and £27.29 (SD £77.86) in
the standard care arm (mean unadjusted difference £18.49, 95% CI –£5.61 to £42.59).
Time off school or nursery
Participants in the silk garment arm missed, on average, 4.17 (SD 10.41) hours off school or nursery as a
result of their eczema in the 6-month trial period, compared with an average of 3.57 (SD 8.15) hours in
the standard care arm (mean unadjusted difference 0.60 hours, 95% CI –1.62 to 2.82 hours).
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Out-of-pocket costs incurred by the family
Families paid out of pocket for an average of 10.66 (SD 21.75) items as a result of their child’s eczema
in the silk garment arm, compared with an average of 9.80 (SD 21.74) items in the standard care arm,
over the 6-month trial period (mean difference 0.86, 95% CI –4.33 to 6.04). On average, the additional
out-of-pocket costs incurred for these items were £65.00 (SD £166.75) in the silk garment arm and
£54.96 (SD £128.75) in the standard care arm over the 6 months (mean unadjusted difference £10.04,
95% CI –£25.38 to £45.46).
Base-case cost–utility analysis
Base-case cost–utility analysis from a NHS perspective
The adjusted mean difference in QALYs per participant was 0.0064 (95% CI –0.0004 to 0.0133) (see Table 29
for the key findings from the base-case analysis). Combined with adjusted mean cost, the adjusted mean
incremental cost per QALY was £56,811 (Figures 15 and 16; see also Table 29), suggesting that silk garments
for moderate to severe eczema are not cost-effective within currently accepted thresholds. At a willingness to
pay of £30,000 per QALY, the probability of silk garments being cost-effective was 12.13%.
TABLE 29 Key findings from the base-case economic evaluation (UK £ 2014/15)
Outcome
Intervention
(n= 134), mean (SD)
Standard care
(n= 139), mean (SD) Mean difference (95% CI)a
Health outcomes
Utility (ADQoL)
Baseline 0.6879 (0.1418) 0.6959 (0.1288) –0.0081 (–0.0404 to 0.0241)
6 months 0.7515 (0.1273) 0.7292 (0.1308) 0.0224 (–0.0084 to 0.0531)
QALYs
> 6 months 0.3598 (0.0561) 0.3563 (0.0562) 0.0036 (–0.0098 to 0.0169);
0.0064 (–0.0004 to 0.0133)
Costs
Garments 318.52 (136.60) 0.00 (0.00) 318.52 (295.71 to 341.33)
Primary care visits 36.52 (57.74) 47.01 (73.71) –10.49 (–26.30 to 5.33)
Secondary care visits 213.09 (604.47) 153.00 (327.13) 60.09 (–55.16 to 175.34)
Prescriptions 119.82 (244.67) 120.86 (243.81) –1.04 (–105.92 to 203.05)
Total health-care costs (excluding
garments)
369.43 (805.88) 320.86 (446.13) 48.57 (–105.92 to 203.05)
Total health-care costs (including
garments)
687.96 (809.27) 320.86 (446.13) 367.09 (212.12 to 522.07);
364.94 (217.47 to 512.42)
Patient additional out-of-pocket costs 65.00 (166.75) 54.96 (128.75) 10.04 (–25.38 to 45.46)
Productivity costs 45.78 (120.61) 27.29 (77.86) 18.49 (–5.61 to 42.59)
Total costs (NHS, patient and employer) 798.73 (970.99) 403.11 (524.10) 395.62 (210.60 to 580.64);
392.98 (216.44 to 569.53)
NHSBSA, NHS Business Services Authority.
a Values in bold denote adjusted mean differences and those in roman are unadjusted values.
ICER = £56,811 per QALY; ICER taking a NHS/family/employer perspective was £61,385 per QALY.
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TABLE 30 Mean (SD) resource use and mean (unadjusted) difference (95% CI) in resource use per participant
Resource use item
Intervention
(n= 134), mean (SD)
Standard care
(n= 139), mean (SD)
Mean difference
(95% CI)
Intervention
Silk therapeutic garments (number
provided over 6 months)
4.15 (1.55) 0.00 (0.00) 4.15 (3.88 to 4.41)
Primary health care
GP (per surgery consultation) 0.78 (1.08) 1.06 (1.74) –0.29 (–0.64 to 0.06)
GP (per telephone consultation) 0.01 (0.09) 0.01 (0.12) –0.007 (–0.03 to 0.02)
GP (per consultation out of hours) 0.00 (0.00) 0.01 (0.06) –0.01 (–0.02 to 0.01)
Practice nurse (per consultation) 0.13 (0.40) 0.07 (0.35) 0.06 (–0.03 to 0.15)
Community eczema nurse
(per consultation)
0.03 (0.27) 0.01 (0.08) 0.02 (–0.02 to 0.7)
Community nurse (per consultation at
home)
0.01 (0.09) 0.00 (0.00) 0.01 (–0.01 to 0.02)
Pharmacist (per contact) 0.00 (0.00) 0.01 (0.08) –0.01 (–0.02 to 0.01)
Health visitor (per contact) 0.00 (0.00) 0.01 (0.09) –0.01 (–0.3 to 0.01)
Nutritionist (per telephone contact) 0.00 (0.00) 0.01 (0.08) –0.01 (–0.02 to 0.01)
Homeopathic (per visit) 0.01 (0.17) 0.07 (0.55) –0.06 (–0.15 to 0.04)
Blood test (per test) 0.01 (0.09) 0.01 (0.17) –0.007 (–0.04 to 0.03)
Influenza vaccination 0.00 (0.00) 0.01 (0.06) –0.01 (–0.02 to 0.01)
Total number of primary care visits 0.98 (1.17) 1.28 (1.87) –0.30 (–0.68 to 0.07)
Secondary health care
A&E (per visit) 0.01 (0.17) 0.01 (0.12) 0.001 (–0.03 to 0.04)
Outpatient first visit (dermatology,
per consultation)
1.04 (1.69) 0.83 (1.50) 0.21 (–0.17 to 0.59)
Dermatology consultation
(per telephone call or e-mail contact)
0.01 (0.17) 0.01 (0.11) 0.001 (–0.03 to 0.04)
Consultant eczema nurse
(per telephone consultation)
0.00 (0.00) 0.01 (0.08) –0.01 (–0.02 to 0.01)
Eczema nurse (per telephone contact) 0.00 (0.00) 0.01 (0.08) –0.01 (–0.02 to 0.01)
Paediatric assessment unit 0.00 (0.00) 0.02 (0.19) –0.02 (–0.5 to 0.01)
Children’s ward (number of visits) 0.04 (0.36) 0.03 (0.34) 0.01 (–0.07 to 0.09)
Inpatient stay for skin disorder without
intervention
0.04 (0.27) 0.02 (0.19) 0.02 (–0.03 to 0.08)
Patch test (per test) 0.00 (0.00) 0.02 (0.25) –0.2 (–0.06 to 0.02)
Total number of secondary care visits 1.16 (2.12) 0.98 (1.65) 0.18 (–0.27 to 0.63)
Total number of health-care visits 2.13 (2.79) 2.26 (2.55) –0.12 (–0.76 to 0.51)
Medications
Prescription items (number) 12.56 (17.97) 12.60 (13.90) –0.04 (–3.86 to 3.78)
Topical corticosteroid (g) 139.03 (212.49) 169.03 (295.14) –30.00 (–91.47 to 31.47)
A&E, accident and emergency.
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TABLE 31 Mean (SD) cost and unadjusted cost difference (95% CI) per participant over the 6 months (in 2014/15 UK
pounds sterling)
Resource use item
Intervention
(n= 134), mean (SD)
Standard care
(n= 139), mean (SD)
Mean difference
(95% CI)
Intervention resource use
Silk therapeutic garments (including
replacements) (base case)
318.52 (136.60) 0.00 (0.00) 318.52 (295.71 to 341.33)
Primary health care
GP (surgery consultation) 28.72 (39.98) 39.40 (64.43) –10.68 (–23.51 to 2.15)
GP (telephone consultation) 0.16 (1.90) 0.32 (2.63) –0.15 (–0.70 to 0.40)
GP (consultation out of hours) 0.00 (0.00) 0.50 (5.84) –0.50 (–1.49 to 0.50)
Practice nurse 1.63 (4.89) 0.87 (4.30) 0.76 (–0.34 to 1.85)
Community eczema nurse 4.81 (43.89) 1.16 (13.66) 3.65 (–4.04 to 11.34)
Community nurse 0.28 (3.28) 0.00 (0.00) 0.28 (–0.26 to 0.83)
Pharmacist 0.00 (0.00) 0.11 (1.24) –0.11 (–0.32 to 0.11)
Health visitor 0.00 (0.00) 0.78 (6.45) –0.78 (–1.87 to 0.32)
Nutritionist (telephone contact) 0.00 (0.00) 0.59 (7.01) –0.59 (–1.78 to 0.60)
Homeopathic visit 0.85 (9.85) 4.10 (31.18) –3.25 (–8.80 to 2.30)
Blood test 0.07 (0.78) 0.13 (1.54) –0.06 (–0.36 to 0.23)
Influenza vaccination 0.00 (0.00) 0.22 (2.56) –0.22 (–0.65 to 0.22)
Total primary health-care costs 36.52 (57.74) 47.01 (73.71) –10.49 (–26.30 to 5.33)
Secondary health care
A&E 1.39 (16.07) 1.34 (11.12) 0.05 (–3.23 to 3.33)
Outpatients first visit (dermatology
consultation)
134.15 (217.53) 107.15 (192.82) 27.00 (–21.94 to 75.93)
Dermatologist consultant (telephone/
e-mail consultation)
0.96 (11.09) 0.92 (7.67) 0.03 (–2.23 to 2.30)
Consultant eczema nurse (telephone
consultation)
0.00 (0.00) 0.21 (2.46) –0.21 (–0.63 to 0.21)
Eczema nurse (telephone contact) 0.00 (0.00) 1.16 (13.66) –1.16 (–3.48 to 1.16)
Paediatric assessment unit 0.00 (0.00) 6.46 (56.64) –6.46 (–16.10 to 3.17)
Children’s ward (observation with no
overnight stay)
11.18 (106.49) 8.62 (101.62) 2.56 (–22.24 to 27.35)
Inpatient stay for skin disorder
without intervention
65.42 (401.7) 24.84 (216.39) 40.57 (–35.94 to 117.08)
Patch test 0.00 (0.00) 1.98 (23.36) –1.98 (–5.96 to 1.99)
Total secondary health-care costs 213.09 (604.47) 153.00 (327.13) 60.09 (–55.16 to 175.34)
Total prescription costs 119.82 (244.67) 120.86 (243.81) –1.04 (–59.25 to 57.18)
Mean total health-care costs
without silk garments
369.43 (805.88) 320.86 (446.13) 48.57 (–105.92 to 203.05)
Mean total health-care costs with
silk garments
687.96 (809.27) 320.86 (446.13) 367.09 (212.12 to 522.07)
continued
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Cost–utility analysis taking a NHS and family/employer perspective
In a separate analysis, taking a NHS and family/employer perspective, the unadjusted mean cost per patient
for the silk garment group was £798.73 (SD £970.99), compared with £403.11 (SD £524.10) in the
control group. The adjusted mean incremental cost per participant was £392.98 (95% CI £216.44 to
£569.53) for those who received silk garments compared with those who did not. The adjusted mean
difference in QALYs per participant was the same as in the previous analysis taking a NHS perspective only,
0.0064 (95% CI –0.0004 to 0.0132), such that the incremental cost per QALY taking a wider perspective
was £61,385.
Cost-effectiveness analysis
Eczema Area and Severity Index
The key results for the cost-effectiveness analysis using proportion of participants achieving a 50%
improvement on the EASI as the measure of outcome are shown in Table 32. The incremental cost per
additional person treated successfully (defined as a reduction in EASI of at least 50% compared with
baseline) was £10,425.67.
TABLE 31 Mean (SD) cost and unadjusted cost difference (95% CI) per participant over the 6 months (in 2014/15 UK
pounds sterling) (continued )
Resource use item
Intervention
(n= 134), mean (SD)
Standard care
(n= 139), mean (SD)
Mean difference
(95% CI)
Wider societal costs
Patient additional out-of-pocket costs 65.00 (166.75) 54.96 (128.75) 10.04 (–25.38 to 45.46)
Productivity costs 45.78 (120.61) 27.29 (77.86) 18.49 (–5.61 to 42.59)
Total costs (NHS, patient and
employer)
798.73 (970.99) 403.11 (524.10) 395.62 (210.60 to 580.64)
A&E, accident and emergency.
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FIGURE 15 Incremental cost-effectiveness plane for the base-case analysis (ADQoL).
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Dermatitis Family Impact
The key results for the cost-effectiveness analysis using change in the DFI instrument as the measure of
outcome are shown in Table 32. The incremental cost for every 1-point improvement on the DFI scale
was £435.46.
Cost–utility analysis for main carer EuroQoL-5 Dimensions-3 Levels
The main results for the cost–utility analysis based on main carer quality of life, as measured using the EQ-5D-3L,
are shown in Table 32. The adjusted mean incremental cost was £369.76 (95% CI £216.02 to £523.51) and
the adjusted mean incremental QALY gain was 0.0029 (95% CI –0.0045 to 0.0102) (Figure 17), giving an ICER
of £251,849 per QALY. At a willingness to pay of £30,000 per QALY, the probability of silk garments being
cost-effective was 1.31%.
Uncertainty and sensitivity analysis
Alternative source of unit costs for the silk garments
To test the impact of taking into account the average discount enjoyed by the NHS, we used an alternative
approach based on the NHS Business Services Authority formula to estimate the actual cost to the NHS.
Using the March 2015 tariff data, where the average discount was 7.43%, the consumables fee £0.0124
per prescription item, the pharmacists’ professional fee £0.90 per prescription item, the analysis was re-run
(see Table 32). This approach reduced the cost of silk garments, but at £53,989 per QALY the estimated
incremental cost per QALY was still above the accepted NICE threshold value, such that silk garments
would still not be considered to offer value for money to the NHS under this approach. At a willingness to
pay of £30,000 per QALY, the probability of silk garments being cost-effective was 10.51%.
Alternative outcome measure: Child Health Utility-9 Dimensions analysis
For the analysis using the CHU-9D instead of the ADQoL to estimate child utility scores, standard care
dominates as silk garments were both more expensive and less effective (in terms of QALYs measured
using the CHU-9D for utility) (Figure 18 and see Table 32) than standard care. The probability of silk
garments being cost-effective at a willingness-to-pay threshold of £30,000 per QALY was 0.06%.
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Discussion and conclusion
Main findings
This is the first economic evaluation of silk therapeutic garment use in children with moderate to severe
eczema. The economic analysis extends the clinical analysis to show that silk garments in addition to
standard care are unlikely to represent value for money for the NHS. In terms of the costs, the additional
costs of providing silk garments to intervention participants were not recouped through cost savings from
lower use of wider health-care resource items nor from families in terms of reduced out-of-pocket costs or
from employers in terms of reduced time off work by parents caring for their child with eczema. In terms
of outcomes (when looking at patient-assessed health-related quality of life), although the ADQoL showed
a very small, non-significant, positive benefit in terms of QALYs in favour of silk garments, this was not
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FIGURE 17 Incremental cost-effectiveness plane (main carer EQ-5D-3L).
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FIGURE 18 Incremental cost-effectiveness plane (CHU-9D).
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sufficient to outweigh the higher costs of providing silk garments. The CHU-9D showed a very small
non-significant decrease in QALYs (suggesting worse health) in the intervention arm. When coupled with
the higher costs, this suggests that silk garments do not represent value for money for the NHS. The small,
non-statistically significant, differences found when estimating QALYs (using the different instruments)
suggest that the difference between intervention and usual care groups is negligible and may have been
due to chance.
The result of this within-trial cost-effectiveness study also provides an indication of the cost of treating
moderate to severe eczema to the NHS. Over a 6-month period, health-care costs were in the region of
£345 (SD £647.40) per child (using 2014/15 costs and excluding the cost of silk garments). In addition,
the reported personal costs and time lost from work/school as a result of eczema were considerable and,
provide important data to inform studies on the societal impact of this condition.
Strengths and weaknesses
Given the clinical result, it could have been argued that an economic evaluation was unnecessary.
However, resource use and quality-of-life data were collected alongside the trial, and these results provide
useful data to inform future studies and decisions regarding health commissioning.
The study did not explicitly ask families to record how much time they spent applying treatments for their
child’s eczema. Were a treatment to be effective at reducing disease severity, it could conceivably reduce
the amount of time a parent or child spends applying/taking medications and it might be important to
capture this effect from a family perspective in future studies.
The study attempted to measure QALYs for the main carer in addition to the child. Our approach had
limitations because children may have also lived with another parent or carer in addition to siblings, and
we did not seek to capture the health-related quality-of-life effects of these extended family members.
It is unclear how best to capture the wider impacts of eczema within a family in an economic evaluation.
Further research looking at whose QALYs to capture, how to aggregate QALYs estimated for patients,
carers and siblings, and how to present such results is needed.64 However, given that this study found no
difference in effect between treatment arms, the results are unlikely to be sensitive to the assumptions
made in relation to such ‘beyond the patient’ effects.64
Conclusion
This economic evaluation shows that in children with moderate to severe eczema, silk garments do not
offer value for money to the NHS.
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Chapter 5 Nested qualitative study
The value of using mixed qualitative and quantitative research methods in trials is increasingly beingacknowledged,70 particularly when investigating complex health-related topics.71 In the CLOTHES trial
we have been mindful that the qualitative work is more than an adjunct to the main trial; it has been
used to elucidate a deep understanding of the ‘what’, ‘why’ and ‘how come’ of participants’ beliefs and
behaviours.72 This nested qualitative study was conducted by colleagues at the University of Hull, who
were not aware of the treatment allocation of the children involved. The results of this nested qualitative
study were collected and analysed separately. The results were not revealed to the rest of the trial team
until the data collection and analysis of the main trial results were complete, at which point the results of
the qualitative study were used to inform interpretation of the trial findings.
It is now widely accepted that when children are the likely end users of a product under investigation,
researchers should consult them directly, rather than depending on second-hand reports from adults.73
In this chapter we have used the term eczema rather than AE in order to reflect the language used by the
parents and children.
The purpose of the qualitative component of the CLOTHES trial was to:
1. qualitatively examine participants’ experiences of using silk garments for the treatment of eczema
2. examine barriers and motivators to prescribing silk garments from the perspectives of clinicians
and commissioners.
Specific objectives were to:
1. explore factors that might influence the use of silk garments in everyday life
2. examine parent and child views on the feasibility and acceptability of using silk garments
3. explore parent and child experiences of using silk garments
4. examine barriers and motivators to prescribing silk garments from the perspectives of clinicians
and commissioners.
This report is divided into three sections:
1. children’s focus groups and interviews
2. parent interviews and focus groups
3. clinician and commissioner interviews.
For each of the three elements, a generic qualitative research method was used.74 The research team
comprised three nurse researchers, all of whom were aware of their own potential impact on the study.
To ensure rigour, the following steps were taken: preconceived beliefs were acknowledged prior to data
collection; each researcher used a reflective log to record their own thoughts; researcher understandings
were checked with participants at the end of each episode of data collection; and analysis was conducted
independently and then as a team.
The study was approved by Nottingham Health Research Authority East Midlands – Nottingham 1 Research
Ethics Committee (13/EM/0255). Ethical guidelines on research with children were followed.75 All
participants gave written or verbal consent or assent depending on their age and on whether the data
collection was in person or over the telephone.
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Views of children in the CLOTHES trial
Data collection
Interviews and focus groups with children were completed from February 2015 to May 2015. Children
were recruited using a convenience sampling strategy76,77 via the study research nurses. They represented
all of the recruiting centres and had all completed the trial before participating. Ten semistructured,
audio-taped face-to-face or telephone interviews were conducted by the researcher (EW). The children in
the interview group ranged in age from 9 to 15 years. There were three focus groups in total, comprising
two groups of 7- and 8-year-olds, each with two participants, and a further group of 5- and 6-year-olds,
with four participants. Parents and siblings accompanied the children during data collection according to
age and personal preference. The demographic details of the children are presented in Appendix 20
(see Table 59). The researcher (EW) used a wide range of developmentally appropriate, child-friendly
techniques, such as drawing, collage, photography, storytelling, stickers and a puppet. The activities were
adapted to the needs and interests of individual children. The resources chosen were sex and ethnicity
neutral. The activities were selected with sensitivity; for example, the use of stickers and foam people
allowed children to illustrate their point without the added pressure of having to be a ‘good drawer’. Care
was taken to enable children to express their views through whatever medium they preferred. A broad
topic guide was used as a basis for interactions with the children (see Appendix 20). This was shared with
the children so that they understood what would happen next. At the end of each interview and focus
group the researcher summed up her understanding of the responses and checked with each child that
this was correct.
All data collection focused on finding out from children what it is like to have eczema, what they thought
of the silk garments and of being in the trial, and whether or not other children with eczema should be
given the garments. All interviews were audio-recorded and transcribed in full. Photographs were taken
of artefacts produced during the sessions, as most children wanted to take these home. The children
enjoyed taking photographs of what they had made and while they were doing this the researcher used
the opportunity to verify her understanding of their thoughts. This was documented alongside the
photographs in preparation for data analysis.
Data analysis
The analysis of the data required a sound understanding of children’s physical, cognitive, emotional and
social development. This contributed to ensuring that the analysis reflected the children’s voices as
faithfully as possible. Interpretation of drawings, collages and craft work was undertaken with the children
at each stage.
The data from the interviews and focus groups were analysed using the three methods of holistic, selective
and detailed data analysis of Van Manen:78 (1) data were viewed as a whole, (2) phrases or illustrations
that seemed to represent the experience under study were identified and (3) written data were reviewed
line by line in order to identify themes.79 The aim was to be attentive to the voices of children and
recognise subtle significations.80 This was achieved through prolonged and intensive engagement with the
totality of the data.
Data analysis yielded six key themes: (1) living with eczema, (2) expectations of the garments, (3) wearing
‘silks’ (a term often used by the children to describe their silk garments), (4) did they help?, (5) thoughts
about the garments and (6) being part of the study. A description and analysis of each theme, together
with supporting illustrations, is provided with a tabulation of each theme containing exemplar
data extracts.
Theme 1: living with eczema
This theme comprises two subthemes: (1) health aspects of living with eczema and (2) social and
emotional implications of living with eczema (Table 33).
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Health aspects of living with eczema
All children portrayed a negative view of living with eczema; they particularly suffered with itching, heat,
and flaking and dry skin, all in different areas of their bodies and with differing severity. A picture by an
8-year-old boy depicts how burning, red and sore the eczema on his back felt (Figure 19). Many said that
eczema affected their sleep at night and that this impacted on their daytime activities, particularly school
and play.
Social and emotional implications of eczema
Several children spoke of the emotional effect that eczema had on their lives, including frustration with the
condition and how it affected their general well-being. The children spoke of how eczema affects their
ability to fit in with their peer group and the limiting effects the condition could have; for example,
most did not like exposing their skin to others and did not enjoy sporting activities for this reason.
Theme 2: expectations of the garments
This theme has three subthemes: (1) use of other treatments, (2) garments and (3) hopes. Many participants
had preconceptions about the garments (Table 34).
TABLE 33 Views of children: theme 1 – living with eczema
Health Social and emotional
Itchy and hot, hands and feet sore. Eczema keeps me
awake at night
It makes me feel sad and grumpy
My skin on my back feels like fire, like rocket fire It’s . . . like poo. I itch all the time and it’s just not fair
It hurts a lot . . . when water touches it, it burns I beat myself up for it because like I really want to get
rid of it
You can't do as many things as you want to and even
the sports you want to do, you can't do it because it
irritates or makes it worse
People say I am ugly
FIGURE 19 Photograph showing depiction of eczema by an 8-year-old boy.
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Use of other treatments
One particularly strongly held belief was that the silk garments would mean that other treatments,
especially creams, would no longer be needed or would at least be reduced. This was also an expectation
that parents had, and so it became a shared belief, and was a significant factor for some children agreeing
to take part in the trial. Children were disappointed when this proved not to be the case. In fact, for some,
cream use actually increased when using the garments.
Garments
Children also had ideas about what the garments would be like; because the garments were silk, the
childen were expecting a soft and luxurious product, and many were surprised by the ‘roughness’ of the
material. This reinforces the need for practitioners to be mindful of children’s cognitive understanding
when ascribing labels to products. A number of children had expected the silks to be cooling, but for
many the effect was the opposite, with the garments making them hot and uncomfortable.
Hopes
Many of the children were excited to try the garments and had very high hopes that they would really help
their eczema. Others were much more cautious, having previously tried so many treatments that they
thought of as failures.
Theme 3: wearing silk garments
This theme recounts when the children chose to wear the silk garments. There are two subthemes:
(1) day versus night and (2) school versus home, leisure and play (Table 35).
Day versus night
Figure 20 is an example of how a child conveyed the times at which he wore the garments. Few children
of any age wore their silks during the day; a majority of the children preferred to wear them at night and
only when at home.
School versus home, leisure and play
Children reported not wanting peers to see the garments for fear of attracting unwelcome questions or
comments. There was a seasonal element to garment wear, particularly not wanting the garments to be
visible when wearing shorts and t-shirts in the summer. There were many issues with being able to wear
TABLE 34 Views of children: theme 2 – expectations of the garments
Use of other treatments Garments Hopes
Still have to use cream [Silks] made me feel hotter, I thought it
would make me cooler
I was a bit dubious because nothing’s
ever really worked that well for me
During the day we use
the silk suits, put the
cream on underneath
I had a lovely silk long-sleeved top and it
was really comfy to wear, very easy,
forgot you had it on, and I think that
was what I thought it would be. If it had
been pure silk and not with all of these
holes . . . that would have worked for
me but . . . it was a bit like a washing
machine bag
I had all these expectations built up . . .
I was really hopeful as well. I was really
willing to wear them to start with, and
then I got them for the start and
everything just turned negative for me
I have to put cream on
every day
If the trousers had been proper silk and
that skin-colour tights, I’d have definitely
worn them a lot longer because I think
that would have really helped me
I just put them on because I think
they’re going to help
I was a bit confused because I thought
it was meant to be really good and I
thought it was meant to be really soft . . .
I wasn’t too happy with it
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them for school, ranging from fit, uniform-requirements, physical education issues and the reactions of
other school children. Peer groups and friendships were very important for all children; only those with
very secure friendships felt that they could openly speak about their eczema and the garments.
Theme 4: did they help?
This theme has three subthemes: (1) getting better, (2) getting worse and (3) no difference but liked
them anyway. There was a real mixture of perceived success of the garments, ranging from a perceived
complete cessation of eczema to no effect at all, to worsening of symptoms (Table 36).
Getting better
Some children reported that the silks had improved their sleep, whereas others felt that the silks had made
them more comfortable in bed but had not improved their eczema per se. Improved sleep was linked with
better well-being at school and at home the following day. A few children stated that the clothing
improved their mood.
TABLE 35 Views of children: theme 3 – wearing silk garments
Day vs. night School vs. home, leisure and play
Always wear them at night I wore them to school but not PE [physical education]
days . . . people would laugh
During the day we use the silk suits, put the cream on
underneath, then put all the suits on . . . and that sort of
stops my clothes rubbing against my skin. Wearing the
tights day and night
Poor fit trousers so not worn to school/don’t fit
under tights
I prefer to wear them during the day rather than the
night because the silk is really comforting on my skin
One of the problems was that at school – because
they’re quite strict on uniform – that’s a problem
Wearing them at night because some people ask like
what’s that and it’s a bit annoying
Yes I wore them to school but it was a bit weird when
like everyone was like ‘What is that?’
I wear them mainly at night I did the upper body one once at school . . . but
everyone kept on asking about it and I just didn’t like it
I usually just wear them at home
I wouldn’t wear them at a sleepover just because I
would find that really embarrassing, because no
offence, it didn’t really look that good
FIGURE 20 Photograph showing a child’s depiction of times garments were worn.
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Getting worse
Other children were disappointed in the effect of the garments, which affected their self-esteem.
Some children suggested that it was their own fault the garments had not worked for them.
No difference but liked them anyway
Some children liked wearing the garments, even if they had no perceptible effect on their eczema. This
was predominantly because they were comfortable, although some parents reported that the garments
made their child feel special. Figure 21 shows what an 8-year-old girl thought other children should know
about what was ‘good’ and ‘bad’ about the silks. The blue-stamped areas represent where the garments
were hot and uncomfortable.
Theme 5: thoughts about the garments
This theme comprises three subthemes: (1) quality and cost, (2) fit and fabric, and (3) design and appearance
(Table 37).
TABLE 36 Views of children: theme 4 – did they help?
Getting better Getting worse No difference but liked them anyway
It made it feel better but the
crusty is still there
I stopped wearing them as soon as I
realised they were making [my] eczema
worse. It helped the cream absorb
better but it did make it all inflamed
and more itchy
It was comfy. Top and bottoms
were smooth
Better, the itch goes away It kind of got worse. It just got more
dry and really red
Feels nice on my skin
At night I got to sleep
through for the first time. It
made me feel good inside
[At] night, it wakes you up because it is
scraping at my skin and because you
have got loose bits of dead skin . . . it
catches and it rips it
They feel nice, I like wearing them.
They . . . helped me be less annoyed
It’s kind of helping the
eczema go away. Less sore
FIGURE 21 Photograph of an 8-year-old girl’s thoughts on garments.
NESTED QUALITATIVE STUDY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
64
Quality and cost
Children were remarkably aware of cost and quality issues. Many thought that the garments were quite
poor quality in fit, appearance, design or the fabric itself, especially given the cost. They were disappointed
in the shape, size and colour. The cost was an issue for further purchase for a few, with older children
(and their parents) feeling that the garments should be available on prescription from a GP.
Fit and fabric
Many felt that the sizing and fit, especially of the trousers, were poor. Children were aware that the
garments did not always wash well, turning baggy and grey, and affecting fit over time as illustrated in
Figure 22. Most children used the garments with creams, which made the silks sticky and oily, and,
in some cases, smelly. Some felt the texture was rough and actually irritated their skin more; some also felt
that the silks actually made them hotter.
TABLE 37 Views of children: theme 5 – thoughts about the garments
Quality and cost Fit and fabric Design and appearance
Looked like a trial clothing
rather than a purchase
‘Random sizing’ poor fit.
Uncomfortable – too tight
[Didn’t like] that you could see
through them
I’ve got massive holes
gaping wide
I would make them a bit tighter,
problem with the elastic, and they
bunch at the bottom
It’s not . . . that private to be wearing
something basically see-through . . .
like wearing cling film
Get hot . . . and they can tear I just found them really, really
uncomfortable. They were tight.
There wasn’t the give in them
Gap between trouser and top
untreated and elastic waistband itchy
I think the best thing about
them is that they are 100% silk
and they don’t have any
. . . elastic
Kind of transparent – needed to
wear pants under
No good for summer – long sleeves
We didn’t think they were
going to be as expensive
They look really grubby
They are not very pretty
FIGURE 22 Child’s illustration of garments over time.
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Design and appearance
The fact that the silks were see-through was an issue for many; this limited their use to the home, and
many children had to wear another layer of clothing over the silks. At night, the garments tended to be
worn under pyjamas or onesies. Issues of fit, appearance and smell compounded children’s sense of being
‘different’ from their peers. Children commented that, although three sets of garments were provided,
these did not reflect sex differences in relation to puberty nor the normal varied physical growth spurts
experienced at this time.
Children suggested a range of improvements to the garments, including using smoother and more closely
woven fabric, resembling ‘proper’ silk. Some wanted the garments to be tighter, but others preferred the
looser fit. A few thought that different colour options would be good, especially the youngest and oldest
children. In terms of design, a ‘onesie’ was seen as a positive option, as were short-sleeved tops and shorts
for summer. Others felt that additional protection for hands and feet would be beneficial, as these areas
were not covered by the trial garments (except for those aged < 2 years) and were often troublesome.
Children suggested that a few changes would make the garments more wearable in the daytime provided
that this was under normal clothing, including school uniform, in the colder winter months. All except one
participant felt that they would recommend other children to try the garments, even if they had not been
particularly successful personally. Many of the children recognised that everyone’s experience of eczema
was different and that they would respond differently to different treatments, and they seemed keen to
ensure that other children did not miss any opportunity to improve their eczema.
Theme 6: being part of the study
This theme comprised two subthemes: (1) helping others and (2) the research process (Table 38).
Helping others
Many of the children were really pleased to be taking part in the trial. Indeed, the majority of children
demonstrated a significant level of altruism, wanting to be part of the trial particularly if it would help
other children.
The research process
All children relished the opportunity to be with others with eczema and to talk about their experiences.
Many were disappointed that the data collection was a one-off event. Most enjoyed the whole research
process, and younger children valued the small gifts they received and enjoyed charting their progress.
A few of the older children reported that they would ‘give the garments another try’, having had the
opportunity to talk about them with the researcher.
Children engaged readily in the interviews and focus groups. Older children appreciated the chance to
discuss their experience of eczema and the garment trial. In addition to the activities outlined in previous
sections, all children were encouraged to feed back to the researcher throughout the process. All children
in focus groups and face-to-face interviews chose to ‘mark’ the researcher’s work in a similar way to
TABLE 38 Views of children: theme 6 – being part of the study
Helping others The research process
Happy to know I am helping everyone in the world,
who has eczema probably in the world
It felt quite good because I was doing it in a trial
It felt like I was helping the other people who had it
as well so then they got some research. It felt
quite good
[The focus group was] lots of fun it gives you a chance to
talk to others about your feelings . . . you get to do lots of
fun stuff at the end!
I didn’t mind wearing them because I knew it was for
a trial to see if it could help people with eczema
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their experience of their schoolwork being marked by a teacher. The researcher’s understanding and
performance, including whether or not she had asked all of the pertinent questions and understood their
answers, were assessed by the children ‘ticking’ the work with carefully selected coloured pens.
Children took home all their artwork and checked the final photographs for use by the researcher, which
gave them a sense of achievement and accomplishment. Children were asked how the findings of the
project would best be communicated: most advocated either posters or a website, which they felt should be
fun and incorporate activities. Figure 23 shows a dissemination poster designed in one of the focus groups.
Child participants presented a range of views about the silk garments. All had high hopes when they
entered the trial and, with few exceptions, their expectations were not realised. Some found the garments
comfortable but many did not like the look, feel and fit of them. Even those children of a relatively young
age were aware that the garments were expensive. Patterns of use varied, but most children reported
wearing the garments fairly regularly at night. Although the children tended to report a limited effect on
their skin condition, they almost universally recommended that other children should ‘give the garments
a try’, perhaps exemplifying their experience of trying different treatment options and recognition of
individual differences and needs.
Views of parents of children taking part in the CLOTHES trial
Data collection
A series of in-person focus groups and telephone interviews with the parents of children in the trial was
conducted between November 2014 and August 2015. A convenience sample of parents was recruited via
trial information leaflets and invitations, and with the support of the research nurses.76,77 All participants
had reached the end of the trial prior to participating and they represented all recruiting centres. In total,
28 mothers and five fathers participated, representing 11% of all trial participants. The age range of their
children was 2–14 years and the sex split was 19 boys and 13 girls; 17 of the children were allocated to
the standard care group and 15 were allocated to the intervention group. The demographic details are
summarised in Appendix 20 (see Table 60).
FIGURE 23 Dissemination poster designed by a child.
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The researcher (FC) conducted the semistructured focus groups and telephone interviews using a prepared
topic guide (see Appendix 20). The four focus groups had between two and four participants and lasted
between 42 and 95 minutes. Telephone interviews lasted between 18 and 50 minutes. All data were
audio-taped and transcribed verbatim.
Data analysis
Data were analysed using the five-stage Framework Analysis process.81 The five stages comprise
(1) familiarisation with the data through reading full transcripts; (2) development of a theoretical framework
through identification of recurring and important themes; (3) indexing and pilot charting; (4) summarising
data in an analytical framework; and (5) synthesising data by mapping and interpreting. In line with usual
qualitative research practice, the researcher completed a reflective account and this was used to inform the
analysis process. Stages 1–3 of the framework are illustrated in detail in Appendix 20 and stages 4 and 5 are
documented below. The analysis process yielded four key themes: (1) despair and hope, (2) fit, durability
and care, (3) perceived impact of the garments and (4) engaging in the trial. A total of 13 subthemes were
identified. A description of each theme is provided below, and this includes a tabulation of each theme and
subtheme with exemplar data extracts.
Theme 1: despair and hope
The theme concerning despair and hope comprises four subthemes: (1) treatments, (2) adjustments,
(3) quality of life and (4) hopes for the trial (Table 39).
Treatments
Participants presented differing accounts of the various treatments used through the course of their
children’s eczema. Virtually all had used emollients, often working their way through the ‘full gamut’ of
products to find one that suited their child, and topical steroids of different potencies. Smaller numbers
had been prescribed wet wraps, oral steroids, protopics, antihistamines or bleach baths, or offered
photochemotherapy. Complementary therapies and specialised clothing (non-silk) had been used by some.
Parents appeared to relish having the opportunity to have time to recount the ups and downs of their
child’s eczema treatment; for many it was a long and challenging attempt to find the best regimen. In the
focus groups there was a tangible sense of relief that their stories were typical of others. Parents tended to
minimise the use of topical steroids because of concerns about side effects and long-term impact on the
skin condition. They also described the development of ‘immunity’ to treatments, which resulted in the
need for periodic changes of medication. Faith in the medical profession was variable, with some parents
recounting excellent experiences and others less so, particularly those receiving only primary care services.
There appeared to be different approaches to treatment escalation across study sites. A small number of
parents felt the need to stop treatments for a day or two before a medical consultation to ensure that the
doctor saw the eczema at its worst and so would take the problem more seriously.
Adjustments
Adjustments to life had been made in a number of ways and to varying degrees that did not always
obviously correlate with the described disease severity. At one extreme, one parent who received Disability
Living Allowance had employed a carer to accompany her child to playgroup to apply emollients and
change his nappy every hour. This mother had prepared an individual ladder of care to guide the actions
of the carer and this had allowed the mother to continue with her own job and ensure that her child lived
as normal a life as was possible. Many parents made adjustments such as buying only cotton clothing for
their children, using natural fibre bedding, often laundered very frequently, and avoiding soft toys. Many
children had sensitivities or allergies; most of these had been medically diagnosed, but some were based
on the observations of parents. This led to modifications to lifestyle and diet that caused varying levels of
disruption; these ranged from accepted changes, such as replacing carpets with wooden flooring, to
constantly monitoring diet and living in fear of anaphylaxis. It was notable that some parents and children
had managed to adapt effectively even to seemingly major lifestyle changes. For some parents, eczema
care, more than quality of education, influenced the choice of their child’s pre-school and school.
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TABLE 39 Views of parents: theme 1 – despair and hope
Treatments Adjustments Quality of life Hopes for the trial
We’ve probably tried
every cream that can
be prescribed
We have really invested
heavily into our
property . . . we
invested quite a lot in
everything to help her
with her eczema
It’s really bad head to
toe at the moment it’s
gone mental . . . we
can’t get control of it
at all . . . it’s a bit of
a nightmare
Really I was hoping, you
know, praying that it was
going to be the answer
Medication wise he’s
used everything under
the sun literally
Limited soft toys,
changing all his
bedding, washing
his bedding at a
higher temperature
It has affected all of us,
all of our lives, totally
I would do anything for
my daughter not to have
eczema . . . I would pay
anything if it meant she
didn’t have to suffer . . . I
am desperate now, I am at
my wits’ end now . . . I’m
praying that someone
somewhere can do
something for her
She’s on a rigmarole of
steroids, protopics and
emollients and there’s a
whole bathing regime
. . . basically we’ve
never really won the
battle . . . the only thing
that ever might keep it
at bay is really strong
steroid cream and even
that stings . . . I’ve got
real issues covering her
in steroids
I wouldn’t let her go to
anyone else’s
[friend’s houses]
It doesn’t really, really
affect his life too much.
He’s just used to being
itchy and uncomfortable
Trying to look for the
miracle cure really
[Steroids] we don’t like
to use them too much
for too long they just
thin the skin
[At school] she has a
space she can go where
she can keep her
cream, she’s got a
health plan
She just wants to be
normal, she doesn’t
want to stand out in
any way
But you would love to
have the magic answer . . .
that’s why you just try
anything. You’re always
searching for answers
aren’t you
Time consuming doing
all the creams and
treatments and if she
doesn’t want to
do them
He lives with it, he just
seems to get on with it
. . . there are times
when he’s had to come
home from school,
sometimes he’ll take a
shower and go back in
again
When he was scratching
at his most he would be
red, he would be
bleeding, he would get
frustrated, but it never
stopped him doing
anything . . . I think it’s
more down to our
attitude because we
didn’t want him to stop
doing things because he
had this illness
At first we thought . . .
brilliant, brilliant, we’ve
got something, it’s kind of
what we’ve been looking
for
Hated being creamed
. . . would run away
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They generally reported that care in the early years was excellent, but provision from Year 1 upwards was
much more unpredictable; this provoked concern or even fear in some parents.
Quality of life
Eczema and the treatment required had a mixed impact on the quality of life of both children and their
families. Every parent mentioned the scourge of itch and the disruption of sleep, with a few reporting that
the whole family was disturbed by the child with eczema during the night. Listening to some parents, it
was evident that they were struggling with their perceived inability to care for their child. They reported
the challenges of applying topical medication regularly, in terms of both the child disliking application and
the time taken to apply it. Several spoke of having tried ‘everything’ and conveyed their feelings of despair
each time another treatment failed. Others appeared to feel this burden less and again this was not
necessarily related to the described disease severity. Parents of children from the age of 5 years upwards
talked about concerns regarding self-consciousness; some had deliberately encouraged their children to
simply explain their condition to others and this had generally proved to be an effective strategy.
Hopes for the trial
Parents had a range of hopes for the trial. A few had very low expectations, but many had reached a point
of desperation and were hoping for a ‘miracle cure’.
Theme 2: fit, durability and care
Participants expressed a range of views on the garments encompassing the subthemes of (1) look, fit and
feel, (2) durability and (3) laundry care. Many parents and children awaited the arrival of garments with a
sense of optimistic anticipation. Positive comments on the aesthetics of the garments were not forthcoming.
Some suggested that they would be more attractive to children if they were coloured or decorated; however,
they understood the hazards of introducing dyes to the fabric (Table 40).
Look, fit and feel
Fit was an issue for many participants. On the whole, the garments fitted reasonably well for the youngest
children. The exception to this was the styling of the neck, which was so loose on some that it slipped over
their shoulders and gave easy access for scratching; some parents resorted to partially sewing up the neck
seams. Garments for older children often bore no relation to their size or age range (despite actual height
measurements being used to guide size selection); this was rectified by provision of alternative sizes by the
trial team. There was marked uncertainty about how the garments should fit, although several parents
commented that this information was provided. A snug fit was the preference for some, as this was
viewed as an effective way to keep topical medications on the skin. Others favoured a looser fit on the
assumption that this would make the garments cooler and more comfortable to wear.
‘Soft’ was a frequently used descriptor of the garments, although some parents were surprised by the
texture as they had expected a feel more akin to normal silk. Parents who returned garments for
replacement noticed that the texture of fabric was not consistent and, although some reported that
softness was maintained over time, others suggested that the garments quite quickly became ‘crispy’ and
‘rough’. A few reported that their children found the garments scratchy and that they had a tendency to
stick to their skin.
Durability
The issue of durability was raised regularly, seemingly more so for younger children, particularly boys.
Although a few parents reported that the garments had lasted for the full 6 months of the trial, more
recounted signs of wear and tear occurring after only a few days. Specifically, the garments were prone to
the fabric pulling away from the seams, laddering and developing holes in areas of persistent scratching.
This was managed by either returning the garments for replacement or, by some, creative methods of
repair including the removal of the feet of the garments and the concoction of new garments from parts
of damaged ones.
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Laundry care
Parents adopted habits for washing the garments ranging from daily hand-washing using non-biological
products to washing them every 2–3 days in a mixed family load. It appeared that washing was not a
problem for parents who already laundered small loads separately, but it was burdensome to others and
sometimes resulted in children missing wear for brief periods. The garments’ quick drying time was universally
commended. There were reports of shrinkage after washing and some reported gradual discolouration over
time. Many parents found that three sets of garments was insufficient; this was predominantly, but not
exclusively, the case among younger children and those wearing them both day and night.
TABLE 40 Views of parents: theme 2 – fit, durability and care
Look, fit and feel Durability Laundry care
[Daughter said] they’re just
horrible . . . ugh, they’re just vile
They started off really nice . . .
might as well have been putting
dish rags on him by the end of it,
they had holes in them
Mine fell apart because I was
washing them so much
To be honest they are very
clinical looking aren’t they, they
are very basic
They start off like holes and
they’d ladder round the
edge almost
I couldn’t get the stains out
They weren’t tight enough . . .
they’re a little bit baggy . . . in
some places they were tight and
in other places, the arms and
that, were loose
Fabric’s just really . . . it just pulls
apart . . . the material just
disintegrates
[Three sets] . . . nowhere near
enough, you’re always washing
The trousers won’t stay up so
that’s why I had to do the top up
under, to keep the trousers up
I cut the feet out because of the
holes, they used to get holes in
the toes where he used to scratch
[He wore them] as often as I could . . .
unless I got behind in washing . . . it
was all the time basically
He’s quite a skinny, tall lad but
yes, they fitted quite well
They were getting trashed, you
know, little boys outside
Three sets make sense but I could
have done with a couple of extra . . .
they get muddy or the odd explosive
nappy
Actually after 6 months they still
felt as they did at the beginning
. . . they were still soft
They’ve been quite hard wearing Three garments were fine, because
he always had at least one fresh pair
at any stage . . . they didn’t
deteriorate at all
They didn’t feel right . . . they
felt twisted . . . felt really
awkward
They wore very, very quickly . . .
and in the end we had holes in
them and they were all pulled
and grey
They went from white to grubby
yellow-grey at the end of it
He thought they were really
comfortable
. . . they have shrunk quite
significantly . . . he’ll wear his
underpants over the top of it . . .
because it doesn’t stay up
I’d probably have three sets so I didn’t
have to do the washing every day
She calls it her scratchy clothes . . . they are totally worn . . . I
think they are very badly made
. . . they just tore from the seams
. . . we sewed them up and we
did everything we could to the
last set
[Washing] was a struggle . . . I would
only want her to wear them like one set
for the day and one set for the night . . .
because she shed so much skin
She didn’t find them particularly
comfortable . . . they stuck really
badly to her skin . . . it was like
putting on clothes when you
are wet
They are a funny sort of shape after
washing . . . the tops go sort wide
and the trousers were a bit shorter
Because it was silk he could feel
the coolness on his skin
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Theme 3: perceived impact of the garments
As seen in theme 2, parents had differing views on the look, feel and fit of the garments and this,
combined with their commitment to being in the trial (subtheme 2 of theme 4), influenced patterns of
usage, which forms the first subtheme of theme 3. Subsequent subthemes are the effect of the garments
and intentions regarding continued use post trial (Table 41).
TABLE 41 Views of parents: theme 3 – impact of the garments
Patterns of usage Effect of the garments Continued use post trial
He started asking for it ‘cos I think
they kept him quite cool
We noticed a difference very
quickly . . . within the first month
. . . we don’t know if that’s why it’s
cleared up or are we consciously
putting the cream on more often
So the silks have actually retired to
the drawer now . . . they are
getting a bit small and tight now I
think I just need to throw away my
love affair with them and forget
about them, which is a shame
. . . she wore them at school . . .
[friends] just asked her what they
was and she just told them
It made an immediate impact . . .
this is the first time in 8 years that
we’ve had a full nights sleep from
him and this has absolutely 100%
broken it [itch–scratch cycle], do
you know this is the thing I’ve been
waiting for, it’s brilliant . . . once we
got the silk clothing, literally, it was
like the light switched off
I wouldn’t recommend the clothes
to anyone based on my experience
. . . very, very disappointed
He was quite excited about
[wearing the garments] we told
him they were special clothes,
his ‘whites’
A little bit better but not massively
better
I’ve since bought them, I buy them
now, because they do work for us
. . . she didn’t do very well wearing
them . . . because it hurt so much
to pull them off . . . in the night
when she does her damage the
most and claws at herself then by
the morning it’s stuck to the
wounds she’s made . . . I just
thought I can’t do this, it’s not
worth getting her stressed out
trying to get the garment on
I wouldn’t say they medically helped
her and made it better, they just
make her more comfortable and
more bearable with the itching
and stuff
We were looking at buying it . . .
the cost of it! So I thought I can
afford to buy a couple of pairs . . . I
asked them to prescribe a couple of
pairs and they did
She felt embarrassed because she
said they were too see-through
I think it has contributed but it
didn’t have an instant effect . . . it’s
hard to pinpoint one thing
Would you ever consider buying
them . . . no, not worth the money,
no . . . if I could get them on
prescription I’d definitely have them
She didn’t actually like wearing
them . . . she had just come out of
hospital and she had wet wraps
. . . because they were white she
thought I was going to wet wrap
her . . . she got a bit wary of them
Well I think her skin improved, but I
have to say that I couldn’t say that
was because of the silk, but I do
think . . . I think it has helped . . . I
can’t 100% say that the clothing
had definitely cured and fixed it, I
think it has aided the whole process
If I had to pay . . . I probably
wouldn’t invest in them . . . if the
doctor would prescribe them, then
yes, I’d definitely have some
To be honest they made no
difference at all to her eczema
Yes, even if I had to pay for them I
think I would in the long run, just
for his comfort
I thought that was just too
expensive . . . I would probably say I
would not because of the cost
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Patterns of usage
Patterns of usage varied enormously, from children wearing the garments virtually 24 hours per day
throughout the trial, to the other extreme where one teenage girl could be persuaded to wear them for
one night only. Parents reported differing thoughts from children about their family and friends seeing
them in the garments; this appeared to be loosely related to developmental stage. Younger children quite
enjoyed the attention of having something different, whereas older children preferred to wear them only
at home, often covered with other clothing, partly because of their see-through nature. Most children
wore the garments each night and a smaller proportion chose to wear them in the daytime. Garment
usage is summarised in Appendix 20.
Effect of the garments
The reported effect of garments was wide ranging and not necessarily linked to frequency or consistency
of wear. A minority stated that the garments had had a significant positive impact on skin condition. The
most frequently cited benefits were comfort and coolness, sometimes leading to improved quality and
quantity of sleep and providing an effective barrier to scratching. A few were very disappointed to find
that the garments had no impact whatsoever.
Generally, those parents who reported improvements in their child’s skin condition or quality of life found
it difficult to assess whether or not this was wholly a result of garment usage. Parents often suggested
that the garments were just one element of a complex mixture of influencing factors. Other reasons for
improvement in the eczema were suggested as being the usual waxing and waning nature of eczema,
seasonal change, holidays in the sun and greater concordance with other treatments prompted by weekly
reporting for the trial.
Continued use of garments
Parents were generally equivocal about continued use of the garments after the trial. A minority stated
that they already had or definitely intended to buy further garments; for some this was because of a
tangible improvement in the skin condition, whereas for others it was predominantly for comfort. Several
parents had investigated the cost of garments and found this prohibitive, particularly because they were so
quickly damaged or outgrown. In some cases parents continued to use garments that had become very
tatty and in need of repair or were too small to the absolute end of useful life. A few parents considered
requesting the garments on prescription, but did not have high hopes of success; although one parent had
managed to obtain a GP prescription.
Theme 4: engaging in the trial
Participants were forthcoming about their engagement with the trial. This theme comprises three
subthemes: (1) experience of participation, (2) commitment to the trial and (3) important outcome
measures (Table 42).
Experience of participation
Experiences of participation in the trial were almost universally positive. Parents were complimentary about
the organisation of the process. In particular, they commented on the quality of information provided, the
ease of communication with the trial team when required and the friendliness of the research nurses. The
only minor negative was the need to return damaged or outgrown garments before new ones could be
issued, sometimes leading to a break in wear for a day or two. All found the questionnaires and diaries quick
and easy to complete, and appreciated the e-mail reminders. Several commented that the completion of the
questionnaires had been useful in prompting more regular use of usual eczema treatments. Three issues were
raised by a minority of parents. First, online questionnaires were available for only a finite time and this meant
that they were occasionally missed. Second, in some cases the worst areas of eczema were on the hands and
face, which were not covered by the clothing; parents suggested that this could lead to an unfairly negative
evaluation. Third, parents thought that they were repeating themselves each week and that this may not be
helpful. Older children sometimes completed information with parents and some parents were pleased to
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keep a personal copy of progress through the trial. Appointments were routinely made at convenient times
and several parents were particularly grateful for home visits by the research nurses. Younger children were
reported as having enjoyed being in the trial, particularly liking the sticker charts (see Appendix 8) and gifts.
One boy objected to being undressed to be examined. Parents of older children reported that they were quite
content to take part. Unsurprisingly, both parents and children allocated to the standard care group felt a
great sense of disappointment on hearing their treatment allocation.
Commitment to the trial
Commitment to the trial revealed some insights into individual beliefs about levels of participation and about
future recruitment, specifically to nested qualitative studies. All parents agreed that it was important to
complete questionnaires and diaries. However, views on wearing the trial garments varied from wholehearted
commitment to others who, not unreasonably, left the choice to their child. Parents who spoke of their
engagement in the qualitative study reported that this opportunity was revealed right at the end of the study,
TABLE 42 Views of parents: theme 4 – engaging in the trial
Experience of participation Commitment Important outcome measures
I think the way the trial was run
is fantastic . . . it was always
made very, very easy for us.
The nurses were always so lovely
with her
I was incredibly compliant to the
enth degree
How his general well-being is,
within himself
He loved getting the card . . . they
made it special, a fun thing rather
than a chore . . . he loved the fact
that when we came here he
couldn’t tell the lady
I busted a . . . because I thought if I’m
doing this I’m doing it properly . . . I
wanted it to be my magic cure
Well for me, it was just being
avoiding having to use the steroid
cream. That would be the
ultimate goal
It is good to be involved and
learn whilst the research has
actually been taking place . . . we
have really been excited to have
been part of that
She was too embarrassed to wear
them to school, so I didn’t overstress
her . . . I don’t get into battles with her
A bit calmer and not be so itchy
I was always glad of the reminder
email . . . it was good, it wasn’t
too much . . . 5 minutes
Well we sort of discussed it with him
and said look, there is really no point
in saying you are going to do the trial
if you are not going to be prepared to
wear it all the time . . . he was quite
on board with that
One hope really was for his
eczema to get better and reduce
the reliance on the steroid creams
. . . you don’t want to keep
putting toxic chemicals all over
your child do you?
We had to send them back [and
were told] we can’t send you
some more until we’ve received
the old ones back . . . and for us
they were working so well I didn’t
want him not to have them
The more we can invest in research, I
think it’s the better. And if I can help
that, then that benefits everybody
doesn’t it?
Itching and flares
It’s easier to kind of forget about
it . . . it only takes a few minutes
. . . it’s more about remembering
to fill in the form
I’m curious about this . . . I guess I’m
quite scientifically minded so I wanted
it to be a good result
How he looks
Going to the appointments was
fine. Obviously I was able to pick
times and days what suited me so
that was fine
I just felt we were trying to make a
difference so I didn’t mind . . . I
realised that in order to maybe get
better results from the study you
would need to talk to people and it is
like only a few minutes out of my time
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and that this may have been detrimental to recruitment as some parents may have considered that the trial
had already finished for them. Telephone calls from the research nurses who already had a relationship with
parents were by far the most effective method of recruiting to focus groups and interviews. Some parents
who were willing to take part struggled with the time and location of the focus groups, despite the variety of
times and places offered. Those who did participate offered two major reasons for this: (1) they tended either
to feel a sense of duty to give something back having been involved in the study or (2) they had some
knowledge or interest in research and could therefore see the value of their contribution.
Important outcome measures
Parents unexpectedly found it difficult to talk about outcome measures that were important to them.
On discussion, the most important success factors identified were comfort, improved sleep and general
well-being, and reduced itching. Reduced medication usage, specifically steroids, was important to a fair
proportion of parents. A few parents mentioned appearance and even less reduction in flares or disease
severity per se.
Overall, the 34 participants in these focus groups and interviews presented mixed views on the usefulness of
the silk garments. Many had struggled for years to effectively care for their child’s eczema and had tried an
array of treatments, both prescribed and over the counter. Only a few had tried any type of garments. Most
had very high hopes for the garments and were particularly enthusiastic about this non-pharmacological
intervention. Patterns of wear varied enormously, as did views on the fit and durability of the garments.
Many reported that the garments were of poor quality. Although a few parents reported unequivocal
success in using the garments, many more were more circumspect about their impact, suggesting that they
may have been helpful as part of a broader treatment regimen. In common with clinician and commissioners,
parents had little knowledge about the silk garments and many were dubious about whether or not they
represented value for money, particularly if they were purchased rather than prescribed.
Views of clinicians and commissioners
Data collection
Interviews with clinicians and commissioners in England were completed from June 2014 to January 2015.
A purposive76,77 sample of participants was recruited via advertisements on health professional and
dermatology websites, and snowballing. This approach yielded a range of dermatology specialist and
primary care generalist participants from across the country. Some had dual roles, for example GP and
commissioner, so they have been categorised by their stated primary role, and included dermatology
specialist nurses (n = 9), dermatologists (n = 4), GPs (n = 3), pharmacists (n = 3) and health-care
commissioners (n = 2). All clinicians had a minimum of 5 years’ experience of caring for people with
eczema. Demographic information about the 21 participants is summarised in Appendix 20 (see Table 63).
Semistructured telephone interviews using an interview guide (see Appendix 20) were conducted by the
researcher (FC) lasting from 9 to 24 minutes. Interviews were audio-recorded and transcribed verbatim.
Data analysis
Data were analysed using the five-stage Framework Analysis process, described in Data analysis, and the
researcher’s reflective account was used to inform the analysis process. Stages 1–3 of the framework are
illustrated in detail in Appendix 20 and stages 4 and 5 are documented below. The analysis process yielded
four key themes: (1) knowledge base, (2) reasons to use silk garments, (3) reasons for not using silk
garments and (4) outcome measures. A total of 14 subthemes were identified. A description and analysis
of each theme is provided below, and this includes a tabulation of each theme and subtheme with
exemplar data extracts.
DOI: 10.3310/hta21160 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 16
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Thomas et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
75
Findings
Theme 1: knowledge base
The theme concerning knowledge base comprises three subthemes: (1) lack of evidence base, (2) information
from manufacturers and (3) treatment protocols. Participants presented differing views on the level of
evidence available and the quality of evidence they required prior to prescribing silk garments (Table 43).
Lack of evidence base
The majority agreed that there was a significant lack of high-quality evidence and reported that until this
was produced they would not consider prescription of silk garments. There was universal agreement on
the need for the CLOTHES RCT, and many participants indicated that the outcome of this trial and of
subsequent studies would influence their future practice. Participants noted that many treatments currently
used are underpinned by very limited research evidence, citing the example of wet wraps, which are
commonly used in childhood eczema. It was noted that lack of empirical evidence does not mean that a
treatment does not work.
Information from manufacturers
A very limited number of participants were aware that more than one brand of silk garments is available,
and most had received information from only one company representative; several could name individual
representatives, but were hazy in their recollection of the product name. Views on the value of
manufacturer information varied. Several participants stated that it was limited and potentially biased and
that they largely discounted it; some suggested that, as this was virtually all that was available, it should be
considered. Others took a more pragmatic view and were willing to base their treatment decision on this
imperfect information combined with clinical need and personal experience.
Treatment protocols and guidelines
Treatment protocols and guidelines were raised predominantly by commissioners and GPs, some of whom
stated that there were clear protocols in their local area. However, it was evident that the existence of such
guidance was patchy, which led to a ‘postcode lottery’ on prescribing practice. The majority of participants
implied the need for robust protocols that provide clear information about when and in what circumstances
silk garments should be prescribed. Clarity about who should prescribe and in what quantity was also
considered essential to ensure equity of provision. On the whole, participants favoured silk garments being
part of a clear ladder of treatment and something to be used when other treatment options had been
exhausted. This subtheme is allied to the first subtheme of theme 2 (failure of other treatment regimens);
however, this subtheme refers to population-wide protocols, whereas failure of other treatment regimens
applies more to decision-making in relation to individual patients.
TABLE 43 Views of clinicians and commissioners: theme 1 – knowledge base
Lack of evidence base Information from manufacturers Treatment protocols
There isn’t actually much evidence
out there
I had contact with a rep[resentative]
some while ago and was given
some leaflets
There is a description of an
appropriate place in treatment
There’s not enough big studies . . .
to convince prescribers
I’ve got some of the manufacturers’
product information
A lot of CCGs [Clinical
Commissioning Groups] will have
issued guidance on the prescribing
of silk products
But because there isn’t any
evidence doesn’t mean that
something doesn’t work
Rep[resentative]s have visited and
given us evidence
We would expect them to go
through all the NHS treatments first
I’m not keen until research
evidence has been proven
You don’t just take the
rep[resentative]’s word for it
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Theme 2: reasons to use silk garments
Participants cited a number of reasons that silk garments may be used as a treatment option, and this
theme comprises four subthemes: (1) failure of other treatment regimens, (2) greater concordance,
(3) avoiding referral to secondary care and (4) cost-effectiveness. Around one-third of participants had
prescribed, or recommended prescription of, silk garments in practice, but none claimed to be an expert in
the use of these products or prescribed them on a regular basis (Table 44).
Failure of other treatment regimens
All participants agreed that silk garments were not a first-line treatment, but rather that they were
considered to be a ‘last resort’ for children who had already used emollients, topical steroids and
sometimes also specialist cotton clothing and wet wrapping.
Greater concordance
Participants highlighted the challenges of treatment adherence with traditional eczema regimens. Several
mentioned the acceptability and ease of use of silk, and proposed that this may lead to greater concordance
with treatment plans.
Avoiding referral to secondary care
Participants, particularly nurses, suggested that, based on their clinical experience, silk garments had a value
for children who were ‘hot’, ‘miserable’ and ‘itchy’ with their eczema, and that these symptoms were more
likely than an objective measure of eczema severity to lead them to prescribe silk garments. An alternative
reason for prescription, more commonly mentioned by GPs, was avoidance of costly referral to secondary care.
TABLE 44 Views of clinicians and commissioners: theme 2 – reasons to use silk garments
Failure of other treatment
regimens Greater concordance
Avoiding referral to
secondary care Cost-effectiveness
It’s not a first-line
treatment
If they were motivated
because they liked
something . . . then I
would certainly carry on
recommending it
If I saw a person was
struggling . . . even to the
point of considering
secondary care referral . . .
I’d probably feel
confident in considering
that prescription
It might potentially be a
cost-effective option . . .
don’t say cheaper
At the moment silk
would be the last option
The goal of eczema
treatments to give
patient as much control
as possible
I mean . . . it costs
enough to refer them
(to secondary care)
When they use the silk
garments they need less
steroid creams and
obviously emollients
Once we’ve exhausted
the usual treatments of
emollients and topical
steroids
It certainly gets rid of
the wet wrap business
The most attractive place
to use it is an alternative
to secondary care referral
We are sometimes
short-sighted in the way
we look at costs . . . we
should look at overall
costs
It’s like a last resort Compliance is obviously
the biggy isn’t it . . . we
do have some patients
with cupboards full of
stuff that hasn’t been
used
. . . they don’t need as
many visits . . .
I tend to reserve it for the
most severe cases
It’s a cost saving in the
long run
More likely to prescribe if
I can say we have tried
this and it didn’t work
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Cost-effectiveness
Some were able to quote the cost of both silk garments and secondary care referral, and considered that
the choice of silk garments may be more cost-effective. In these cases cost alone was the dominant feature
of decision-making. The price of silk garments was raised on many occasions. Some participants took a
literal view of cost per item and this is discussed in more detail in the second subtheme of theme 3. In this
subtheme participants took a far broader view. They acknowledged that the silk garments were ‘expensive’,
but when set within a context of potential reduction in use of topical medication, alternative clothing, wet
wraps and medical consultations, participants proposed that they could be a cost-effective option. In this
group, participants also took into account the impact that these products may have on the health and well-
being of both the child with eczema and his or her family.
Theme 3: reasons for not using silk garments
As seen in theme 2, many practitioners suggested that there was a place for silk garments in the armoury of
childhood eczema care, but equally they were cautious and balanced this view with a number of reasons
why these products should not be used at present. Theme 3 was generated from the following subthemes:
(1) lack of familiarity or experience, (2) cost, (3) contentious prescription and (4) quality of product (Table 45).
Lack of familiarity or experience
All participants stated that they were not particularly familiar with silk garments and none prescribed them
regularly. Some GPs believed that they would never have sufficient expertise or confidence to prescribe
them, but a small number suggested that nurses, either dermatology specialist nurses or practice nurses,
would be better placed to be experts in practice.
TABLE 45 Views of clinicians and commissioners: theme 3 – reasons for not using silk garments
Lack of familiarity/
experience Cost Contentious prescription Quality of product
We haven’t used them a
lot . . . so we haven’t got
a lot of experience
We don’t want to see a
sort of explosion [of
prescriptions] . . .
because that’s to
no-ones benefit
Well there’s absolutely
no doubt, this is a
primary care
prescribing thing
Within a couple of
washes very dirty, look
grey and have gone
very baggy
As a GP many of us
would struggle to have
the time and the
expertise
I mean it’s not that
massive . . . it would be
a manageable cost
More for secondary care
I feel to prescribe it
Rep[resentative] says
‘oh they’ll wash for
about a year’ . . . their
knees get very thin and
sometimes they only
last about half of
that time
I would never prescribe
them by myself
It would worry me . . .
we’re going to get
inundated wanting all
these little garments
Should be initiated by
dermatology clinics and
then obviously continued
by GPs
They rip very easily
The problem with GPs
initiating this is that you
get creep prescribing . . .
it escalates
Patients should be
clinically assessed . . .
and then it’s down to
accountability and
clinical confidence
Impractical in terms of
current construction
and surprisingly
undesirable for teenage
. . . patients
Very good idea but
practically rather
expensive
Some GPs will and some
GPs won’t [prescribe]
They get discoloured
[parents] didn’t like the
look of them
My fear would be that I
prescribed some very
expensive item and they
There has to be some
regulation here because
pushy parents are going
to get what they want
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Cost
Silk garments were generally perceived as an expensive treatment option. The estimates of cost per set of
top and leggings varied from around £40 to £100. The assumed cost of the garments, together with lack
of familiarity, led to robust beliefs about responsibility for prescription.
Contentious prescription
There was a balance of views that prescriptions should be either from primary or secondary care, or be
initiated in secondary care and continued by GPs. There was uncertainty from some participants about
whether or not they were ‘allowed’ to prescribe these garments. Discussion of nurse prescribing was scant,
and nurse participants generally reported that they advised medical colleagues to prescribe rather than
undertaking the process themselves. Views on who should prescribe did not necessarily correlate with the
participant’s job role; so, for example, not all GPs suggested that secondary care should prescribe and vice
versa. A minority of participants suggested that the key factor in successful prescription was competent and
thorough clinical assessment, preferably by a clinician who provides the most dermatology care for the
patient. Commissioner and GP participants had concerns that if GPs began to prescribe silk garments this
may open the floodgates to a widespread, costly and ineffective prescribing practice.
In practice, most prescriptions involved secondary care providers writing to GPs recommending silk
garments; however, such requests were fairly regularly rejected on personal and unpredictable whim,
rather than a clear clinical reason. Concerns were expressed that this could lead to treatment inequity,
as ‘pushy’, ‘middle-class’ parents were more likely to persist with requests until they were met, whereas
less affluent and less vocal parents were likely to give up.
Quality of product
The few participants who were relatively familiar with silk garments commented that there were quality
issues, particularly considering the expense. They suggested that the garments did not wear well and that
they looked unattractive and ‘grubby’ after several washes. A few participants reported that they were not
acceptable to patients, particularly older children, and that if not used would lead to valuable resources
being wasted; clearly, this argument could be applied to any treatment.
Theme 4: outcome measures
Participants acknowledged the need to measure outcomes of all treatments; however, the value they
placed on different measures was notable. Theme 4 comprises three subthemes: (1) existing measures,
(2) clinical improvement and (3) patient/parent reports (Table 46).
Existing measures
Participants generally talked in the abstract about what they considered to be best practice in measuring
outcomes. None used an objective measure of disease severity, although one participant suggested that the
use of EASI31 would be useful. Others raised the importance of patient/parent-based symptom or experience
measures. Specifically, they advocated POEM34 and the Dermatology Life Quality Index (including child and
family measures). No participants had used POEM with this patient group and a very small number had used
formal quality-of-life measures. A few participants alluded to the need for measures but were not familiar
with those already available.
Clinical improvement
Subjective measures of practitioner-assessed clinical improvement were much more commonly suggested.
The constituents of clinical improvement included the child being more ‘settled’ and ‘comfortable’, and
specifically less ‘hot’, and experiencing improved sleep and a reduction in itching, scratching and episodes
of infection. A reduction in the use of topical medication was also used as a measure of effective treatment.
Several participants suggested that parent and patient reports of improvement were every bit as valuable as
clinicians’ views, and some stated that these alone would be sufficient for them to advise the continued use
of silk clothing. The impact on family as well as children was particularly highlighted by nurse participants.
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Patient/parent reports
The few participants who had prescribed silk garments reported positive, but not overwhelming, feedback
from parents. They reported that children found the garments ‘cooling’ and that they did not adhere to
the skin and could be used even in the presence of infection.
Overall, the 21 participants in this study had limited experience in the use of silk garments for childhood
eczema, and anecdotally this is a fairly typical picture across the country. It was stated that there is a
dearth of evidence about the effectiveness of these garments, a position that participants were keen to see
rectified through the CLOTHES trial and subsequent studies. On the whole, silk garments were perceived
as expensive, although when put into a wider context many participants suggested that they may provide
value for money. The prescribing of silk garments was contentious, with participants holding firm beliefs
about whether this should be the responsibility of primary or secondary care. There was consensus that
use of these products should be monitored and evaluated, although there was little agreement on the
preferred outcome measures to be used.
Conclusion
In this nested qualitative study children and parent participants have provided insights that correlate closely
with the quantitative results in that there was some limited improvement in eczema for some children,
but the hoped-for ‘miracle cure’ did not transpire. On the whole, clinicians and commissioners had limited
TABLE 46 Views of clinicians and commissioners: theme 4 – outcome measures
Existing measures Clinical improvement Patient/parent reports
I assess . . . using a child or
infant DLQI
Clinical improvement . . . a little bit
hard to quantify
What the parent or child thinks . . .
a description of severity
Eczema severity . . . we can do
some kind of scoring tool
It’s clinical judgement . . . you’d be
assessing social factors as well
In reality on the ground I would
just say how have they improved?
Mums and dads know pretty
promptly whether it has
I suppose initially we would carry
out an EASI score and a DLQI,
that’s kind of like a measurable
thing . . . we’d probably reassess
every 3–4 months
Reduction in use of other
treatments such as emollients
and steroids
I would probably go by what the
parents say
POEM . . . It’s easier to understand Amount of flare ups they’re having If the parent thinks it’s helping I’m
okay with that
POEM is nice because you can
share it with the patient
Are they sleeping better, are they
feeling more comfortable, are they
less itchy, scratching less
All the ones that had used them
have had very positive results
You want two measures . . .
quality of life and severity of the
eczema . . . there must be some
sort of graded . . .
The child is more relaxed because
they’re sleeping and they’re not
scratching all the time
Certainly the ones who’ve used them
regularly do find them beneficial
Much more settled, that there’s
not as many flares, that it’s not
got infected
The parents said they thought they
had helped
How much distress the family
suffers . . . you can’t necessarily
gauge that by looking at the skin
DLQI, Dermatology Life Quality Index.
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knowledge and experience and were reluctant to prescribe garments that they perceived as costly and
lacking in robust evidence of effectiveness. Collectively, the qualitative component of the CLOTHES trial
illustrates a very mixed picture of knowledge, beliefs and experiences of using the silk garments.
Limitations
There are two limitations to this nested study. First, participants were essentially self-selecting and may
therefore not be representative of the trial cohort. Second, the recruitment of children from recruitment
centres in prescribed age bands was difficult and we would have preferred to recruit more children. We
considered recruiting to wider age bands for the focus groups, but made the decision not to do this as it
would have compromised the value of using age-appropriate activities to enable children to convey their
thoughts and feelings.
Key learning points
Implications for interpretation of trial results
l Children’s responses were particularly helpful in providing additional detail on possible reasons for
non-adherence in wearing the garments.
l Parents and children portrayed mixed views on the garments. Few, if any, reported the longed-for
‘miracle cure’ and there was a significant sense of disappointment in relation to effectiveness and the
quality, fit and durability of garments.
l Some parents found the weekly questionnaires useful in prompting more regular use of their child’s
usual eczema care.
l Clinicians and commissioners were generally equivocal about the use of silk garments. Most wanted
a robust evidence base to inform treatment decisions and were eager to see the results of the
CLOTHES trial.
l Results of the qualitative studies were in line with the quantitative trial data, suggesting that important
differences between the groups had not been missed.
Added value of qualitative studies within trials
l The added value of the qualitative work is that it has provided a deeper, richer and more detailed
understanding of the ‘what’, ‘why’ and ‘how come’ underpinning participant’s beliefs and behaviours.
It has uncovered understandings, which help to inform interpretation of the results of the study.
l Parents who participated were universally positive about having an opportunity to talk with a
researcher who was interested in their child’s condition, but, perhaps more importantly, focus group
participants relished meeting other parents in the same situation.
l Likewise, children wanted to talk with the researcher and were very able to express their views with
clarity, given age-appropriate means of communication.
Lessons for conduct of nested qualitative studies
l Recruitment to qualitative studies nested within RCTs can be challenging. Research nurses who had
personal contact with participants were crucial to successful recruitment. Participants in some centres
were geographically widespread and the ages of children completing the trial at a time suitable for
involvement in the focus groups meant that many participants were unable to take part.
l Early awareness of the forthcoming focus groups may help to boost recruitment.
l Child data added a valuable dimension to our understanding of childhood eczema and the use of silk
garments. However, these were time-consuming to collect as there was a need for pre- and post
‘playtime’. Recruitment was particularly challenging, as the groups were age banded to ensure the
appropriateness of data collection methods.
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Chapter 6 Involvement of patients and the public
Public and patient involvement (PPI) in research has been strongly encouraged for many years,82 but,until recently, the evaluation of PPI activities and the impact that they may have on the design, conduct
and delivery of clinical trials has been limited.83–85
In this chapter, we aim to summarise the breadth and depth of PPI involvement that has taken place
throughout the lifetime of the CLOTHES trial, and to share our experiences in documenting the likely
impact of this activity.
Aims
1. To evaluate the impact of PPI on the design, conduct and dissemination of the NIHR HTA-funded
CLOTHES trial.
2. To add to the literature on PPI and its potential impact on research.
Methods
This report synthesises various strands of activity that have taken place over a period of many years,
spanning October 2009 until now. Diverse methodologies have been employed according to the stage of
the research and the types of PPI input required. In line with INVOLVE guidance,82 specific ethical approval
was not required for the majority of the described engagement activities.
Throughout the study, we adopted the eight core principles framework identified by Telford et al.,86 as
outlined in Table 47. Documentation of impacts throughout the stages of the research from prioritisation
of the topic through to dissemination of the findings has been presented using the framework proposed
by the Public Involvement Impact Assessment Framework Study Group87 and reported according to the
Guidance for Reporting Involvement of Patients and Public guidelines.85
For the purposes of this report, we define PPI as being inclusive of all relevant stakeholders and users of
the research. As well as focusing primarily on involvement of patients, their carers and the general public,
we also include examples of involvement with other key stakeholders including health-care professionals,
commissioners, providers of health information, guideline writers and researchers.
Patient and public information activities were logged on an ongoing basis throughout the trial using a
dedicated PPI log that all members of the trial team had access to.
Results
Contextual factors relating to patient and public information involvement
Many factors contributed to ensuring strong PPI in the CLOTHES trial.
Funding body
The CLOTHES trial was funded by the NIHR HTA programme. This public funding body was one of the
first in the world to recognise the importance of PPI, both at an organisation level (with PPI members on
funding panels and PPI reviewers) and through the research projects that it funds. This strong endorsement
by the funding bodies meant that PPI was embedded within the prioritisation process in identifying the
topic area for research, encouraged the involvement of a patient representative as a co-applicant on
the grant, and allowed the inclusion of costs and time to facilitate PPI input.
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Research group
The trial was developed by a research group with a strong track record of conducting AE research (thus
allowing ready access to patient partners and relevant networks, to facilitate speedy engagement with
users). This group had organisational structures in place prior to starting the CLOTHES trial, including an
established patient panel whose members receive training and support through face-to-face workshops,
newsletters and attendance at relevant training courses/conferences. The panel is supported by a dedicated
member of staff (PPI manager) who maintains regular newsletter communication with members of the
panel and signposts members to upcoming projects requiring PPI input.
Sponsor organisation
The School of Medicine at the University of Nottingham places strategic importance on the involvement of
patients and the public in both teaching and research activities across the school. It funds a PPI co-ordinator
post to support researchers in developing PPI initiatives and runs regular training workshops to ensure that
researchers have the necessary skills to engage effectively with PPI partners.
Patient support groups
The research team had strong pre-existing links with two active patient support groups (National Eczema
Society and the Nottingham Support Group for Carers of Children with Eczema). Both support groups
were very familiar with our research activity, had participated in the James Lind Alliance Eczema Priority
Setting Partnership6 and were keen to support the trial.
TABLE 47 Summary of core principles for PPI involvement in the CLOTHES trial86
Core principles How evidenced in CLOTHES trial
Principle 1: the roles of the consumers are agreed
between the researchers and the consumers involved
in the research
The role of the PPI representatives was documented in the funding
application, protocol and final report
Principle 2: researchers budget appropriately for the
costs of the consumer involvement in research
PPI costs were included in the budget (0.6–1.6% of total budget)
and PPI representatives were reimbursed for their travel and child
care (and in some instances, their time)
Principle 3: researchers respect the differing skills,
knowledge and experience of consumers
Contribution of PPI representatives’ skills, knowledge and
experience has been included in research reports and papers
Principle 4: consumers are offered training and
personal support to enable them to be involved in
research
Support and training in research methodology and understanding
of key terminology was provided by the Centre of Evidence-Based
Dermatology’s Patient Panel, and by a dedicated member of staff
who is responsible for co-ordination of PPI and engagement
activities within the research group
Principle 5: researchers ensure that they have the
necessary skills to involve consumers in the research
process
Researchers involved in the design and conduct of the CLOTHES
trial attended the Centre of Evidence-Based Dermatology’s
Patient Panel training events and were encouraged to attend
conferences and workshops addressing the importance of PPI
involvement in research
Principle 6: consumers are involved in decisions about
how participants are both recruited and kept informed
about the progress of the research
PPI representatives involved in meetings to discuss trial design
and conduct and were involved in amending paperwork in
response to potential difficulties with recruitment. PPI
representatives were involved in writing and communicating
updates about the trial and helping with trial updates via social
media and websites
Principle 7: consumer involvement is described in
research reports
PPI contribution and analysis of its impact included in the final
report and written up as a separate paper
Principle 8: research findings are available to
consumers, in formats and in language that they can
easily understand
Trial disseminated widely with the help of PPI representatives,
including lay summaries, contributions to patient support group
newsletters, social media, websites and podcasts
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Stages of research and opportunities for patient and public information impact
A summary of the stages of research that provided opportunities for PPI engagement are summarised in
Table 48, along with details of the PPI activities and their impact.
Research agenda setting
The CLOTHES trial was developed in response to a commissioned call by the NIHR HTA. This pre-dated our
formal James Lind Alliance Priority Setting Partnership, in which patients and health-care professionals
identified the most important areas of treatment uncertainty.6 Nevertheless, results of the Priority Setting
Partnership confirmed patients’ strong interest in non-pharmacological interventions for the treatment of AE.
TABLE 48 Summary of PPI methods used and likely impacts (framework adapted from Public Involvement Impact
Assessment Framework Study Group recommendations)88
Stage of the
research Methods used in CLOTHES trial Measures of impact
Research
agenda setting
l James Lind Alliance Priority Setting
Partnership for eczema,6 which included
PPI representation on the steering group,
identified non-pharmacological
interventions as an important area of
interest for patients
l Trial discussed by the UK Dermatology
Clinical Trials Network’s prioritisation group
and presented at the Steering Group
meeting in October 2009 – provided
feedback from patients and other health-
care professionals involved in delivering
AE care
l Prioritised trial confirmed to be an important
topic and one that both patients and health-care
professionals would like to see addressed
l Informed choice of comparators, the need
for feasibility work and consideration of
implementation issues
Research
design and
delivery
l Patient representative co-applicant and
member of Trial Management Group
(mother of two children with severe AE,
previous participant in an AE trial, member
of the CEBD patient panel). Contributed to
meetings during design phase of the trial
(both before and after funding)
l Patient online survey (n= 475) to gather
patients’ views on issues relevant to the
design and conduct of the CLOTHES trial
(see Table 47 for details). Survey designed
with input from patient partners
l HOME initiative developing a core outcome
set for AE trials. Patients are active partners
in the HOME initiative and provide vital
insight into the face validity of chosen
outcome instruments
l Workshop discussion group at CEBD patient
panel event to discuss how to encourage
patients to participate in the trial, choice of
comparator, the needs for specific washing
instructions and barriers to adherence
l Engagement with patients support groups
(National Eczema Society and Nottingham
Support Group for Carers of Children with
Eczema) to support awareness of the trial
(through websites and social media) and
help with distribution of online survey
l Members of CEBD patient panel provided
advice in developing appropriate washing
guidance that would be acceptable
to participants
PPI input informed multiple trial design decisions
including:
l Choice of comparator (no clothing, cotton
clothing or other ‘placebo’ garment)
l Eligibility criteria (use of wet-wrap dressings in
the previous month, concurrent use of other
specialist clothing)
l Understanding likely adherence in wearing the
garments. This informed our stopping rules and
analysis plan for reporting adherence
l Barriers to participation, particularly the need
to provide garments to all participants after
6 months in order to limit differential drop-out in
the control group
l Choice of outcome measures (selected
HOME-approved core outcomes)
l The need for clear washing instructions that were
not too onerous for families to implement
continued
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TABLE 48 Summary of PPI methods used and likely impacts (framework adapted from Public Involvement Impact
Assessment Framework Study Group recommendations)88 (continued )
Stage of the
research Methods used in CLOTHES trial Measures of impact
Ethics and
oversight
l Patient co-applicant and members of the
CEBD patient panel helped to produce and
comment on patient-facing materials,
especially the information sheets and
online questionnaires
l PPI member of the Trial Steering Group
provided patient-focused oversight of the
trial and facilitated links with the National
Eczema Society and the HOME initiative
(both of which this PPI member is an active
member of)
l Resulted in amendments to wording and
introduction of more detailed information on
what participants would be required to do when
participating in the trial. For the online
questionnaires, PPI members recommended
improved signposting throughout the
questionnaire and amended the wording
l Ethics committee feedback on the trial was that
the team were to be commended for the quality
of the patient information leaflets provided
l Patients’ views were voiced during Trial Steering
Group meetings and was particularly helpful
when we experienced supply problems with one
of the brands of garments
Recruitment l PPI members contributed to media
broadcasts about the trial to boost
recruitment: PPI co-applicant (and her son)
agreed to be interviewed for BBC local TV
news, Nottingham Evening Post and BBC
local radio. Another patient (and parent)
agreed to be interviewed for ITV local news,
and a parent was interviewed on local radio
in Cambridge
l Feedback from some trial participants
suggested that those children allocated
to the control group felt extremely
disappointed. We worked with our PPI
members and the Medicines for Children
Research Network, to redesign some of our
participant information sheets, retrained our
research nurses to ensure that they
explained fully the importance of the
control groups during the recruitment
process and introduced a ‘welcome’ pack
for all children, which reinforced the
importance of all participants in the trial,
regardless of group allocation
l Resulted in a considerable boost to recruitment,
which ensured that the CLOTHES trial was ahead
of its recruitment targets throughout the trial,
and was delivered on time and budget
l Videos and podcasts also used on the trial
website and continued to provide awareness of
the trial89
l Feedback from participants was that the children
appreciated the ‘welcome packs’ and felt less
upset about being allocated to the control group
l Parents were able to communicate the
importance of the ‘control group’ in language
that both they and their children could understand
l Children of our PPI co-applicant were unable
to take part in the trial because of a conflict
of interest
Reflections from PPI partner:
It was disappointing for my son, who wanted to
be part of the trial after helping to raise the
profile of the trial through a TV report and
newspaper article. However the training
provided to the PPI partner in previous years had
explained the issues around ‘conflict of interest’.
The research team managed this sensitively by
sending a written letter of appreciation with a
voucher and framed picture from a local
newspaper article
Data collection l PPI members commented on the data
collection tools (especially the online
questionnaires) to ensure that they were
easy to use and not confusing for
participants
l Completion of the weekly questionnaires was
excellent – 85% of participants completed ≥ 12
of the weekly questionnaires over the trial period
Data
analysis and
interpretation
of results
l Patients have contributed to our
understanding of the minimum clinically
important difference in the EASI and POEM
scores through patient involvement in the
HOME initiative
l Two PPI members attended the results
reveal meeting, where interpretation of the
trial results was discussed. Their input was
vital in helping to understand how best to
present the results to the general public
l Understanding what is considered to be clinically
important improvements in the EASI and POEM
scales was vital to the overall interpretation of
the trial results. This was particularly important
for the CLOTHES trial, where a statistically
significant, but small, between-group difference
was observed in the secondary outcome (POEM)
–this was not felt to be clinically meaningful
for patients
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TABLE 48 Summary of PPI methods used and likely impacts (framework adapted from Public Involvement Impact
Assessment Framework Study Group recommendations)88 (continued )
Stage of the
research Methods used in CLOTHES trial Measures of impact
l Nested qualitative study involving 34
parents of children taking part in the trial,
17 children and 20 health-care
professionals and commissioners. This
qualitative study provided vital information
to help in interpreting the trial results
and planning for dissemination and
implementation of the trial findings
l The nested qualitative study provided greater
insight into the expectations of trial participants
prior to entering the trial (which informed our
interpretation of the results – especially in
relation to subjective patient-reported outcomes
that were more likely to be susceptible to
expectation bias)
l Interviews with health-care professionals and
commissioners enabled us to prepare documents
that would address their needs and be more
likely to inform clinical decisions
Writing up l PPI members contributed to trial write-up of
the main report (including the Plain English
summary), academic publications, news
items, tweets and podcasts
l Patient-facing materials were created in a variety
of engaging formats
Dissemination l PPI members used their existing networks
and social media channels to help in
disseminating the trial results
l Contact details of trial participants who
were willing to talk to the media in each of
our five recruiting regions were prepared in
advance, ready for speedy uptake once
results were released
l We were in a position of readiness to engage
with media interviews and able to develop a
patient-friendly video to convey the results
l Engaging through existing networks (patient
support group, professional networks and links
with guideline writers and patient information
resources) meant that the results were rapidly
disseminated and taken up
l Ongoing engagement with commissioning
groups during the trial meant that many were
waiting the results of the CLOTHES trial prior to
making prescribing recommendations
Time and cost l PPI costs were included in the CLOTHES
budget (0.6% of total award, 1.6%
including costs of nested qualitative study)
l Procedures for claiming expenses were in
place to ensure timely payment. In addition,
non-pay gifts were sent to PPI partners in
recognition of their input at Christmas and
for special birthdays or milestones in the
project
l Existing infrastructure was utilised to
support PPI members and provide training –
this meant that it was easier (and less time-
consuming) to engage effectively with our
PPI partners. It also meant that we were
able to access a range of experienced PPI
partners quickly if timely responses were
required or there was a need for
multiple perspectives
l Our PPI co-applicant was paid for time
spent working on the trial, and had travel
and child care costs reimbursed. All other
PPI contributors received travel expenses
and costs of printing where applicable, but
did not receive recompense for time spent
contributing to the project
l Having a dedicated patient panel and PPI
manager to support many research projects was
a big advantage for the CLOTHES trial and
made PPI engagement easier for the trial team
(who had less experience of managing PPI
contributions). It also meant that PPI input was
available in a timely manner, thus minimising
delays in the research timelines
l Although money had been allocated within
the budget to recompense our PPI co-
applicant for her time on the project, she
was very reluctant to accept the payment
and felt uncomfortable in doing so
l Payments made in this way are subject to
tax and it is the responsibility of the PPI
partner to submit relevant tax returns
BBC, British Broadcasting Corporation; CEBD, Centre for Evidence Based Dermatology; HOME, Harmonising Outcome
Measures for Eczema; ITV, Independent Television; TV, television.
Bold text denotes potentially negative impacts.
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Trial design
In order to inform trial design from an early stage (pre-funding), we conducted an online patient survey
(Survey MonkeyTM, SurveyMonkey, Palo Alto, CA, USA) that was designed with the assistance of PPI
members of our patient panel. The survey consisted of 25 questions, took approximately 10–15 minutes to
complete and was open from January to April 2012. Links to the survey were distributed via the National
Eczema Society and the Nottingham Support Group for Carers of Children with Eczema [which has a
Twitter (Twitter, Inc., San Francisco, CA, USA) following of 5600] to patient participants of the James Lind
Alliance Priority Setting Partnership, to AE patients who had taken part in previous AE trials conducted
at the Centre of Evidence Based Dermatology, and through social media and other personal and
professional networks.
Participants were asked to complete the survey if they were a parent of a child with AE. A total of 475
parents completed the survey [296 (62%) completed all 25 questions]. All responders were included in the
analysis regardless of completeness of individual questions.
The survey confirmed that having AE influenced parental choice of clothing for their children (69% quite a
lot, 26% a little and 5% not at all) and 293 out of 454 (65%) participants said that they had bought
special clothing because of their child’s AE. Factors parents considered important when choosing clothing
to be used next to the skin were natural fibres (85%), avoidance of wool or scratchy fabrics (79%),
softness (56%), cost (43%), fit (42%) and ease of washing (41%).
Specific issues relating to trial design and the impact of PPI input are summarised in Table 49.
Trial delivery and recruitment
Following publication of a press release announcing the start of recruitment into the CLOTHES trial, the
trial team received considerable interest from media outlets including television, radio, newspapers and
magazines. Having access to PPI partners who were willing to give interviews about the impact that AE has
on their lives ensured that the news stories were widely distributed and engaging. In total, three parents,
two children with AE and a representative from the National Eczema Society gave media interviews
(Figure 24).
As a result of this media coverage, the trial team received 492 expressions of interest from potential
participants in the space of 3 months. This resulted in a surge in recruitment at the start of the trial and
meant that the trial was consistently ahead of recruitment targets throughout the study (Figure 25).
Interpretation of results
The nested qualitative study involving health-care commissioners, health-care providers and participants of
the trial was extremely useful in providing additional contextual information to aid interpretation of the
trial result, in guiding how best to disseminate the trial results to ensure speedy uptake and in helping to
understand potential barriers to the use of silk clothing in children with eczema (see Chapter 5).
Reflections from our patient and public involvement partners
As a member of the CEBD [Centre for Evidence Based Dermatology] panel I was part of the initial
priority-setting research which led to this trial and have felt privileged to be given the opportunity to
play such an active role in this research, which is close to my heart.
Early mainstream media interest in this trial has made me to feel more involved than I may have had in
other projects, making it a pleasant and rewarding experience. Throughout the research process I feel
my contribution has been valued and treated with professionalism and the team have made a
conscious decision to drive inclusive behaviours through the use of ‘simple’ plain English versus
technical jargon.
Amina (PPI co-applicant)
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TABLE 49 Design issues informed by PPI input
Design issue
Why decision required PPI
input PPI feedback Design decision
Eligibility criteria
Should age of
participants be limited
to children aged
≤ 5 years?
l AE is most common in
children aged ≤ 5 years
l Possibly easier to ensure
adherence in wearing
the trial garments in
younger children
l Less influenced by peer
pressure (as pre-school)
l Fewer sizes of garments
needed (so logistically
easier)
48% of children who
expressed an interest in
taking part in a trial of
specialist clothing were
aged > 6 years (35% were
aged 6–11 years and 13%
aged 12–16 years)
Eligibility criteria were broadened
to include all children up to the
age of 15 years in order to be as
inclusive and generalisable as
possible
Should patients who
routinely use wet
wraps be excluded?
l Patients who use wet
wraps frequently would
not be able to benefit
from the intervention
clothing (as the skin
would not come into
contact with the
clothing)
l Occasional use of wet
wraps may be possible
within a pragmatic trial,
but unclear what
‘cut-off’ to use in
defining ‘regular users of
wet wraps’
Of those currently using wet
wraps (n= 89), 46% used
wet wraps < 10 times in the
previous 6 months, but
38% used them > 30 times
in the last 6 months
Exclusion criteria were defined to
exclude participants who used
wet wraps very frequently (≥ 5
times in the previous month) –
equivalent to 30 times in the last
6 months
Definition of intervention
How should clothing
be prescribed for use
(wear 24 hours per
day, night-time only,
or as preferred)?
l Needed to ensure
sufficient exposure to the
intervention in order to
test its efficacy
l Wanted to reflect what
might happen in normal
practice (pragmatic trial)
Of 269 responders, 52%
said their child would be
willing to wear the clothing
only at night, while 46%
said that their child was
willing to wear the clothing
day and night; 19% would
wear the clothing during the
day, but not during
PE/games lessons
Children were asked to wear the
clothing as often as possible,
and as a minimum every night
Trial design: impact on trial delivery
Should participants
allocated to standard
care receive silk
clothing after the
randomised allocation
follow-up is
complete?
l Concerned that high
expectation around the
use of silk clothing would
result in differential loss
to follow-up in the
standard care group
Of 298 responses, only 59%
said they would still be
willing to take part if they
were allocated to standard
care
Trial design amended to allow
participants allocated to
standard care group to receive
the silk clothing after 6-month
primary outcome assessment
was complete
Trial analysis
How much would
parents be willing to
pay for specialist
clothing?
l Useful information to
inform health economic
analysis and
interpretation of
trial results
l 361/422 (86%) of
responders were willing
to pay only £20 or less
for special clothing
l 10% would use the
clothing only if it was
provided free of charge
on prescription
l Therapeutic silk garments
typically cost £60–75 per
set, depending on size
and type
l Willingness to pay used to
inform interpretation
of results
PE, physical education.
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FIGURE 24 Patient and public involvement co-applicant Amina being interviewed with her son Tahmid about the
trial for BBC local news. BBC, British Broadcasting Corporation.
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FIGURE 25 Recruitment graph for the CLOTHES trial showing impact of initial media interest.
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As an attendee at the original Centre of Evidence Based Dermatology Patient Panel where the concept
for the CLOTHES trial was first aired, I have been delighted to be involved at various stages of this
well-run trial. I know the result will be of use and interest to the followers of the Nottingham Support
Group for Carers of Children with which I am involved.
Amanda (member of CEBD patient panel and main contact for Nottingham Support Group for Carers
of Children with Eczema)
As the lay member of the Trial Steering Committee I did not have as active a role as the other PPI
members, but took part in all the meetings and kept up to date with the progress of the trial. I also
liaised with the National Eczema Society and took part in the CLOTHES Collaborators meeting in June
2015. I am impressed with the interest in non-pharmacological interventions for the treatment of AE
shown by the patients and carers in this trial and with the PPI input at all stages of the trial.
Rosemary (PPI member of Trial Steering Committee)
Discussion
This chapter documents the breadth and diversity of PPI experience that has contributed to the success
of the CLOTHES trial. PPI was an integral element throughout the research life cycle of this national,
multicentre RCT. It involved engagement with both children and their families, thus presenting additional
challenges and opportunities for engagement. We have demonstrated how the contribution of PPI to this
study has resulted in measurable impact, and hope to have inspired future researchers to think creatively
about how best to engage with patient partners and the wider community to improve research.
By necessity, we have worked extremely closely with some of our patient partners and these individuals
have now become skilled researchers in their own right. This phenomenon of ‘professional patients’ has
been documented previously90,91 and requires awareness of the shifting roles of members of the team as
time progresses. We sought to limit the impact of this effect by reaching out through social media to as
many patients as possible at crucial times; to ensure that diverse views were captured (in particular through
online surveys and the nested qualitative study). Wider engagement is often particularly important while
setting research priorities, in finalising the trial design, and during dissemination and implementation of
the results.
Documenting evidence of impact of PPI is a constant challenge and one that requires a systematic
approach involving all members of the research team. It is the responsibility of the lead researcher to
ensure that all members of the trial team understand the importance of PPI and how to record it. The
documentation of negative impacts of PPI remains a particular challenge, and may well require different
methods to elicit feedback and documentation of such effects.
Involvement in teleconference conversations that involve multiple people can often be particularly
challenging for new PPI partners. Special efforts should be made by the chairperson of such meetings to
ensure that PPI partners feel supported and able to voice their opinions freely.92 It is often advisable to
provide specific training prior to participation in such meetings, or to have a pre-meeting conversation
with PPI members so that they have an opportunity to clarify the proposed agenda items and to ask any
questions that they might feel uncomfortable in asking in the wider group.
Conclusion
The NIHR-funded CLOTHES trial was a successful trial for many reasons. Having strong PPI embedded
within an environment that values PPI input was just one aspect of a strong multidisciplinary team with
experienced CTU support. However, the benefits of PPI far outweighed any potential negative impacts and
contributed in diverse ways throughout the lifetime of the project.
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Chapter 7 Experiences of working with clothing
suppliers
Background
Collaboration between academia and industry in delivering clinical research has been given high priority
within the UK’s research agenda.93 The advantages of collaboration can be multifaceted, bringing mutual
benefits to all parties. However, working together with industry partners to deliver publicly funded research
can also be challenging as a result of the differing expectations and priorities.
Industry partners often have varying levels of engagement with the research process, depending on the
needs of the individual project. Having previously collaborated with industry to successfully deliver the NIHR
HTA-funded SWET,61 the CLOTHES trial team sought to draw on lessons from this previous experience in
establishing a successful collaborative relationship.
Delivery of the CLOTHES trial was supported by two silk garment suppliers (Espère Healthcare Ltd, UK
distributor of DermaSilk, and DreamSkin Health, manufacturer of DreamSkin). These two companies donated
the silk garments for use in the trial free of charge. This donation was made on the basis that the companies
had no input into the trial design, conduct, analysis or interpretation of the trial results (other than to inform
logistics of trial delivery, and to advise on appropriate use and care instructions for the garments).
This chapter describes the role that the clothing suppliers played in ensuring the success of the CLOTHES
trial and reflects on lessons learned for future trials.
Priorities and responsibilities
Working with industry can highlight differences in culture between the private and public sector, as the
needs and drivers for both parties are necessarily different. For the public sector, the primary aim is to
provide better quality evidence to inform medical decision-making and health commissioning, as well as
academic drivers ensuring the need to publish in high-impact scientific journals. For the private section,
any commercial venture clearly relies on making a financial profit to pay their employees and to satisfy
shareholders.
For the companies involved in supplying garments for the CLOTHES trial, there were many benefits of
being involved in such a high-profile, publicly funded clinical trial. However, there were also considerable
financial risks, should the study show that the products were not effective.
For the trial team, the benefits of having the garments donated from the two participating companies meant
that trial set-up was expedited with regard to negotiation of treatment costs with participating NHS trusts.
Under the terms of research funding within the UK, these costs are not covered from within the research
budget and are negotiated with participating health-care providers prior to starting the trial. The main risk
for the trial team was the potential for perceived lack of independence in conducting and reporting the trial,
and potential risks over continued supply of the interventional product throughout the trial.
We sought to build a working relationship between the trial team and the clothing suppliers that was fair
to all parties, and ensured that any perceived or actual influence from the clothing suppliers was minimised
(Box 2). This approach was taken in order to protect the core principle of research independence and to
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ensure validity of the results. To achieve this, a number of processes were put into place, based on the trial
team’s previous experience and the recommendations laid out in Maskell et al.94 (Table 50).
Involvement of the clothing suppliers in trial design and set-up
The original NIHR HTA commissioning brief did not specify any particular brand of silk garment to be used
in the trial. At the time of trial design, two CE-marked brands of commercially produced silk garments
were available on the NHS formulary (DermaSilk and DreamSkin). The suppliers of these two brands
agreed to support the trial and supplied a letter of agreement to donate the garments to support the
funding application.
At the trial design stage, engagement with industry representatives was most helpful in four key aspects:
1. Helping to secure NIHR funding. Having letters of support from each of the clothing suppliers was
helpful in demonstrating to the funders (NIHR HTA) that the clothing suppliers were fully committed to
the trial.
2. Informing correct use of intervention. Advising on appropriate use of the silk garments (e.g. washing
instructions, concurrent use of AE medications, number of garments required, best ways of measuring
the size of the child to ensure the correct size of garments).
3. Facilitating site set-up. Having donations of the garments meant that our planned recruiting sites were
opened quickly and with minimal difficulties in negotiating NHS treatment costs. However, one
potential recruiting centre was unable to open as a result of unwillingness on the part of the NHS trust
to agree to the low risk of paying for the silk garments, should the clothing companies be unable to
fulfil their offer of donation.
4. Trial conduct and logistics of supply. The trial team worked closely with company representatives to
establish appropriate systems for ensuring delivery of the product in a timely manner, as well as
minimising the requirement to hold multiple sizes and styles of garments at the co-ordinating centre.
BOX 2 Responsibilities of clothing suppliers and the trial team
Responsibilities of the clothing suppliers were to:
l supply silk garments for the trial
l provide replacement garments for any worn-out or outgrown garments
l provide guidance to the trial development team on appropriate use of the garments
l establish a system for supplying garments as required
l advertise support for the trial in a responsible manner.
Responsibilities of the CLOTHES trial team were to:
l design and conduct the trial according to a pre-defined and registered protocol
l secure ethics and R&D approvals as needed, and to conduct the trial in line with local and national
governance requirements
l pre-define the statistical analysis plan before locking the data set
l maintain independence and clinical equipoise in relation to the trial results
l clearly communicate with clothing suppliers over progress of the trial and the rationale for design and
analysis decisions.
R&D, research and development.
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TABLE 50 Summary of recommendations for successful delivery of academic research in collaboration with industry
partners (adapted from Maskell et al.94 and reflections from our previous NIHR HTA-funded trial61)
Recommendation Implementation within the CLOTHES trial
Provision of regular written reports for the
industry partner
l Clothing suppliers were regularly updated on trial progress via
e-mail and sent newsletter updates
Continual monitoring and prompt resolution of
concerns
l The central trial management team at Nottingham CTU monitored
garment stock control and flagged up any issues with the
companies (e.g. sizing queries, participant concerns)
Basic research practices education for industry
partners
l We held face-to-face meetings between members of trial
management group and the clothing suppliers before start of
recruitment, after database lock and after completion of the final
report, to clarify key aspects of the trial design and implications for
interpretation of the results
l The meeting at the beginning of the trial included a presentation of
the protocol, explanation of the reasoning behind key decisions
regarding trial design and clarified the use of the intervention
according to manufacturers’ instructions
l The meeting held after data collection was complete and the
database had been locked, was used to explain the statistical
analysis plan, and key aspects of trial design were re-emphasised
(e.g. pragmatic design of the trial; the need for an objective primary
outcome measure). We also emphasised the need to maintain
independence during the analysis and write-up of the trial, and
clarified timelines for release of the results
l A final meeting after analysis and write-up was complete was used
to clarify the results and to address any remaining questions
regarding trial design and interpretation. We were careful to ensure
that this meeting did not take place until after the final report was
complete and had been submitted to the funders
Minimisation of industry partner contact with
participants
l The trial participants had no contact with the clothing suppliers
Clear roles and responsibilities of all
stakeholders
l The need for trial independence was emphasised by the trial team
in early contacts with the clothing suppliers and throughout
the trial
l Prior to commencing the trial, written agreement was sought from
both clothing suppliers to confirm that they would supply the
garments for the trial, although there were no penalty clauses for
failure to comply with this agreement as the garments were being
donated free of charge
l Trial team committed to providing the clothing suppliers with
regular updates about trial progress and to give them advanced
notice of when the results were to be released
Clarify and have a clear understanding of roles
and responsibilities of research governance
departments and ethics committees to avoid
confusion and potential disagreements
l Clothing suppliers had no contact with the research ethics
committee that reviewed the trial
l Clothing suppliers had no contact with research governance
departments in the recruiting centres
Communication through an independent third
party if possiblea
l Independent arbiters were chosen to manage communication
between the chief investigator, trial team and the two
clothing suppliers
Engage with multiple partners to ensure
generalisability of findings and to limit
commercial advantage to any one companya
l Two suppliers of silk garments were approached to support the trial
a Recommendations from the CLOTHES trial team based on previous experience of working with industry on academic trials.
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Involvement of clothing suppliers during the trial
Trial logistics
Both clothing suppliers were supportive and were responsive in addressing questions or concerns about
use of the silk garments. They worked closely with the trial co-ordinators at the Nottingham CTU to ensure
efficient supply of the garments and development of an audit trail.
The central team at the CTU acted as the distribution hub for all trial garments to increase efficiency of
stock supply, to maintain blinding of local site staff and to act as an intermediary between participants and
the clothing companies (in the event that questions arose regarding the clothing). A detailed inventory of
stock was kept so that supplies could be ordered weekly, providing accountability of garment usage and
serving as a reordering system. Any returned stock (because of ill fit, excess wear or child growth) was
returned to the manufacturers for them to see how the clothing held up with regular use.
Although three sets of garments were supplied to all participants, the need for replacement garments
during each participant’s 6 months’ involvement in the trial was underestimated during our planning
phase. This presented an increased financial burden on the companies, which remained supportive and
supplied the additional garments after discussions with the trial team about why they were required. In
this regard, it was helpful to work with two companies, so that the financial burden could be shared.
Having two companies involved in the study was also particularly beneficial when one of the companies
experienced supply problems partway through the recruitment period. Each supplier remained supportive
of the trial, doing all they could to allow the trial to continue. The company that experienced stock
shortages kept back reserves of their dwindling stock for the trial, leaving them with fewer to sell on the
market. The other company provided cover for their commercial competitor, providing more garments to
the trial than originally intended.
Independence from the trial team
As outlined in Table 50, we attempted to replicate the model of engagement with commercial companies
through an independent third party, as was successfully achieved in our previous NIHR HTA-funded SWET.
To achieve this, we asked a representative of the lead NHS trust and the local lead for the comprehensive
research network to be independent arbiters between the companies and the Trial Management Group.
However, despite initial agreement from all parties, this approach did not work well in reality. This was
largely because the nature of the ordering and stock control system meant that it was necessary for the
trial management team to have weekly contact with representatives from the clothing suppliers. As a good
working relationship developed, the majority of trial communication inevitably involved the trial manager.
Nevertheless, this situation ensured that any concerns were resolved quickly, which was beneficial for
delivery of the trial, and direct contact with the rest of the Trial Management Group (including the chief
investigator) was kept to a minimum.
Training in trial design and interpretation
Given the importance of this trial to the financial concerns of both companies, we strove to ensure that
the rationale for our trial design was clearly explained before, during and after the trial, so that the
clothing suppliers had a good understanding of the trial design and conduct. In particular, we explained
our approach to controlling for bias and the implications of running a pragmatic RCT.
As outlined in Table 50, we conducted face-to-face meetings to discuss these issues prior to start of
recruitment, and again prior to data analysis, to ensure that the clothing suppliers understood the
reasoning behind trial design decisions. In particular, these meetings focused on explaining the following
key aspects:
l what a pragmatic trial is and implications for the design of the trial
l importance of the primary outcome and the need for an objective primary outcome
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l interpreting unblinded trials
l understanding p-values and CIs
l individual versus group mean effects
l the need for transparent reporting of results
l timelines and availability of the findings
l ownership of the data and write-up of study results.
Involvement of clothing suppliers after completion of the trial
Given that the CLOTHES trial failed to find any clear benefit of silk clothing for improving eczema severity,
it is perhaps not surprising that the final dissemination stage of the project has also been the most
challenging to manage. Both suppliers are passionate about their products and about the potential health
benefits that the garments could bring to patients. Their passion is reflected in the significant investment
both suppliers made in the trial. This belief in their product based on earlier, smaller, sponsored, studies
and testimonies from satisfied customers undoubtedly led to an expectation, both implicit and explicit, that
the trial would show the garments to be beneficial.
The need to ensure academic independence until the data had been fully analysed and interpreted, and
the trial report had been subject to peer scrutiny was a difficult balance to achieve in a manner that was
acceptable to all parties. Our two clothing suppliers were understandably eager to receive the trial results
and to ask questions, but it was important that we did this in a transparent and accountable way, and
without allowing them an opportunity to change any of the pre-planned analyses or the interpretation of
the results. Both companies received a copy of the full report after it had been through peer review, but
prior to publication. The companies provided reflections to the trial team that were incorporated into the
report at the team’s discretion. The feedback included notification that a mistake had been made in
applying the unit costs of the garments in the health economic analysis, which resulted in the analysis
being corrected and re-run prior to publication. Other minor amendments to the report at this stage are
listed in Appendix 21.
Of particular concern to the companies was the desire to explore the results specific to their individual
brands (in addition to the combined results). This was potentially problematic as the trial was not powered
to look for such comparisons, although those allocated to receive the intervention were randomised to the
two brands, which allowed exploration of brand effects in tertiary analysis.
Discussion
This chapter has provided brief reflections on our experiences of delivering a large, independent trial with
support from clothing suppliers in the form of donation of the trial intervention. This co-operative partnership
has brought many benefits, but also challenges, particularly as the commercial needs of the companies are at
odds with the overall findings of this trial. A summary of our key reflections on completion of the CLOTHES
trial is presented in Box 3.
Despite our best efforts to maintain independence between the trial team and the companies involved,
the need to work together over the past 3 years has meant that a relatively close relationship has been
established for some members of the team (especially those at the co-ordinating centre). However, contact
with research nurses and investigators at recruiting centres was successfully limited.
Our agreements with the clothing suppliers took the form of letters of agreement to supply the garments.
At the time, this was felt to be sufficient to document the agreement between the University of Nottingham
and the clothing suppliers. However, a formal contract that outlined key responsibilities for all parties,
defined expectations and clarified ownership of intellectual property may have been useful, and we would
recommend this approach for future trials.
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For the CLOTHES trial, there were benefits of working with two suppliers:
l better generalisability of study results
l security of supply (not reliant on a single supplier for the success of the trial)
l reduced financial burden for individual companies.
However, for non-drug trials, where the comparability of the interventions may be less clear than in drug
trials, there is also a risk to the trial integrity, particularly if different products, which were assumed to be
functionally similar, prove to be different in terms of treatment response. Thankfully, for the CLOTHES trial,
this was not the case and the ability to generalise from one branded product to a class of products is
helpful for informing clinical decision-making.
Alternative models of industry involvement in academic trials are available and these may warrant further
consideration. In particular, our relationship with the companies may have been very different had the
garments been supplied at a reduced cost rather than free of charge. However, in such a scenario, the
delays in negotiating NHS treatment costs with each participating site would still have been present,
potentially delaying the start of the trial and choice of recruiting centres. We would be pleased to see
further consideration of appropriate funding models to address excess treatment costs within the UK
funding landscape, as this currently represents a considerable source of delay and wasted resource.
BOX 3 Top tips for conducting academic trials in collaboration with industry colleagues
l Ensure roles and responsibilities are documented for both parties from the outset – particularly in relation
to continuity of supply, when and how the results will be shared, and intellectual property.
l Ensure sign-off of the trial protocol by all stakeholders prior to commencing the trial.
l Be aware of the benefits and potential difficulties of using multiple brands to represent one
randomised intervention.
l Early engagement with suppliers to establish ‘how to use their product’ can help to avoid claims of
inappropriate use at a later date.
l If planning a pragmatic clinical trial to establish effectiveness of an intervention in normal practice, special
efforts should be made to ensure that all industry colleagues understand the concept of a pragmatic trial
(sometimes referred to as a comparative effectiveness trial), and the implications for trial analysis
and interpretation.
l Keep detailed notes of what is discussed during meetings – this can be helpful in preventing debate at the
end of the study as to what was agreed and when.
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Chapter 8 Discussion
Main findings
This trial found no evidence of any clinical or economic benefit of using silk garments compared with
standard care in children with moderate to severe AE.
There were no differences between the treatment groups for any of the blinded outcomes. Furthermore,
the 95% CIs around the primary efficacy estimates were narrow, suggesting that a clinically important
treatment effect is unlikely to have been missed. Sensitivity analyses (imputing missing values, adjusting for
baseline imbalances and exploring the impact of adherence in wearing the garments) supported the
primary analysis.
Subgroup analysis based on FLG genotype showed no evidence of differential treatment response in
children with an inherited impairment in the skin barrier function. A post hoc analysis exploring the impact
of baseline severity on the primary outcome also showed no effect, suggesting that children with more
severe disease were unlikely to benefit from the clothing more than children with milder disease.
It is possible that silk garments could prove beneficial in the absence of a change in disease severity if the
garments resulted in a sparing effect on topical corticosteroid use. However, the proportion of days on
which topical corticosteroids or calcineurin inhibitors were used did not differ between the groups.
The intervention garments are marketed as possessing antimicrobial properties, but this trial found no
evidence to suggest a reduction in the number of skin infections in those using the garments compared
with those randomised to standard care alone.
Of the seven unblinded secondary outcomes, only POEM and PGA showed differences in favour of the silk
garments. However, the observed differences in POEM and PGA were small, making them unlikely to be
clinically meaningful for patients.40 These effects appeared to be most prominent during the first 3 months
of the trial, when belief in the effectiveness of the garments was most likely to influence responses.
It is possible that these effects occurred by chance, as many secondary outcome variables were assessed.
However, a previous AE trial of non-pharmacological interventions has reported similar differences between
blinded and unblinded outcomes.61 The nested qualitative study highlighted the high hopes that both
children and parents placed on the trial intervention from the outset and would suggest that risk of bias for
participant-reported outcomes is likely to be high in a trial of this kind.
Relevance to existing literature
There have been no further RCTs on the use of silk garments for AE since the CLOTHES trial began (search
updated 13 April 2016) and meta-analysis of the four existing silk trials (including CLOTHES) is not possible
because of the heterogeneity of designs. Additional brands of silk garments have since become available
for use in AE (e.g. Skinnies), but these have not been formally evaluated in RCTs.
At the time of commissioning this research (2011), £840.272 was spent on prescriptions for silk garments
in England alone. By 2015, this amount had risen to £2,039,575 per annum.
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Strengths and limitations
This was an adequately powered, independent RCT, with high follow-up rates and good adherence to the
trial intervention. The trial placed special emphasis on objective outcome measures in order to minimise
detection bias and the pragmatic study design meant that use of silk garments was evaluated as they
might be used in normal practice with mixed patterns of adherence.
It is possible that our emphasis on objective AE severity outcomes meant that some important potential
benefits were not captured in the primary analysis. Other factors, such as improvements in quality of life or
a reduction in symptoms (especially itch and sleep loss, as recorded in POEM), may be important drivers in
determining whether or not parents choose to purchase silk garments for their children. However, the
magnitude of any such benefits was small, and we found no evidence of improved quality of life among
trial participants using a range of validated quality-of-life scales.
It is also possible that treatment effects were masked by enhanced adherence to standard AE care, which
may have resulted from participating in a study such as this in which AE activity and treatment usage were
monitored weekly.
It is also possible that the effects of silk garments are best realised during a period of AE flare rather than
wearing the garments all the time (day and night). Daily use of the garments in the CLOTHES trial could
have led to more rapid degradation of the product than might have been seen if the garments were worn
occasionally when the AE was at its worst.
Generalisability
The study has good external validity as it was pragmatic in design, recruited children with a range of AE
severities and reflected normal clinical practice in the UK. Participants were able to use existing AE
treatments alongside their allocated trial intervention, as would be the case if used in practice.
Participants were recruited from five UK centres covering a range of urban and rural settings. The mix of
ethnic groups was broadly representative of that in the UK.
This trial included children with moderate to severe AE on the grounds that these were the patients most
likely to receive silk garments from their health-care providers. However, some children in the trial had
milder disease on the day of recruitment as AE severity was assessed over the previous year for eligibility.
Although AE is most common in children aged < 5 years, we included children of all ages to improve the
relevance of the study results to all children with AE.
DISCUSSION
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Chapter 9 Conclusion
Main conclusions
This is the first large, independent trial to have evaluated silk garments for the management of AE, and
the nested economic evaluation and qualitative studies support the conclusion that use of silk garments is
unlikely to be cost-effective for health providers.
It is hoped that these trial results provide health commissioners with a better evidence base on which to
make informed decisions about the use of silk garments for AE.
Implications for clinical practice
l Although patients are keen to identify non-pharmacological interventions to help in the management
of AE, it would appear from this trial that silk garments provide false hope for the majority of patients
and high costs for health-care providers.
l In a world where health-care resources are finite, the use of silk therapeutic garments for the
management of AE appears to represent poor value for money. Whether or not parents feel that the
small benefits identified in some of the secondary outcomes are sufficient to justify purchasing these
garments for themselves is something for individuals to consider on a case-by-case basis.
Implications for research
l Although this trial proved negative, patient interest in the role of non-pharmacological interventions for
AE remains high, and priority areas for future research have been identified in a James Lind Alliance
Priority Setting Partnership.6 Prioritised topics relating to non-pharmacological interventions include:
i. What role might food allergy tests play in the management of AE.
ii. What is the best psychological treatment for itching/scratching in AE?
iii. Which is the best way for people with AE to wash: frequency of washing, water temperature or
bath versus shower?
iv. What are the best and safest natural products to apply to the skin for AE?
v. How much does avoidance of irritants and allergens help people with AE?
vi. What is the role of diet in treating AE: exclusion diets and nutritional supplements?
vii. Which is more effective in the management of AE: education programmes, GP care, nurse-led care,
dermatologist-led care or multidisciplinary care?
l The CLOTHES trial has evaluated just one of many types of garments that have been purported to be
effective in the management of AE. Some, such as silver-impregnated fabrics, are available on
prescription and are currently recommended in clinical guidelines in some countries, whereas other
fabrics and products are still experimental; none have been well evaluated.
It remains entirely possible that wearing soft, smooth fibres next to the skin can prove soothing for AE
patients, and further trials of other fabric types are needed.
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As with many areas of research, outcomes remain a challenge for the evaluation of AE treatments.
Although the HOME initiative95 has made much progress with regard to development of a core outcome
set for AE,96 further work is still required in establishing how best to capture long-term control and quality
of life in AE trials. In this respect, it is important for researchers throughout the world to work together
and to share data sets, such as the CLOTHES data set, to allow further validation of outcomes and testing
of their performance in different clinical settings and types of patients.
CONCLUSION
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Appendix 1 Additional studies on therapeutic
garments
TABLE 51 Summary of RCTs investigating therapeutic clothing (other than silk) for AE
Type of
clothing Reference Participants Interventions Main results
Silver textile Juenger et al.
(2006)17
30 Group 1 (n= 10): silver textile
undergarments
Group 2 (n= 10): silver-free textile
undergarments
Group 3 (n= 10): prednicarbate
ointment
For phase 1 (days 1–14) the three
interventions were applied. For
phase 2 (days 14–28) all groups
wore undergarments made with
silver textile. In phase 3 (days
28–56) all treatments were
withdrawn except for
prednicarbate ointment
Median SCORAD at 14 days was
29.9 in group 1, 48.2 in group 2
and 24.0 in group 3
Change in scores between day 1
and 14 in groups 1 and 3 differed
significantly compared with the
change in score in group 2
between day 1 and 14 (p= 0.03
and p= 0.14, respectively)
Silver textile Gauger et al.
(2006)16
68 (57 analysed) Group A (n= 37): silver-coated
textile consisting of micromesh
material (82% polyamide, 18%
lycra) with woven silver filaments
with a silver content of 20% in
total
Group B (n= 31): placebo pure
cotton textile of equal size
Both interventions worn day and
night next to the skin (except for
consultations) for 2 weeks
Reduction in SCORAD index after
2 weeks: 27.4% in silver group
and 16.3% in placebo. No
significant differences between
the two groups
Cellulose fibres
with seaweed
enriched with
silver ions
Araújo et al.
(2013)18
19 Group A (n= 12): clothing made
with a biofunctional textile
consisting of 70% cotton fibres,
20% cellulose fibres with algae
extracts and 10% silver-activated
algal cellulose fibres. The textile
contains about 6000 p.p.m.
(0.6%) silver
Group B (n= 7): 100% cotton
clothing, woven similarly to the
trial textile
From day 0 the clothes were worn
continuously 24 hours a day until
day 7 when intermittent use of
the clothing started. The clothes
were worn only at night until the
end of the study (day 90)
In group A at 90 days, mean
SCORAD was 24.0 (SD ±12.5)
compared with 24.2 (SD ±12) in
the cotton clothing group, with no
difference between the groups
(p= 0.97)
continued
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TABLE 51 Summary of RCTs investigating therapeutic clothing (other than silk) for AE (continued )
Type of
clothing Reference Participants Interventions Main results
Cellulose
seaweed fabric
with silver
Park et al.
(2012)19
14 (12 analysed) Garments (top and leggings)
consisting of two parts: one half
made from silver-loaded cellulose
fabric made from seaweed
(SkinDoctor®, Ventex Co. Ltd,
Korea), and the other half 100%
cotton, so participants were
exposed to both interventions at
the same time
Garments worn during the day
and night for 4 weeks
SCORAD decreased from 30.8
(SD ±8.4) to 19.5 (SD ±6.3) on
Skin Doctor side, and from 30.7
(SD ±8.8) to 25.33 (SD ±8.2) on
cotton side after 4 weeks
(p< 0.001, 95% CI 3.60 to 8.43)
Cellulose
seaweed fabric
with silver
Fluhr et al.
(2010)20
37 Group A: silver-loaded seaweed-
based cellulose fibre garments
(SeaCell® Active, SeaCell GmbH,
Rudostadt, Germany) (n = 19)
Group B: cotton garments (n= 18)
Long-sleeved t-shirts worn for
8 weeks
Change in Staphylococcus aureus
colonisation after 8 weeks was
10 participants in silver group
compared with four participants in
the cotton group (p = 0.0120)
Cellulose fibre Love and
Nedorost
(2009)21
15 with AE
and 15 control
(27 analysed)
Intervention A: cellulosic fibre
(lyocell, Lenzing AG, Lenzing,
Austria) garments
Intervention B: 100% cotton
garments
Short sleeved t-shirts, long-sleeved
pyjama tops and trousers and
bedding were provided.
Participants were randomised to
use either the lyocell or cotton for
1 week. Following this, all used
their normal clothes for a 1-week
wash-out period and then crossed
over to the other intervention for
1 week
Atopic participants’ average itch
score was lower during the week
they used lyocell (2.08) than the
week they wore cotton (2.67).
Both lyocell and cotton produced
a lower itch score then usual
clothing (3.42)
Anion textile Kim et al.
(2012)22
52 (44 analysed) Intervention A (n= 30):
undergarments made from an
anion textile (constructed from
pure polyester filaments
containing nanosized, fine-crusted
tourmaline powder)
Intervention B (n= 22):
undergarments made from pure
cotton
Participants were instructed to
wear the undergarments at all
times during the 4-week study
period
Mean SCORAD decreased from
47.2 (SD ±14.0) to 36.1
(SD ±16.5) in the anion group,
and from 41.8 (SD ±16.3) to 37.7
(SD ±17.2) in cotton group at
4 weeks. A significant difference
was detected between the groups
(p= 0.03)
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Search strategies used to identify studies
l Global Resource for Eczema Trials (GREAT) database was searched on 18 May 2016. The full search
strategy used for the GREAT database can be found at www.greatdatabase.org.uk/GD4/Home/
Strategy.php (accessed 18 May 2016).
l PubMed (www.ncbi.nlm.nih.gov/pubmed) was searched on 11 May 2016 using the following terms:
(‘dermatitis, atopic’ [MeSH Terms] OR ‘eczema’ [MeSH Terms] OR ‘eczema’ [All Fields] OR ‘atopic
dermatitis’ [All Fields] OR ‘neurodermatitis’ [All Fields]) AND (clothes OR clothing OR ‘clothing’
[MeSH Terms] OR fabric OR fabrics OR textile OR textiles OR ‘textiles’ [MeSH Terms] OR silk OR ‘silk’
[MeSH Terms] OR garment OR garments).
TABLE 51 Summary of RCTs investigating therapeutic clothing (other than silk) for AE (continued )
Type of
clothing Reference Participants Interventions Main results
Ethylene vinyl
alcohol (EVOH)
fibre
Ozawa et al.
(2008)23
30 Group A: EVOH copolymer fibre
underwear (MEDIELE®)
Group B: Cotton underwear
Both groups wore the intervention
for 4 weeks, and then crossed
over to the other intervention for
4 weeks
No difference in local SCORAD
between groups
EVOH fibre Yokoyama
et al. (2009)24
21 Group A (n= 10): EVOH fibre
underwear (short sleeved)
Group B (n= 11): cotton
underwear
Followed up for 4 weeks
Mean SCORAD decreased from
22.1 (SD 19.1) to 10.7 (SD 12.1)
in EVOH group, and from 21.4
(SD 17.0) to 15.1 (SD 14.3) in the
cotton group at follow-up
Borage oil-
coated cotton
Kanehara
et al. (2007)25
32 Group A: cotton undershirt
coated with borage oil (n= 16)
Group B: non-coated cotton
undershirts (n = 16)
Garments worn for 2 weeks
In the borage oil group, itch
improved from 1.44 (SD ±0.51) to
0.94 (SD ±0.57) and erythema
from 0.81 (SD ±0.83) to 0.31
(SD ±0.48) after 2 weeks. No
changes observed for papules,
erosion, scaling or lichenification
in borage oil group. No
differences in clinical symptoms
observed in the non-coated cotton
group after 2 weeks
Chitosan-
coated cotton
Lopes et al.
(2015)27
78 (69 analysed) Group A: chitosan-coated cotton
(n= 43)
Group B: cotton (n = 35)
Long sleeved pyjama tops and
trousers worn at night for
8 weeks
SCORAD improved in both groups
after 8 weeks: 44.2 (95% CI 34.5
to 53.9) to 29.4 (95% CI 21.4 to
37.4) in chitosan group and 41.4
(95% CI 34.3 to 48.6) to 25.7
(95% CI 18.3 to 33.1) in cotton
group, with no significant
difference observed between the
groups
Cotton and
synthetic fibres
Diepgen et al.
(1990)26
86 participants
(55 with AD and
31 healthy
controls)
Intervention A: cotton shirts
Interventions B–D: shirts made of
synthetics with different fibre
structure
Intensity of itching/discomfort with
synthetic shirts higher in patients
with AD. Cotton shirts were best
tolerated
AD, atopic dermatitis; EVOH, ethylene vinyl alcohol; p.p.m., parts per million; SCORAD, SCORing Atopic Dermatitis.
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Appendix 2 Parent/guardian information sheet
 
Parent_Guardian Info Sheet_Final 2.0_03 Feb 2014 
 
 
CLOTHES Trial 
 
Parent/guardian information sheet 
(Final version 2.0. 3 Feb 2014) 
 
Title of study:   A clinical trial to see if using silk clothing helps in the relief of 
eczema symptoms 
 
Name of Chief Researcher(s): Professor Kim Thomas 
Name of Local Researcher(s): Local details to be added 
 
 
Where the word “parent” is used, please read parent/guardian i.e. those who have parental responsibility, which may 
include a legal representative such as a grandparent. 
 
 
Your child is being invited to take part in a research study. Before you decide if you wish 
your child to take part, it is important for you to understand why the research is being done 
and what it will involve. Please take time to read the following information carefully.  
 
What is the purpose of the study? 
It has long been understood that clothing can cause irritation to the skin, and current 
guidelines recommend the use of loose cotton clothing and the avoidance of wool and other 
itchy or synthetic materials next to the skin.  In recent years, new silk clothing products have 
been developed for the management of eczema symptoms, but there is no firm evidence to 
suggest that they work. 
 
In order to decide whether silk clothing is a useful addition to the treatments currently 
available for children with eczema, 300 children with eczema will be asked to take part in this 
study: 150 children will be asked to wear the clothing straight away, and 150 children will be 
asked to wear the clothing in 6 months’ time. This will allow us to compare if the clothing has 
any effect on the eczema 
Why has my child been invited? 
Your child has been invited to take part in this study as they are between 1 and 15 years old 
and has been diagnosed as having quite bad eczema. 
 
Does my child have to take part in this study? 
No.  It is up to you and your child (where possible) to decide whether or not to take part.  
Your decision will not affect the standard of eczema care your child receives. 
 
You are both free to withdraw from the study at any time without giving a reason.  This will 
not affect the standard of eczema care your child receives or their legal rights. 
 
What will happen to my child if s/he takes part? 
The study will last for 8 months and your child will be asked to come into clinic at the hospital 
four times in total.  A contribution towards reasonable travel expenses will be offered.  
 
Screening 
On your first visit to the nurse, the study will be explained to you and your child (if 
appropriate).  If you are happy for your child to take part, you will be asked to sign a consent 
form.  If your child is old enough, they can sign the form too, if they wish. 
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They will then be examined by a research nurse to make sure that they are suitable to take 
part in the study. If they are suitable, your child’s eczema will be examined by the research 
nurse and you will be asked some questions about the eczema, the treatment they use and 
whether they experience many skin infections.  You will also be asked to complete some 
short questionnaires. 
 
This first visit will be between 60 and 90 minutes. 
 
Group Allocation 
In order to find out if silk clothing (bodysuits, leggings and vests) alongside normal eczema 
treatment is effective in the long term management of children with eczema, the children in 
this study will be split into two groups: one group will wear the clothing from the onset of their 
participation in the study, the other group will continue with their normal eczema treatment.  
 
 
 
 
 
 
 
 
 
 
 
 
   Clothing for babies / infants                                 Clothing for older children 
 
The decision as to which group your child will be allocated to will be done randomly by a 
computer and they will have an equal chance of being in either group.  You will be sent a 
letter from the unit who are running the study, soon after your first visit with the nurse, that 
outlines what group your child is in and what to do next. 
 
It is important to realise that we currently do not know if the silk clothing will have any effect 
on the eczema so there is nothing to lose, or gain, by being in either of the two groups. 
 
Clothing Now Group 
For the first 6 months of the trial this group will be given the clothing to wear whilst 
continuing with their normal eczema care.  
 
Three sets of garments will be sent after the first visit with the nurse, and you will be able 
request replacement clothes in the first 6 months if the clothing starts to wear out or 
becomes too small.  You will be asked to return the clothing you would like replaced.  
 
Over this first 6 months you will be asked to complete a short questionnaire each week to 
record information about your child’s eczema, whether they saw any healthcare 
professionals about their eczema, whether they had any prescriptions for their eczema, and 
how many days and nights they actually wore the clothing that week.   
 
This questionnaire can be completed either on-line or by post.  If you choose to complete it 
on-line, we will ask for your e-mail address. 
 
You will be given a diary card and a wall chart (with stickers if your child would like!) to help 
you remember this information from one week to the next. 
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Clothing Later Group 
This group will continue with their normal eczema care over the first 6 months of the study. 
Over this first 6 months you will be asked to complete a short questionnaire each week to 
record information about your child’s eczema, whether they saw any healthcare 
professionals about their eczema, and whether they had any prescriptions for their eczema. 
This questionnaire can be completed either on-line or by post.  If you choose to complete it 
on-line, we will ask for your e-mail address. 
You will be given a diary card and a wall chart (with stickers if your child would like!) to help 
you remember this information from one week to the next. 
Nurse Visits 
Your child will need to visit the nurse 3 times: at 2, 4 and 6 months. Your child will be 
examined by the research nurse and you will be asked about the eczema treatments they 
have used (not including the silk clothing) and if they have had any skin infections.  You will 
also be asked how you think your child’s eczema is by completing a short questionnaire. 
These three visits should take no longer than 30 minutes.  
It is important that the research nurse looking after your child doesn’t know whether your 
child is wearing the clothing or not.  If the nurse knew this information it might mean that 
assessments of your child’s skin might be influenced by this knowledge.  This is called bias.  
We would ask that your child does not wear the clothing to any clinic visit or talk to the 
research nurse about the clothes. 
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Last two months of the study 
For the last two months of the study, all children in the study will wear the clothing. The 
children who wore the clothing for the first 6 months will continue to wear the clothing they 
already received. 
 
For the group who receives the clothing after the 4th visit with the nurse, 3 sets of garments 
will be sent to you at this point. If they do not fit when you receive them you will have an 
opportunity to send them back immediately and receive a replacement set in the correct size. 
 
All children should continue wearing the clothing for the next two months of the study. At the 
end of the 8 month mark, a short questionnaire will be sent to you, and this will mark the end 
of the trial. 
 
After the end of the trial, all children get to keep the clothes they were given during the trial, 
to wear as often or as little as they choose. 
 
 
Saliva (spit) sample 
During a clinic visit you will be asked if you are willing for your child give a saliva (spit) sample. 
If you don’t want your child to give the sample, that’s fine – they can still take part in the main 
study.  Please just say that you would rather not take part in this. 
 
If you choose for your child to give a sample, we will ask them to spit into a small pot, or if they 
are too young to spit, the nurse will collect some saliva on an absorbent cotton bud. . 
 
What are the alternative treatments for my child? 
This study does not restrict your child’s current or future treatment and your child will still 
receive all their normal eczema treatments while in the study.  The wearing of the clothes 
being tested is in addition to their normal treatment. 
 
What are the possible disadvantages and risks of taking part? 
Since your child will be receiving their normal eczema treatment throughout the study, no 
major risks or disadvantages to their eczema is expected.  It may be that your child finds the 
clothing uncomfortable or that it makes them too hot.  This can be addressed by checking 
that the size is correct for your child and perhaps using lighter clothing on top of the silk trial 
clothing (or wearing them as pyjamas at night). 
 
Are there any possible side effects? 
There are no known side effects to wearing the clothing but we will be collecting the 
information on the number of skin infections experienced by the children, just in case this is 
affected. 
 
What are the possible benefits of taking part. 
There are no direct benefits to you or your child from taking part in this study, although you 
may feel that visits to the research nurse is helpful.  Some past study participants have said 
that they found regular monitoring of their eczema at home useful. 
 
It is possible that your child’s skin may improve through wearing the clothing, but we do not 
know if this is the case, and it is possible that the clothing may have no impact or make the 
eczema worse. 
 
What happens when the research study stops? 
When your child completes their 8 months in the study, the results of the study will not be 
known so we cannot make any recommendations for their future treatment at that time.  You 
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will be able to keep the clothing at the end of the study. You can also speak to your child’s 
doctor about their future eczema treatment. 
 
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak to the local 
researchers (their contact details are at the end of this sheet) who will do their best to 
answer your questions. If any questions remain you can contact the Chief Investigator of this 
study Professor Kim Thomas (kim.thomas@nottingham.ac.uk).  If you remain unhappy and 
wish to complain formally, you can do this by contacting NHS Complaints via the Patient 
Advisory and Liaison Service (PALS).  The details are at the end of this leaflet. 
 
In the event that something does go wrong and your child is harmed during the research 
study there are no special compensation arrangements.  If they are harmed and this is due 
to someone’s negligence then you may have grounds for a legal action for compensation but 
you may have to pay your legal costs.  The normal National Health Service complaints 
mechanisms will still be available to you. 
 
Will my child taking part in this study be kept confidential? 
Yes. We will follow ethical and legal practice and all information about your child will be 
handled in confidence. 
 
If your child joins the study, some parts of the data collected for the study will be looked at by 
authorised persons from the University of Nottingham who are organising the research. They 
may also be looked at by authorised people to check that the study is being carried out 
correctly. All will have a duty of confidentiality to your child as a research participant and we 
will do our best to meet this duty. 
 
All information which is collected about your child during the course of the research will be 
kept strictly confidential, stored in a secure and locked office, and on a password 
protected database.  Any information about your child which leaves the research centre will 
have your name and address removed (anonymised) and a unique code will be used so that 
your child cannot be recognised from it.   
 
All research data will be kept securely for seven years.  After this time your child’s data will 
be disposed of securely.  During this time all precautions will be taken by all those involved 
to maintain your child’s confidentiality.  Only members of the research team will have access 
to their personal data. 
 
In order to be able to contact you about how your child is getting on, your child’s name and 
contact details will be made available to the researchers running this study.  These details 
will be kept securely, with access restricted. Your child will not be named or otherwise 
identified in any study publication. 
 
You will be asked to consent to your child’s identifiable details being registered with the NHS 
Information Centre. These may be used to help us keep in touch with you and to follow up 
your child’s health status. We will have confidentiality and security agreements in place to 
ensure your child’s details are dealt with in the strictest confidence. 
 
With your permission we will inform your child’s GP that they are participating in this 
research study. 
 
We have a mailing list to inform parents and guardians about skin research that is being 
carried out. If you would like to be added to that list you can indicate this on the consent form.  
The contact email address you provide will be held in a separate secure database. 
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What will happen if I don’t want to carry on with the study?  
Your child’s participation is voluntary and they are free to withdraw at any time, without 
giving any reason, and without your or your child’s legal rights being affected. If your child  
withdraws then the information collected so far cannot be erased and this information may 
still be used in the project analysis. 
 
 
Will any genetic tests be done? 
If you agree, the research nurse will collect some saliva from your child’s mouth to test for a 
gene which may play a part in childhood eczema. The sample will be sent to a genetics 
laboratory at the University of Dundee for analysis. 
 
We will only test for a gene that may be relevant to childhood eczema and we will not do any 
other genetic testing. Current guidelines suggest that you should not be informed of the 
results of this test as the findings will not be used to influence your child’s clinical care.  The 
research nurse can explain why this is if you would like to know more. 
 
The results from this testing will be sent securely back to the Nottingham Clinical Trials Unit 
(the co-ordinating centre). 
 
What will happen to any samples my child gives? 
Any remaining samples may be stored and used to test for other genes found to be 
associated with eczema in the future – this is optional (please indicate you agree to this on 
the consent form). The samples will be stored with a code unique to your child and securely 
at the Centre for Dermatology & Genetic Medicine of the University of Dundee (Ethics 
number 12/ES/0083).  The samples will only be made available to the existing study team. 
 
Any samples or data will be anonymised, and your child will not be identified in anyway. You 
do not have to agree to store your child’s sample to be able to take part in the genetics study. 
If you do not agree to this, any remaining samples will be disposed of in accordance with the 
Human Tissue Authority’s codes of practice. 
 
What if relevant new information becomes available about the topic being studied?   
Sometimes during the course of a research project new information becomes available 
about the topic being studied.  If this happens, a member of the research team will tell you 
and your child (if applicable) about it and discuss whether you want your child to continue in 
the study.  If you decide that you wish your child to continue in the study you will be asked to 
sign an updated consent form, which your child may also sign if they wish.  Also, on 
receiving new information the research team might consider it to be in your child’s best 
interests to withdraw them from the study.  If this happens, they will explain the reasons why.   
If the study is stopped for any other reason, you will be told why.  
 
What will happen to the results of the research study? 
When the study has been completed, the data will be analysed and the results published in 
a medical journal and presented at medical meetings.  You will be sent a copy of the results 
unless you tell us that you would prefer not to receive them.  The results will allow a 
recommendation to be made to doctors and nurses about whether silk clothing is useful in 
the treatment of eczema in children. 
 
Who is organising and funding the research?   
This research is being organised by the University of Nottingham and is being funded by the 
National Institute of Health Research (NIHR) Health Technology Assessment Programme.  
The clothing being used in the study has been donated by the clothing suppliers for these 
garments. 
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Who has reviewed & approved the study? 
All research in the NHS is looked at by independent group of people, called a Research 
Ethics Committee, to protect your interests. This study has been reviewed and given 
favourable opinion by [NAME] Research Ethics Committee. 
 
Further information and contact details 
Contact Details of your local Research team 
 
Name__________________________ and Telephone Number______________________ 
 
 
Contact details for any questions about the clothing 
 
Name__________________________ and Telephone Number______________________ 
 
 
If you have any general queries about participating in research you can contact the Patient 
Advisory and Liaison Service (PALS) Local PALS details to be added.  
 
THANK YOU FOR READING THIS INFORMATION SHEET 
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Appendix 3 Child information sheet
(for age 1–5 years)
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Appendix 4 Child information sheet
(for age 6–10 years)
Clothes N Clothes Later
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Great!! Rubbish! 
It would be really good if you 
could tell your mum or dad what 
you think about the clothes.  You 
don’t have to say that they are 
good if they aren’t. 
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Appendix 5 Child information sheet
(for age 11–15 years)
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Appendix 6 Statistical analysis plan
1132CLOTHES_SAP_final_v1.0_15thDecember2015 
 
Randomised controlled trial of silk therapeutic 
clothing for the long-term management of eczema in 
children  
 
FINAL Statistical Analysis Plan 
 
Version 1.0 (15th December 2015) 
 
Based on Protocol version 3.0  
(dated 11 February 2014)
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Appendix 7 Eczema Area and Severity Index
resources for research nurses
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Appendix 8 Participant sticker charts
(intervention and control)
Month: …………………………………     Month: …………………………………   Month: ………………………………… 
01       01       01     
02       02       02     
03       03       03     
04       04       04     
05       05       05     
06       06       06     
07       07       07     
08       08       08     
09       09       09     
10       10       10     
11       11       11     
12       12       12     
13       13       13     
14       14       14     
15       15       15     
16       16       16     
17       17       17     
18       18       18     
19       19       19     
20       20       20     
21       21       21     
22       22       22     
23       23       23     
24       24       24     
25       25       25     
26       26       26     
27       27       27     
28       28       28     
29       29       29     
30       30       30     
31       31       31     
Please use this chart to record how long you have been in the study 
 
 
 
 
If you don‛t want to put the stickers on, you could cross the suns or moons out. 
CLOTHES control sticker chart Final 1.0 – 5 Sept 2013 
Place a sticker on the moon       
for each night you have been 
in the study. 
Place a sticker on the sun         
for each day you have been in 
the study. 
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Appendix 9 Case report form worksheet
CLOTHES WORKSHEET, Final Version 26 MAR 2014        
 
 
 
 
CLOTHES 
 
Randomised controlled trial of silk therapeutic clothing for the 
long-term management of eczema in children  
 
 
WORKSHEET 
 
 
 
 
 
 
 
 
 
 Participant Initials:  
 
 Participant ID:  
 
 Sponsor: University of Nottingham 
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CLOTHES WORKSHEET, Final Version 26 MAR 2014
General Instructions 
Determining Eligibility 
Visit 1 should be performed to determine the eligibility of the participant for inclusion into the trial. 
If at any point it is determined that the participant is not eligible for inclusion it is not necessary to 
continue with any further assessments. 
 
Randomising  
If all assessments have been performed and the patient is eligible: 
• Proceed to enrol and randomise the patient by following this link: 
https://ctsu2.nottingham.ac.uk/1132/login.asp 
 
Enrol the participant by entering the:  
• Gender 
• Date of Birth 
• Initials  
• Height in cm 
Then on the contacts page add: 
• Contacts details and preference for either online or postal weekly questionnaires. 
 
Once enrolled the participant will be assigned a unique participant ID. Please record this on the 
worksheet. It is only necessary to enrol participants who will be randomised. 
 
Once the enrolment details and contact details have been added the participant can be 
randomised. 
 
Completing the eCRF 
Once the participant has been randomised please follow this this link and enter the visit 1 data 
within 7 days of the visit: 
https://mcwapctu01.nottingham.ac.uk/macro/ 
 
The worksheets should be filed locally in a locked filing cabinet (there is no need to copy and 
send to the co-ordinating centre) 
 
Serious Adverse Events 
If the participant experiences any adverse events after being randomised these should be 
reported on the paper SAE form and faxed into the NCTU.  Please see Trial Manual for Fax 
details. 
 
Completing this worksheet 
This is a worksheet to help collect the information in the clinic.  
Worksheets will need to be retained if information is not being recorded into the patient’s notes, 
as they constitute source data. 
 
Participant initials                          
 
These should be recorded as 3 digits eg HKP, however if the participant does not have a middle 
initial it should be recorded as eg: H-P 
 
Participant ID: 
 
The 5 digit participant ID will be assigned once randomised, it is made up of 2 digit site ID 
followed by a sequential 3 digit number. 
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CLOTHES WORKSHEET, Final Version 26 MAR 2014
Online / Postal weekly questionnaires 
 
• If at any point during the study the participant/parent/guardian wishes to change their 
preference for online questionnaires to postal or vice versa this can be updated on the 
contacts details page. 
• If the participant is withdrawn from the study and therefore no longer wishes to receive the 
links/reminders for the questionnaires, the site or the trial manager are able to mark the 
participant as withdrawn. 
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Participant initials: 
 
Participant ID: 
 
 
  VISIT 1 - BASELINE  
 
 
CLOTHES WORKSHEET, Final Version 26 MAR 2014
VISIT INFORMATION  
Date of Visit: 
                                                                                    
   
                                            DD/MMM/YYYY  
 
     
      DEMOGRAPHY 
 
 
Date of birth: 
 
 
 
                              DD/MMM/YYYY 
 
Initials: 
 
Gender: Male  Female  
Ethnicity 
(tick one only) 
White   Black (Other)  
Indian  Chinese  
Pakistani   Other Asian (non–Chinese)  
Bangladeshi  Mixed Race  
Black Caribbean  Other  
Black African  Not Given  
INFORMED CONSENT 
Consent Type 
Was written 
Informed Consent 
obtained? 
Date of Informed Consent 
DD/MMM/YYYY 
Yes No 
Study Informed Consent  (Mandatory)                                2   0 
Informed Consent for Genetic Study 
(Optional) 
  
   
                         2   0 
Informed Consent for Storage of Genetic 
Samples 
(Optional- if ‘Yes’ above question must also be Yes) 
  
                         
                         2   0 
 
Parent/Guardian agreed to be added to the 
Centre of Evidence Based Dermatology’s 
mailing list  (Optional) 
  
           
                        2   0 
Guardian/Parent would like to receive a copy 
of the study results (Optional)   
                              
                                             2   0 
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Participant initials: 
 
Participant ID: 
 
 
  VISIT 1 - BASELINE  
 
 
CLOTHES WORKSHEET, Final Version 26 MAR 2014
 
• To be eligible at least one patch of eczema should be present on the trunk or the limbs. 
 
BASELINE CHARACTERISTICS 
  No Yes 
Does the child have a history of any of the 
following conditions? 
Asthma   
Allergic rhinitis (hayfever, perennial rhinitis)   
Food allergy (eliminates a food from diet)   
Anaphylaxis (have an Epipen/Jext/Anapen)   
What are the types/patterns of Eczema? 
(currently present) 
Flexural   
Discoid   
Reverse Pattern   
Where on the body is the Eczema?  
(at the moment) 
      
Head and Neck   
Hands and Wrists   
Feet and Ankles   
Limbs   
Trunk   
Has your child’s eczema been previously 
treated by the following: 
GP   
Secondary Care  
(dermatologist or other specialist)   
UK DIAGNOSTIC CRITERIA  
In order to qualify as a case of atopic eczema with the UK diagnostic 
criteria, the child must have: No Yes  
1. Has child had an itchy skin condition in the last 12 months    
Plus three or more of: No Yes N/A 
2. Has child had onset below age 2  (not used in children under 4 years)     
3. Has child had a history of flexural involvement     
4. Has child had a history of a generally dry skin     
5. Has child had a personal history of asthma or hayfever (in children aged under 4 years, history of atopic disease in a first degree relative may be included)    
6. Visible flexural dermatitis as per photographic protocol     
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• See Trial Manual for guidance 
 
ECZEMA TREATMENT  
• Please only record medications used on the areas covered by the clothing, not those used on 
hands/feet 
• If more than 2 medications for each category have been used in the last month please enter the most 
frequently used medication 
• Main emollient/steroid/calcineurin inhibitors = most frequently used  
• Please see emollient ladder/steroid ladders for classification of consistency/potency 
EMOLLIENTS  
Has the child used Emollients on the body within the last month?   No                      Yes   
Name of Emollient 
 Used on Body 
Consistency 
(tick one only) 
Main 
Emollient? 
1. 
__________________ Light  Creamy  Greasy Very Greasy  
Yes  
No  
2. 
__________________ Light  Creamy  Greasy Very Greasy  
Yes  
No  
Please see Emollient ladder for classification of medications into Light, Creamy, Greasy and Very Greasy  
 
TOPICAL STEROIDS  
Has the child used topical steroids on the body within the last month?         No                            Yes   
Name of Steroid  
Used on Body 
Potency 
(tick one only) 
Main 
Steroid? 
1. 
_________________ Mild  Moderate  Potent Very Potent  
Yes  
No  
2. 
_________________ Mild  Moderate  Potent Very Potent  
Yes  
No  
Please see Steroid ladder for classification of medications into Mild, Moderate, Potent or Very Potent. 
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CALCINEURIN INHIBITORS 
Has the child used Calcineurin Inhibitors on the body within the last month?  eg Protopic (Tacrolimus), 
Elidel (Pimecrolimus)       
  No                      Yes   
Name of Calcineurin Inhibitor Used on Body Strength (tick one only) 
Main 
Calcineurin 
Inhibitor? 
1. __________
_____________ Mild  Moderate  
Yes  
No  
2. __________
_____________ Mild  Moderate  
Yes  
No  
Protopic (Tacrolimus)  = 0.03% = Mild 
Elidel (Pimecrolimus) = 1% = Moderate      
 
MEDICATIONS 
How many times have wet/dry 
wraps been used in the last 
month for their eczema? 
(tick one only) 
(this includes tubifast, itchopaste 
bandage) 
None  1-4 times  
5-10 times  >10 times   
(Participant should be excluded if ≥ 5)  
Do you/your child use any other 
treatment in addition to 
Emollients, Steroids and 
Calcineurin Inhibitors for their 
eczema eg tablets, or 
antihistamines? 
No  Yes  
If yes, please specify  
 
_____________________________________________________________________
_____________________________________________________________________ 
Any new prescribable 
treatments used in the last 
month? 
No  Yes  
If yes, please specify 
e.g. methotrexate, cyclosporin, 
aziathioprine, light therapy, 
prednisolone, mycophenolate 
mofetil are prohibited medications 
___________________________________________________________________ 
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NOT FOR DATABASE 
CHECKLIST 
Do you/your child currently 
use silk clothing for 
eczema? 
No  Yes  
If yes, prepared to stop 
using them? 
No  Yes  
If No, then participant is not eligible 
Currently enrolled in any 
other trial? 
No  Yes  
If Yes, then participant is not eligible 
Does the skin show signs of 
Infection? 
No  Yes  
If yes, recommend that the patient contacts their normal medical team (GP, Nurse, 
dermatologist) as appropriate 
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      Mark if not done 
NOTTINGHAM ECZEMA SEVERITY SCORE (NESS) 
 
Surface area measurement using tick boxes 
Record a tick in each box if more than 2cm² (size of a 10 pence coin) is involved with AE. Calculate the total ticks by  
adding together the number of recorded ticks for both the front and back of the surface diagram.  The final score is 
calculated using the table below. 
 
 
 
 
 
Number of ticks Score Final score (tick one) 
0-2 1  
3-5 2  
6-10 3  
11-20 4  
>20 5  
© R.M. Emerson, H.C. Williams, Department of Dermatology, University Hospital, Queen’s Medical Centre, 
Nottingham, NG7 2UH, U.K. 
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1. Clinical Course (ask the Parent) 
In the Last 12 months has your child’s skin condition been: Score (please circle one answer) 
a). Present for less than 6 weeks in total? 1 
b). Present for between 6 weeks and less than 3 months in total? 2 
c). Present for between 3 months and less than 6 months in total? 3 
d). Present for between 6 months and less than 9 months in total? 4 
e).  Present for more than 9 months in total? 5 
2. Clinical Intensity (ask the Parent) 
In the last 12 months, how often has your child’s sleep usually been 
disturbed by itching or scratching due to their skin problem? 
Score (please circle one answer) 
a). Sleep is not usually disturbed 1 
b). 1 night per week on average 2 
c). 2 or 3 nights per week on average 3 
d). 4 or 5 nights per week on average 4 
e). 6 or more nights per week on average 5 
3. Extent of Atopic  Eczema by examination  (see diagram opposite for details) 
Score (please circle one answer) 
1 
2 
3 
4 
5 
4. Final Assessment severity 
Mild: total score 3-8  
Moderate: total score 9-11  
Severe: total score 12-15  
• If total score is 8 or less then they are not eligible to be included in the study. 
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      Mark if not done 
THREE ITEM SEVERITY SCALE (TIS) 
Criteria Score (tick one only) 
Erythema Absent (0)  Mild (1)  Moderate (2)  Severe (3)  
Oedema / papulation Absent (0)  Mild (1)  Moderate (2)  Severe (3)  
Excoriation Absent (0)  Mild (1)  Moderate (2)  Severe (3)  
Representative Body Site: Choose one representative body site to assess all three signs. The representative site 
should be in an area covered by the clothing, and be the area that, in the view of the parent/participant, is most 
bothersome. The representative body site may change from visit to visit. 
Total Score:   
 
DOI: 10.3310/hta21160 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 16
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Thomas et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
167
 
Participant initials: 
 
Participant ID: 
 
 
  VISIT 1 - BASELINE  
 
 
CLOTHES WORKSHEET, Final Version 26 MAR 2014
 
APPENDIX 9
NIHR Journals Library www.journalslibrary.nihr.ac.uk
168
 
Participant initials: 
 
Participant ID: 
 
 
  VISIT 1 - BASELINE  
 
 
CLOTHES WORKSHEET, Final Version 26 MAR 2014
   Mark if not done 
• Assess each body area for redness (erythema), papulation & oedema, scratching (excoriation) and 
lichenification (lined skin) 
• Using the photographic comparison table, assign a score for each of the signs in each of the four body 
areas.  Assess each sign for the entire body region – so for example a patient may have grade 1 erythema 
in some areas, but grade 3 erythema in others.  If that is the case, then the “average of the two” is taken 
and so the score become 2.  Likewise, if they have some areas that are grade 2 and others that are grade 
3, then the score becomes 2.5.   
• Score the percentage area of each region affected by eczema 
ECZEMA AREA AND SEVERITY INDEX (EASI) 
Body 
Area 
% Area affected by 
Eczema  
(tick one only) Criteria 
Score 
 (tick one only) 
Absent 
(0) (0.5) 
Mild 
(1) (1.5) 
Moderate 
(2) (2.5) 
Severe 
(3) 
Head 
and 
Neck 
Nil    50-69%  Redness        
1-9%  70-89%  Oedema/Papulation        
10-29%  90-100%  Scratching        
30-49%    Lichenification        
 
Upper 
Limbs 
Nil    50-69%  Redness        
1-9%  70-89%  Oedema/Papulation        
10-29%  90-100%  Scratching        
30-49%    Lichenification        
 
Trunk 
Nil    50-69%  Redness        
1-9%  70-89%  Oedema/Papulation        
10-29%  90-100%  Scratching        
30-49%    Lichenification        
 
Lower 
Limbs 
Nil    50-69%  Redness        
1-9%  70-89%  Oedema/Papulation        
10-29%  90-100%  Scratching        
30-49%    Lichenification        
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HYPERLINEAR PALMS 
Hyperlinear palms?  No  Yes     Unsure  
 
Please see Trial Manual for details 
 
 
      Mark if not done 
INVESTIGATOR’S GLOBAL ASSESSMENT (IGA) 
 
 
 Tick when completed 
Completed by: 
(tick one only) 
• PATIENT’S GLOBAL ASSESSMENT (PGA) (included in 
‘Clinic Questions’) 
To be completed by parent/guardian or child 
 
Please request that where possible if the child 
performs the baseline assessment, the child 
completes the follow up questionnaires or if the 
parent/guardian performs the baseline 
assessment, the parent/guardian completes the 
follow up questionnaires. 
 
 
Parent/Guardian  
Child  
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INCLUSION CRITERIA 
To be eligible for this trial all the inclusion criteria must be answered Yes No Yes 
1. Child aged 1 to 15 years at baseline.   
2. Diagnosis of moderate or severe eczema (atopic dermatitis). Presence of eczema will be 
confirmed using the UK Diagnostic Criteria for Atopic Eczema and eczema severity judged 
using the Nottingham Eczema Severity Scale (NESS) (Score of 9 or above) 
  
3. Resident within travelling distance of a recruiting centre.   
4. Child should have at least one patch of eczema on the trunk or the limbs.   
5. Parents/legal guardian able to give informed consent   
EXCLUSION CRITERIA 
To be eligible for this trial all the exclusion criteria  must be answered No No Yes 
1. Child who has taken systemic medication (including light therapy) or oral steroids for 
eczema within the previous three months.   
2. Child who has started a new treatment regimen within the last month.   
3. Child who has used wet/dry wraps ≥5 times in the last month.   
4. Child who is currently using silk clothing for their eczema and are unwilling to stop using the 
clothing during the trial.   
5. Child who is currently taking part in another clinical trial.   
   6. Child who has expressed a wish not to take part in the trial.   
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NOT FOR DATABASE 
 
 
SURVEY OF SKIN PROBLEMS – For Parents of children aged 3 and under 
 
1. In the last year, has your child had an ITCHY skin condition – by itchy we mean scratching or rubbing the 
skin?                                          Yes     No 
 
If you have answered “NO” please skip to Question 4 
If you have answered “YES” please answer all the questions  
 
2. At what age did your child’s ITCHY skin condition start?  
 
   ________years ________ months 
 
3. Has this skin condition ever affected the skin creases in the past – by skin creases we mean fronts of 
elbows, behind the knees, fronts of ankles, around the neck, or around the eyes? 
       Yes     No 
 
4. In the last year, has your child suffered from a dry skin in general?  
                                     Yes     No 
 
5. Does anyone in your child’s immediate family (i.e. mother, father, brother or sisters) suffer from:   
eczema?  Yes     No 
hay fever?   Yes     No 
asthma?  Yes     No 
SURVEY OF SKIN PROBLEMS – For Parents of children aged 4 to 15 years 
 
1. In the last year, has your child had an ITCHY skin condition – by itchy we mean scratching or rubbing the 
skin?                 Yes     No 
 
If you have answered “NO” please skip to Question 5 
If you have answered “YES” please answer all the questions  
 
 
2. Has your child had this ITCHY skin condition in the LAST WEEK? 
       Yes     No 
 
3. How old was your child when this skin condition began?  
Under 2 [   ]  2 to 5 [   ] 6 to 10 [   ] Over 10 [   ] 
 
4. Has this skin condition ever affected the skin creases in the past – by skin creases we mean fronts of 
elbows, behind the knees, fronts of ankles, around the neck, or around the eyes? 
       Yes     No 
 
5. In the last year, has your child suffered from a dry skin in general?  
       Yes     No 
 
6. Does anyone in your child’s immediate family (i.e. mother, father, brother or sisters) suffer from:  
eczema?  Yes     No 
hay fever?   Yes     No 
asthma?  Yes     No 
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Please ensure Visit 1 Parent/Guardian/Child Questionnaires are completed during the visit: 
 
 Tick when completed 
Completed by  
• PATIENT ORIENTED ECZEMA MEASURE (POEM)   
To be completed by parent/guardian or child 
 
Patient 
/Guardian 
 
Child  
• CLINIC QUESTIONS 
To be completed by parent/guardian or child 
 
 
• DERMATITIS FAMILY IMPACT QUESTIONNAIRE (DFI) 
To be completed by parent/guardian  
 
 
• EQ-5D-3L 
To be completed by parent/guardian  
 
• THE CHILD HEALTH UTILITY 9 DIMENSIONS  (CHU-
9D) 
To be completed by parent/guardian or child for 
children of aged 5 or over only 
 
 
• ADQoL 
To be completed by parent/guardian or child 
 
 
              Comments on ADQoL:  
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EQ5D: ‘Your Own Health State Today’ 
• If the line does not cross the scale, draw a horizontal line: 
 
• If a circle is drawn, select middle of circle as the measurement. 
• If the response is not clear, please record as ‘missing 
 
 
RANDOMISATION 
Participant randomised into the trial? 
No  Yes  
If yes please fill in participant ID on the front and at the top of 
each page. 
The below information will need to recorded to enable randomisation of the participant, please also 
record all contact details on the contact sheet.  
Please record patient’s height (cm) 
 
Please give details of child’s build/clothing size 
(i.e. any info that will help trial team select the appropriate 
size clothing) 
 
 
 
 
 
Record preference for type of weekly 
questionnaires 
Paper  
Online  
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NOT FOR DATABASE 
REMINDERS 
 
• Discuss with the participant/guardian/carer: 
1. If any visits occurred to a healthcare professional within the last 4 weeks  
2. If any prescriptions were made for eczema within the last 4 weeks  
 
If the response is yes to any of the above please record on pages 33-38.  
 
• Discuss what will happen next 
• Book an appointment  for the next clinic visit 
• If consent has been obtained to collect a saliva sample, has a sample been collected today and recorded 
on the sample collection page?  
• File a copy of consent form in the hospital notes (if recruited by secondary care) 
• Send a copy of consent form to GP (if primary care or direct advert) 
• Send a letter to GP with a copy of Patient Information Leaflet 
• Put recruitment sticker on patient’s notes along with a copy of the Patient Information Leaflet 
 
Please ensure the participant is given the following: 
• Diary  
• Spare weekly questionnaires and envelopes 
• Travel expenses 
• Small gift 
 
 
  
 
 
Investigator’s/designee’s Signature: ______________________  Date D  D  M  M  M  2 0  Y  Y 
                                                                                                                                                                  DD/MMM/YYYY 
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      Mark if visit not done 
VISIT INFORMATION  
Date of Visit: 
                                         
                                             
                                            DD/MMM/YYYY  
 
 
 
MEDICATIONS 
In the last 2 months roughly how 
often have emollients been used? 
(tick one only) 
Never  Rarely  
Sometimes  Often  
Always    
In the last 2 months roughly how 
often have steroids or calcineuron 
inhibitors been used? 
(tick one only) 
Never  Rarely  
Sometimes  Often  
Always    
In the last 2 months roughly how 
often have wet/dry wraps been used 
for their eczema? 
(tick one only) 
(this includes tubifast, itchopaste 
bandage) 
None  1-4 times  
5-10 times  >10 times   
Has the eczema treatment changed 
since the last clinic visit? Yes   No   
If yes, type of change 
Escalation  Neutral Change  
Reduction  Unsure  
 
If Unsure, please specify    ____________________________________________________ 
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      Mark if not done 
THREE ITEM SEVERITY SCALE (TIS) 
Criteria Score (tick one only) 
Erythema Absent (0)  Mild (1)  Moderate (2)  Severe (3)  
Oedema / papulation Absent (0)  Mild (1)  Moderate (2)  Severe (3)  
Excoriation Absent (0)  Mild (1)  Moderate (2)  Severe (3)  
 
Representative Body Site: Choose one representative body site to assess all three signs. The representative site 
should be in an area covered by the clothing, and be the area that, in the view of the parent/participant, is most 
bothersome. The representative body site may change from visit to visit. 
Total Score:   
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   Mark if not done 
• Assess each body area for redness (erythema), papulation & oedema, scratching (excoriation) and 
lichenification (lined skin) 
• Using the photographic comparison table, assign a score for each of the signs in each of the four body 
areas.  Assess each sign for the entire body region – so for example a patient may have grade 1 erythema 
in some areas, but grade 3 erythema in others.  If that is the case, then the “average of the two” is taken 
and so the score become 2.  Likewise, if they have some areas that are grade 2 and others that are grade 
3, then the score becomes 2.5.   
• Score the percentage area of each region affected by eczema 
ECZEMA AREA AND SEVERITY INDEX (EASI) 
Body 
Area 
% Area affected by 
Eczema  
(tick one only) Criteria 
Score 
 (tick one only) 
Absent 
(0) (0.5) 
Mild 
(1) (1.5) 
Moderate 
(2) (2.5) 
Severe 
(3) 
Head 
and 
Neck 
Nil    50-69%  Redness        
1-9%  70-89%  Oedema/Papulation        
10-29%  90-100%  Scratching        
30-49%    Lichenification        
 
Upper 
Limbs 
Nil    50-69%  Redness        
1-9%  70-89%  Oedema/Papulation        
10-29%  90-100%  Scratching        
30-49%    Lichenification        
 
Trunk 
Nil    50-69%  Redness        
1-9%  70-89%  Oedema/Papulation        
10-29%  90-100%  Scratching        
30-49%    Lichenification        
 
Lower 
Limbs 
Nil    50-69%  Redness        
1-9%  70-89%  Oedema/Papulation        
10-29%  90-100%  Scratching        
30-49%    Lichenification        
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Participant initials: 
 
Participant ID: 
 
 
VISIT 2 – 2 Month Follow Up  
 
 
CLOTHES WORKSHEET, Final Version 26 MAR 2014
 
 
      Mark if not done 
INVESTIGATOR’S GLOBAL ASSESSMENT (IGA) 
 
 
 
 
          Please ensure Visit 2 Parent/Guardian/Child Questionnaires are completed during the visit: 
     
 Tick when 
comple
ted 
Completed by: 
(tick one only) 
• PATIENT’S GLOBAL ASSESSMENT (PGA) (included in 
‘Clinic Questions’) 
To be completed by parent/guardian or child 
 
Please request that where possible if the child 
performs the baseline assessment, the child 
completes the follow up questionnaires or if the 
parent/guardian performs the baseline 
assessment, the parent/guardian completes 
the follow up questionnaires. 
 
 
Parent/Guardian  
Child  
• PATIENT ORIENTED ECZEMA MEASURE (POEM)       
To be completed by parent/guardian or child 
 
Parent/Guardian  
Child  
• CLINIC QUESTIONS 
To be completed by parent/guardian or child 
 
 
APPENDIX 9
NIHR Journals Library www.journalslibrary.nihr.ac.uk
180
 
Participant initials: 
 
Participant ID: 
 
 
VISIT 2 – 2 Month Follow Up  
 
 
CLOTHES WORKSHEET, Final Version 26 MAR 2014
 
 
UNBLINDING 
Have you (nurse) become accidentally 
unblinded since last visit? 
No  
  
Yes  
If yes, please briefly describe 
circumstances of unblinding. 
 
 
 
 
 
NOT FOR DATABASE: 
REMINDERS 
Please collect the diary from the parent/guardian/child and ensure it is fully completed prior to the 
parent/guardian/child leaving the clinic.  
• Has the participant had any healthcare visits for eczema?   
• Has the participant been prescribed any topical treatment 
for eczema?    
•  Has the participant had any skin infections? 
• Has the participant or parent/carer made any purchases 
for eczema?     
• Has the participant or parent/carer had any time off work 
and school due to eczema?  
Please use the data recorded in the diaries to 
complete the eCRF, any extra information that is 
gained through the clinic visit can be recorded on the 
pages at the end of the worksheet. 
 
• Please ensure the diary has been issued 
• Book an appointment  for the next clinic visit 
• If consent has been obtained to collect a saliva sample and this has not been previously collected, has a 
sample been collected today and recorded in the CRF? 
• If any protocol deviations have taken place ensure this is recorded on the protocol deviation worksheet. 
  
 
 
Investigator’s/designee’s Signature: ______________________  Date D  D  M  M  M  2 0  Y  Y 
                                                                                                                                                                  DD/MMM/YYYY 
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Participant initials: 
 
Participant ID: 
 
 
VISIT 3 - 4 Month Follow Up  
 
 
CLOTHES WORKSHEET, Final Version 26 MAR 2014
   
      Mark if visit not done 
VISIT INFORMATION  
 
Date of Visit: 
                                         
                                            
                                           DD/MMM/YYYY  
 
 
MEDICATIONS 
Has the eczema treatment changed 
since the last clinic visit? Yes   No   
If yes, type of change  
Escalation  Neutral Change  
Reduction  Unsure  
If Unsure, please specify    ____________________________________________________ 
 
 
      Mark if not done 
THREE ITEM SEVERITY SCALE (TIS) 
Criteria Score (tick one only) 
Erythema Absent (0)  Mild (1)  Moderate (2)  Severe (3)  
Oedema / papulation Absent (0)  Mild (1)  Moderate (2)  Severe (3)  
Excoriation Absent (0)  Mild (1)  Moderate (2)  Severe (3)  
 
Representative Body Site: Choose one representative body site to assess all three signs. The representative site 
should be in an area covered by the clothing, and be the area that, in the view of the parent/participant, is most 
bothersome. The representative body site may change from visit to visit. 
Total Score:   
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Participant initials: 
 
Participant ID: 
 
 
VISIT 3 - 4 Month Follow Up  
 
 
CLOTHES WORKSHEET, Final Version 26 MAR 2014
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Participant initials: 
 
Participant ID: 
 
 
VISIT 3 - 4 Month Follow Up  
 
 
CLOTHES WORKSHEET, Final Version 26 MAR 2014
   Mark if not done 
• Assess each body area for redness (erythema), papulation & oedema, scratching (excoriation) and 
lichenification (lined skin) 
• Using the photographic comparison table, assign a score for each of the signs in each of the four body 
areas.  Assess each sign for the entire body region – so for example a patient may have grade 1 erythema 
in some areas, but grade 3 erythema in others.  If that is the case, then the “average of the two” is taken 
and so the score become 2.  Likewise, if they have some areas that are grade 2 and others that are grade 
3, then the score becomes 2.5.   
• Score the percentage area of each region affected by eczema 
ECZEMA AREA AND SEVERITY INDEX (EASI) 
Body 
Area 
% Area affected by 
Eczema  
(tick one only) Criteria 
Score 
 (tick one only) 
Absent 
(0) (0.5) 
Mild 
(1) (1.5) 
Moderate 
(2) (2.5) 
Severe 
(3) 
Head 
and 
Neck 
Nil    50-69%  Redness        
1-9%  70-89%  Oedema/Papulation        
10-29%  90-100%  Scratching        
30-49%    Lichenification        
 
Upper 
Limbs 
Nil    50-69%  Redness        
1-9%  70-89%  Oedema/Papulation        
10-29%  90-100%  Scratching        
30-49%    Lichenification        
 
Trunk 
Nil    50-69%  Redness        
1-9%  70-89%  Oedema/Papulation        
10-29%  90-100%  Scratching        
30-49%    Lichenification        
 
Lower 
Limbs 
Nil    50-69%  Redness        
1-9%  70-89%  Oedema/Papulation        
10-29%  90-100%  Scratching        
30-49%    Lichenification        
 
 
 
 
 
 
 
 
 
APPENDIX 9
NIHR Journals Library www.journalslibrary.nihr.ac.uk
184
 
Participant initials: 
 
Participant ID: 
 
 
VISIT 3 - 4 Month Follow Up  
 
 
CLOTHES WORKSHEET, Final Version 26 MAR 2014
 
      Mark if not done 
INVESTIGATOR’S GLOBAL ASSESSMENT (IGA) 
 
 
 
           Please ensure Visit 3 Parent/Guardian/Child Questionnaires are completed during the visit: 
 
 Tick when 
comple
ted 
Completed by: 
(tick one only) 
• PATIENT’S GLOBAL ASSESSMENT (PGA) (included in 
‘Clinic Questions’) 
To be completed by parent/guardian or child 
 
Please request that where possible if the child 
performs the baseline assessment, the child 
completes the follow up questionnaires or if the 
parent/guardian performs the baseline 
assessment, the parent/guardian completes 
the follow up questionnaires. 
 
 
Parent/Guardian  
Child  
• PATIENT ORIENTED ECZEMA MEASURE (POEM)       
To be completed by parent/guardian or child 
 
Parent/Guardian  
Child  
• CLINIC QUESTIONS 
To be completed by parent/guardian or child 
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Participant initials: 
 
Participant ID: 
 
 
VISIT 3 - 4 Month Follow Up  
 
 
CLOTHES WORKSHEET, Final Version 26 MAR 2014
 
UNBLINDING 
Have you (nurse) become accidentally 
unblinded since last visit? 
No  
  
Yes  
If yes, please briefly describe 
circumstances of unblinding. 
 
 
 
 
NOT FOR DATABASE: 
REMINDERS 
Please collect the diary from the parent/guardian/child and ensure it is fully completed prior to the 
parent/guardian/child leaving the clinic. 
• Has the participant had any healthcare visits for eczema?   
• Has the participant been prescribed any topical treatment 
for eczema?    
•  Has the participant had any skin infections? 
• Has the participant or parent/care made any purchases 
for eczema?     
• Has the participant or parent/carer had any time off work 
and school due to eczema?  
Please use the data recorded in the diaries to 
complete the eCRF, any extra information that is 
gained through the clinic visit can be recorded on the 
pages at the end of the worksheet. 
 
• Please ensure the diary has been issued 
• Book an appointment  for the next clinic visit 
• The parent who filled in the EQ-5D-3L at visit 1 was __________________________ (see page 17). Please 
request this same parent brings the child to the next visit, if possible, for questionnaire consistency. 
• If consent has been obtained to collect a saliva sample and this has not been previously collected, has a 
sample been collected today and recorded in the CRF? 
• If any protocol deviations have taken place ensure this is recorded on the protocol deviation worksheet. 
 
  
 
Investigator’s/designee’s Signature: ______________________  Date D  D  M  M  M  2 0  Y  Y 
                                                                                                                                                                  DD/MMM/YYYY 
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Participant initials: 
 
Participant ID: 
 
 
VISIT 4 - 6 Month Follow Up 
 
 
CLOTHES WORKSHEET, Final Version 26 MAR 2014
      Mark if visit not done 
VISIT INFORMATION  
Date of Visit: 
                                         
                                              
                                   DD/MMM/YYYY  
 
 
HEIGHT 
This should be entered onto the eCRF as soon as possible, even if the rest of the visit data is not entered until a 
later date 
Height at this visit 
                                               cm  
 
 
ECZEMA TREATMENT  
• Please only record medications used on the areas covered by the clothing, not those used on 
hands/feet 
• If more than 2 medications for each category have been used in the last month please enter the most 
frequently used medication 
• Main emollient/steroid/calcineurin inhibitors = most frequently used  
• Please see emollient ladder/steroid ladders for classification of consistency/potency 
EMOLLIENTS  
Has the child used Emollients on the body within the last month?   No                      Yes   
Name of Emollient 
 used on body 
Consistency 
(tick one only) 
Main 
Emollient? 
1. 
____________ Light   Creamy  Greasy  Very Greasy  
Yes  
No  
2. 
____________ Light   Creamy  Greasy  Very Greasy  
Yes  
No  
Please see Emollient ladder for classification of medications into Light, Creamy, Greasy and Very Greasy  
 
TOPICAL STEROIDS  
Has the child used topical steroids on the body within the last month?         No                            Yes   
Name of Steroid  
used on body 
Potency 
(tick one only) 
Main 
Steroid? 
1. 
_____________ Mild   Moderate  Potent Very Potent  
Yes  
No  
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Participant initials: 
 
Participant ID: 
 
 
VISIT 4 - 6 Month Follow Up 
 
 
CLOTHES WORKSHEET, Final Version 26 MAR 2014
2. 
_____________ Mild   Moderate  Potent Very Potent  
Yes  
No  
Please see Steroid Ladder  for classification of medications into Mild, Moderate, Potent or Very Potent. 
 
CALCINEURIN INHIBITORS 
Has the child used Calcineurin Inhibitors on the body within the last month? (eg Protopic, Elidel)       
  No                      Yes   
Name of Calcinuerin 
Inhibitor used on body 
Strength 
(tick one only) 
Main Calcineurin 
Inhibitor? 
1. 
_____________ Mild  Moderate  
Yes  
No  
2. 
_____________ Mild  Moderate  
Yes  
No  
 
Protopic (Tacrolimus)  = 0.03% = Mild 
Elidel (Pimecrolimus) = 1% = Moderate      
MEDICATIONS 
Has the eczema treatment changed 
since the last clinic visit? Yes   No   
If yes, type of change  
Escalation  Neutral Change  
Reduction  Unsure  
If Unsure, please specify    ____________________________________________________ 
 
SKIN INFECTIONS 
If infection is suspected this should be followed up after the visit and added to the infections log if necessary. 
Does the skin appear infected at this 
visit?  
No  
  
Yes  
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Participant initials: 
 
Participant ID: 
 
 
VISIT 4 - 6 Month Follow Up 
 
 
CLOTHES WORKSHEET, Final Version 26 MAR 2014
 
      Mark if not done 
THREE ITEM SEVERITY SCALE (TIS) 
Criteria Score (tick one only) 
Erythema Absent (0)  Mild (1)  Moderate (2)  Severe (3)  
Oedema / papulation Absent (0)  Mild (1)  Moderate (2)  Severe (3)  
Excoriation Absent (0)  Mild (1)  Moderate (2)  Severe (3)  
Representative Body Site: Choose one representative body site to assess all three signs. The representative site 
should be in an area covered by the clothing, and be the area that, in the view of the parent/participant, is most 
bothersome. The representative body site may change from visit to visit. 
Total Score:   
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Participant initials: 
 
Participant ID: 
 
 
VISIT 4 - 6 Month Follow Up 
 
 
CLOTHES WORKSHEET, Final Version 26 MAR 2014
 
APPENDIX 9
NIHR Journals Library www.journalslibrary.nihr.ac.uk
190
 
Participant initials: 
 
Participant ID: 
 
 
VISIT 4 - 6 Month Follow Up 
 
 
CLOTHES WORKSHEET, Final Version 26 MAR 2014
 
   Mark if not done 
• Assess each body area for redness (erythema), papulation & oedema, scratching (excoriation) and 
lichenification (lined skin) 
• Using the photographic comparison table, assign a score for each of the signs in each of the four body 
areas.  Assess each sign for the entire body region – so for example a patient may have grade 1 erythema in 
some areas, but grade 3 erythema in others. If that is the case, then the “average of the two” is taken and so 
the score become 2.  Likewise, if they have some areas that are grade 2 and others that are grade 3, then 
the score becomes 2.5.   
• Score the percentage area of each region affected by eczema 
ECZEMA AREA AND SEVERITY INDEX (EASI) 
 
Body 
Area 
% Area affected by 
Eczema  
(tick one only) Criteria 
Score 
 (tick one only) 
Absent 
(0) (0.5) 
Mild 
(1) (1.5) 
Moderate 
(2) (2.5) 
Severe 
(3) 
Head 
and 
Neck 
Nil    50-69%  Redness        
1-9%  70-89%  Oedema/Papulation        
10-29%  90-100%  Scratching        
30-49%    Lichenification        
 
Upper 
Limbs 
Nil    50-69%  Redness        
1-9%  70-89%  Oedema/Papulation        
10-29%  90-100%  Scratching        
30-49%    Lichenification        
 
Trunk 
Nil    50-69%  Redness        
1-9%  70-89%  Oedema/Papulation        
10-29%  90-100%  Scratching        
30-49%    Lichenification        
 
Lower 
Limbs 
Nil    50-69%  Redness        
1-9%  70-89%  Oedema/Papulation        
10-29%  90-100%  Scratching        
30-49%    Lichenification        
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Participant initials: 
 
Participant ID: 
 
 
VISIT 4 - 6 Month Follow Up 
 
 
CLOTHES WORKSHEET, Final Version 26 MAR 2014
HYPERLINEAR PALMS 
Hyperlinear palms?  No  Yes     Unsure  
Please see Trial Manual for details 
 
         Please ensure Visit 4 Parent/Guardian/Child Questionnaires are completed during the visit: 
 
      Mark if not done 
INVESTIGATOR’S GLOBAL ASSESSMENT (IGA) 
           Tick when 
completed 
Completed by: 
(tick one only) 
• PATIENT’S GLOBAL ASSESSMENT (PGA) 
(included in ‘Clinic Questions’) 
 To be completed by parent/guardian or 
child 
 
Parent/Guardian  
Child  
• PATIENT ORIENTED ECZEMA MEASURE 
(POEM)       
To be completed by parent/guardian or child 
 
Parent/Guardian  
Child  
• CLINIC QUESTIONS 
To be completed by parent/guardian or child 
 
 
• DERMATITIS FAMILY IMPACT 
QUESTIONNAIRE (DFI) 
To be completed by parent/guardian  
 
 
• EQ-5D-3L 
To be completed by parent/guardian  
  
• THE CHILD HEALTH UTILITY 9 DIMENSIONS  
(CHU-9D) 
To be completed by parent/guardian or child 
for children of aged 5 or over only 
 
 
• ADQoL 
To be completed by parent/guardian or child 
 
 
            Comments on ADQoL: 
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Participant initials: 
 
Participant ID: 
 
 
Visit 4 - 6 Month Follow Up 
 
 
CLOTHES WORKSHEET, Final Version 26 MAR 2014
 
UNBLINDING 
Have you (nurse) become accidentally 
unblinded since last visit? 
No  
  
Yes  
If yes, please briefly describe 
circumstances of unblinding. 
 
 
 
 
NOT FOR DATABASE: 
REMINDERS 
Please collect the diary from the parent/guardian/child and ensure it is fully completed prior to the 
parent/guardian/child leaving the clinic. 
• Has the participant had any healthcare visits for eczema?     
• Has the participant been prescribed any topical treatment for eczema?    
•  Has the participant had any skin infections? 
• Has the participant or parent/carer made any purchases for eczema?     
• Has the participant or parent/carer had any time off work and school due 
to eczema?       
Please use the data recorded in 
the diaries to complete the eCRF, 
any extra information that is 
gained through the clinic visit can 
be recorded on the pages at the 
end of the worksheet. 
 
• If consent has been obtained to collect a saliva sample and this has not been previously collected, has a 
sample been collected today and recorded in the CRF? 
• If any protocol deviations have taken place ensure this is recorded on the protocol deviation worksheet. 
 
 
Investigator’s/designee’s Signature: ______________________  Date D  D  M  M  M  2 0  Y  Y 
                                                                                                                                                                  DD/MMM/YYYY 
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Participant initials: 
 
Participant ID: 
 
 
  END OF TRIAL  
For database: 777  
 
 
CLOTHES WORKSHEET, Final Version 26 MAR 2014
 
To be completed when the participant reaches their 6 month visit or if they choose to withdraw from the trial 
completely. 
 
END OF TRIAL  
Has the participant 
completed the 6 month clinic 
visit? 
No             Yes  
If No, date of withdrawal: 
 
 
                                                    DD/MMM/YYYY 
Participant Status: If No, check the 
primary reason for Discontinuation 
(tick one box): 
Death   
Withdrawal of Consent  
Withdrawal of Consent due to Adverse  Event   
Lost to Follow Up   
Trial terminated by sponsor  
Other     
 If Withdrawal of Consent or other, please specify _____________________ 
 
 
 
Investigator’s/designee’s Signature: ______________________  Date D  D  M  M  M  2 0  Y  Y 
                                                                                                                                                                  DD/MMM/YYYY 
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Participant initials: 
 
Participant ID: 
 
 
  SUMMARY INFORMATION: SAMPLE COLLECTION  
 
 
CLOTHES WORKSHEET, Final Version 26 MAR 2014
A sample should only be collected if consent was obtained for the genetic substudy. 
 
SAMPLE COLLECTION 
 
Was sample 
collected? Date of assessment 
 
DD/MMM/YYYY 
If No, please give reason 
No Yes 
Saliva sample    D D M M M Y Y Y Y  
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Participant initials: 
 
Participant ID: 
 
 
  
SUMMARY INFORMATION: HEALTHCARE VISITS FOR ECZEMA  
 
 
 
CLOTHES WORKSHEET, Final Version 26 MAR 2014
Pages 40-44 can be used to record any information collected during the clinic visit, it is not necessary to 
transcribe all information from the diary to these pages. The diary data can be entered directly into the eCRF. 
 
 
HEALTHCARE VISITS FOR ECZEMA 
Has the participant had any healthcare visits for eczema?    No          Yes   
No. Date of Visit 
Ti
ck
 if
 
es
tim
at
ed
 Type of visit 
1= GP, 2 = Practice Nurse,  
3 = Outpatients, 4= Inpatient, 
5 = Other (If Other, specify) 
Number of nights in 
hospital 
1 D D M M M 2 0 Y Y   ----------------------------  
2 D D M M M 2 0 Y Y   ----------------------------  
3 D D M M M 2 0 Y Y   ----------------------------  
4 D D M M M 2 0 Y Y   ----------------------------  
5 D D M M M 2 0 Y Y   ----------------------------  
6 D D M M M 2 0 Y Y   ----------------------------  
7 D D M M M 2 0 Y Y   ----------------------------  
8 D D M M M 2 0 Y Y   ----------------------------  
9 D D M M M 2 0 Y Y   ----------------------------  
10 D D M M M 2 0 Y Y   ----------------------------  
11 D D M M M 2 0 Y Y   ----------------------------  
12 D D M M M 2 0 Y Y   ----------------------------  
13 D D M M M 2 0 Y Y   ----------------------------  
14 D D M M M 2 0 Y Y   ----------------------------  
15 D D M M M 2 0 Y Y   ----------------------------  
16 D D M M M 2 0 Y Y   ----------------------------  
17 D D M M M 2 0 Y Y   ----------------------------  
18 D D M M M 2 0 Y Y   ----------------------------  
19 D D M M M 2 0 Y Y   ----------------------------  
20 D D M M M 2 0 Y Y   ----------------------------  
APPENDIX 9
NIHR Journals Library www.journalslibrary.nihr.ac.uk
196
 
Participant initials: 
 
Participant ID: 
 
 
  
SUMMARY INFORMATION: ECZEMA PRESCRIPTIONS  
 
 
 
CLOTHES WORKSHEET, Final Version 26 MAR 2014
Pages 40-44 can be used to record any information collected during the clinic visit, it is not necessary to 
transcribe all information from the diary to these pages. The diary data can be entered directly into the eCRF. 
 
*Please have the parent detail all prescriptions, even if repeat prescriptions* 
  
ECZEMA PRESCRIPTIONS 
Has the participant been prescribed any treatment for their eczema?    No          Yes   
No. Date of Prescription 
Ti
ck
 if
 
es
tim
at
ed
 
    What was Prescribed? 
 Details (size/amount)  
1 D D M M M 2 0 Y Y    
2 D D M M M 2 0 Y Y    
3 D D M M M 2 0 Y Y    
4 D D M M M 2 0 Y Y    
5 D D M M M 2 0 Y Y    
6 D D M M M 2 0 Y Y    
7 D D M M M 2 0 Y Y    
8 D D M M M 2 0 Y Y    
9 D D M M M 2 0 Y Y    
10 D D M M M 2 0 Y Y    
11 D D M M M 2 0 Y Y    
12 D D M M M 2 0 Y Y    
13 D D M M M 2 0 Y Y    
14 D D M M M 2 0 Y Y    
15 D D M M M 2 0 Y Y    
16 D D M M M 2 0 Y Y    
17 D D M M M 2 0 Y Y    
18 D D M M M 2 0 Y Y    
19 D D M M M 2 0 Y Y    
20 D D M M M 2 0 Y Y    
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Participant initials: 
 
Participant ID: 
 
 
  
SUMMARY INFORMATION: SKIN INFECTIONS  
 
 
 
CLOTHES WORKSHEET, Final Version 26 MAR 2014
Pages 40-44 can be used to record any information collected during the clinic visit, it is not necessary to 
transcribe all information from the diary to these pages. The diary data can be entered directly into the eCRF. 
 
   
SKIN INFECTIONS 
Has the participant had any skin infections which required treatment with 
antibiotics or antivirals?         No          Yes   
No. Start date of Skin Infection 
Ti
ck
 if
 
es
tim
at
ed
 
1 D D M M M 2 0 Y Y  
2 D D M M M 2 0 Y Y  
3 D D M M M 2 0 Y Y  
4 D D M M M 2 0 Y Y  
5 D D M M M 2 0 Y Y  
6 D D M M M 2 0 Y Y  
7 D D M M M 2 0 Y Y  
8 D D M M M 2 0 Y Y  
9 D D M M M 2 0 Y Y  
10 D D M M M 2 0 Y Y  
11 D D M M M 2 0 Y Y  
12 D D M M M 2 0 Y Y  
13 D D M M M 2 0 Y Y  
14 D D M M M 2 0 Y Y  
15 D D M M M 2 0 Y Y  
16 D D M M M 2 0 Y Y  
 
 
              The start date of the infection should be considered as the date of the prescription.
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Participant initials: 
 
Participant ID: 
 
 
  
SUMMARY INFORMATION: PURCHASES FOR ECZEMA  
 
 
 
CLOTHES WORKSHEET, Final Version 26 MAR 2014
Pages 40-44 can be used to record any information collected during the clinic visit, it is not necessary to transcribe 
all information from the diary to these pages. The diary data can be entered directly into the eCRF. 
 
 
 
PURCHASES FOR ECZEMA 
Has the participant or parent/carer made any purchases or incurred any out of pocket expenses as a 
result of eczema?    No          Yes   
No. Date of Purchase 
Ti
ck
 if
 
es
tim
at
ed
 
Item Bought 
 
Cost 
££:pp 
Estimated 
cost if you 
didn’t need 
to buy a 
specialist 
item 
1 D D M M M 2 0 Y Y     
2 D D M M M 2 0 Y Y     
3 D D M M M 2 0 Y Y     
4 D D M M M 2 0 Y Y     
5 D D M M M 2 0 Y Y     
6 D D M M M 2 0 Y Y     
7 D D M M M 2 0 Y Y     
8 D D M M M 2 0 Y Y     
9 D D M M M 2 0 Y Y     
10 D D M M M 2 0 Y Y     
11 D D M M M 2 0 Y Y     
12 D D M M M 2 0 Y Y     
13 D D M M M 2 0 Y Y     
14 D D M M M 2 0 Y Y     
15 D D M M M 2 0 Y Y     
16 D D M M M 2 0 Y Y     
17 D D M M M 2 0 Y Y     
18 D D M M M 2 0 Y Y     
19 D D M M M 2 0 Y Y     
20 D D M M M 2 0 Y Y     
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Participant initials: 
 
Participant ID: 
 
 
  
SUMMARY INFORMATION: TIME OFF WORK AND SCHOOL DUE 
TO ECZEMA 
 
 
 
CLOTHES WORKSHEET, Final Version 26 MAR 2014
Pages 40-44 can be used to record any information collected during the clinic visit, it is not necessary to transcribe 
all information from the diary to these pages. The diary data can be entered directly into the eCRF. 
 
 
 
TIME OFF WORK AND SCHOOL DUE TO ECZEMA 
Has the participant or parent/carer had any time off work and school due to eczema?      No        Yes  
 
No. Date started 
Ti
ck
 if
 
es
tim
at
ed
 Time off 
school/nursery 
HH:MM 
 
Parental/carer 
time off from 
paid 
employment  
HH:MM 
Reason 
1 D D M M M 2 0 Y Y     
2 D D M M M 2 0 Y Y     
3 D D M M M 2 0 Y Y     
4 D D M M M 2 0 Y Y     
5 D D M M M 2 0 Y Y     
6 D D M M M 2 0 Y Y     
7 D D M M M 2 0 Y Y     
8 D D M M M 2 0 Y Y     
9 D D M M M 2 0 Y Y     
10 D D M M M 2 0 Y Y     
11 D D M M M 2 0 Y Y     
12 D D M M M 2 0 Y Y     
13 D D M M M 2 0 Y Y     
14 D D M M M 2 0 Y Y     
15 D D M M M 2 0 Y Y     
16 D D M M M 2 0 Y Y     
17 D D M M M 2 0 Y Y     
18 D D M M M 2 0 Y Y     
19 D D M M M 2 0 Y Y     
20 D D M M M 2 0 Y Y     
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Appendix 10 Participant diary
Participant ID:   Participant initials:                       
Date of birth: 
CLOTHES Diary 
 
Date of first visit d d/ m m m/ y y y y 
         
Date you received letter/clothing d d/ m m m/ y y y y 
         
Date of next clinic visit d d/ m m m/ y y y y 
Diary number                   (to be completed by the research nurse) 
Useful Contact Details 
General study questions and 
appointments 
Local Research Nurse: 
You/your child’s eczema treatment 
You/your child’s GP or consultant: 
Clothing and re-ordering of clothing
Study manager 
Nottingham Clinical Trials Unit 
Nottingham Health Science Partners 
C Floor, South Block 
Queens Medical Centre 
Nottingham 
NG7 2UH 
Tel: 0115 8844938 
E-mail: clothes@nottingham.ac.uk 
General clinical trial queries and 
complaints 
Patient Advice and Liaison Service 
(PALS): 
 
 
 
 
 
 
 
 
 
 
REMEMBER NOT TO TELL THE NURSE IF YOUR CHILD 
HAS BEEN WEARING THE CLOTHING OR NOT! 
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Participant ID:   Participant initials:                       
 
Date of birth: 
 
What to put in this diary 
This diary is for you to write down information about details of eczema-related appointments, 
prescriptions or things that you have bought because of your child’s eczema, plus time which 
has been missed at school and work.  There is also space for you to jot down anything you 
would like to discuss with the nurse at your next clinic visit. 
 
We would ask you to complete this diary when necessary and to bring it with you each time 
you visit the hospital where the research nurse will discuss it with you.  You will be given a 
new diary at the end of each appointment. 
 
Can we remind you that the nurse does not know whether or not you/your child has been 
wearing the clothing, so please do not wear the clothing to your visit or discuss any 
aspects of your clothing with the research nurse.  Also – please do not write anything in 
this diary about the clothing, as the research nurse may see this.  
 
If you have any questions about the use of the clothing, then please contact the study 
manager as detailed on the front cover and NOT the research nurse. 
 
Washing instructions for trial clothing 
How do I use the garments? 
Please wear the garments as often as possible, both during the day and at night (either as 
underwear or as pyjamas). 
 
Moisturising creams should be applied thinly to the skin (just enough for the skin to glisten) 
and should be applied a few minutes before putting on the clothing to allow the creams to be  
absorbed into the skin.  
 
How do I care for the garments? 
You will be given 3 sets of garments during the trial. This will allow one set to be in use, one 
in the wash and one spare. We recommend that you use all three sets within one week, 
rotating frequently.   
 
To machine wash: Wash at up to 40°C using your usual mild non-biological detergent. The 
fibres of the garment are quite delicate and washing the garment inside a pillowcase on a 
delicate cycle will protect it during the wash. If possible, lay the garment flat to dry.  
 
To hand wash: place in hand-hot water containing your usual mild non-biological detergent 
and agitate by hand for a few minutes. Rinse well with plenty of warm, clean water and 
squeeze dry. Do not wring. If possible, lay the garment flat to dry. 
 
Other important points: 
• Please don’t use bleach. Make sure there are no bleaching agents in your detergent 
(such as Vanish) 
 
• Please don’t use fabric softeners 
 
• Please do not tumble dry 
 
• Any reduction in garment length is likely to be due to a tightening of the knit. A cool 
steam iron can be used to restore the shape of a garment that appears to have 
shrunk.  
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Participant ID:   Participant initials:                       
 
Date of birth: 
 
CLOTHES: Examples of out of pocket expenditure related to eczema  
During the study we are asking you to make a note of anything you pay for out of 
pocket as a result of your child having eczema that you would not otherwise have 
had to purchase.  
Based on experience some parents/carers find it difficult to know what type of items 
we are interested in them recording. Here are some examples of the type of things 
we would like you to record purchasing and the price you paid. This list is not 
exhaustive, there may be other items you think are relevant that are not on the list. 
Equally there may be things on this list which you haven’t had to purchase any 
differently as a result of your child having eczema and thus you should not record 
these. 
We are interested in the difference in cost of looking after a child with eczema to a 
child without eczema thus you should only put the whole price down if the item is 
something you would not have bought if your child did not have eczema (e.g. an 
emollient). Some items you may have bought even if they had not had eczema (e.g. 
sun cream, washing powder) but you have to buy a more expensive make/brand in 
order to get one that does not irritate your child’s eczema, in this case please record 
how much this cost, and if you know, how much you would have paid for the same 
thing if your child did not have eczema. 
Please only record those items actually purchased during the time you are 
involved in the study. 
Clothing Special food 
Night wear, underwear, school 
uniform, and  day wear made from 
natural fibres such as cotton 
Nut-free foods 
Special milk e.g. goats, oat or lacto free milk 
Over the counter products Laundry and bedding 
Emollients, moisturiser, bio oil, sun 
cream 
Special shampoos, shower or bath 
gels 
Vitamins & mineral supplements, 
anti-histamines, herbal remedies 
Bandages, tubi-grips 
Purchased bedding (sheets, pillow cases, 
duvet cases) made of natural fibres 
Anti-allergic pillows and duvets 
Bath towels made from natural fibres 
Special laundry powder/liquid 
undertake more laundry increasing electricity 
bills & amount of liquid used 
Equipment Appointments 
Air cooler 
Water softener 
Travel and parking costs to NHS or private 
visits 
Appointments with alternative medicine 
practitioners e.g. allergy testing, homeopath 
etc 
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Appendix 11 Weekly participant questionnaire
Participant ID:  Participant initials:                       Date of birth: 
Date of completion: 
 
CLOTHES on-line questionnaire – weekly –Final 2.0 1 August 2013 
     
 
 
 
 
Weekly questionnaire      Week number  
We hope that you/your child has had a good week.  Please select one response for each 
of the seven questions below about your child’s eczema.  If your child is old enough to 
understand the questions then please fill in the questionnaire together.  Please leave 
blank any questions you feel unable to answer. 
Over the last week 
 
1 On how many days has your/your child’s skin been itchy because of their eczema? 
 No days 1-2 days 3-4 days 5-6 days Every day 
      
2 On how many nights has your/your child’s sleep been disturbed because of their eczema? 
 
 No days 1-2 days 3-4 days 5-6 days Every day 
      
3 On how many days has your/your child’s skin been bleeding because of their eczema? 
 No days 1-2 days 3-4 days 5-6 days Every day 
      
4 On how many days has your/your child’s skin been weeping or oozing clear fluid because 
of their eczema? 
 
 No days 1-2 days 3-4 days 5-6 days Every day 
      
5 On how many days has your/your child’s skin been cracked because of their eczema? 
 No days 1-2 days 3-4 days 5-6 days Every day 
      
6 On how many days has you/your child’s skin been flaking off because of their eczema? 
 
 No days 1-2 days 3-4 days 5-6 days Every day 
      
7 On how many days has you/your child’s skin felt dry or rough because of their eczema? 
 
 No days 1-2 days 3-4 days 5-6 days Every day 
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Participant ID:  Participant initials:                       Date of birth: 
 
 
CLOTHES on-line questionnaire – weekly –Final 2.0 1 August 2013    
    
Please select one response for each of the questions below. 
Over the last week: 
Has your child had any visits to a health care professional? 
Yes No  If yes please record 
details in the diary card 
 
Has your child had any prescriptions for eczema? 
Yes No If yes please record 
details in the diary card 
   
Have you bought anything specifically because of your child’s 
eczema? 
 
Yes No If yes please record 
details in the diary card 
   
Have you had any time off work and/or has your child had any 
time off school or nursery because of their eczema? 
 
Yes No If yes please record 
details in the diary card 
 
Please select one response for each of the questions below. 
Over the last week, on how many days have you/your child used the following: 
Topical Steroids 
0 1 2 3 4 5 6 7 
        
Emollients 
0 1 2 3 4 5 6 7 
        
Topical Calcineurin Inhibitors 
0 1 2 3 4 5 6 7 
        
Wet/Dry Wraps 
0 1 2 3 4 5 6 7 
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Participant ID:  Participant initials:                       Date of birth: 
 
 
CLOTHES on-line questionnaire – weekly –Final 2.0 1 August 2013    
    
Only for patients randomised to clothing 
Over the last week 
On how many nights has the clothing been worn for at least some of the night? 
 
0 1 2 3 4 5 6 7 Not 
Known 
         
On how many days has the clothing been worn for at least some of the day? 
 
0 1 2 3 4 5 6 7 
Not 
known 
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Appendix 12 Participant week 24 (6-month)
questionnaire
Participant ID:  Participant initials:                       Date of birth: 
Date of completion: 
 
CLOTHES 6 month on-line questionnaire –Final 2.0_05 Sept 2013 
 
 
Six-month questionnaire     Week 24 (6 months) 
We hope that you/your child has had a good week.  Please select one response for each 
of the seven questions below about your child’s eczema.  If your child is old enough to 
understand the questions then please fill in the questionnaire together.  Please leave 
blank any questions you feel unable to answer. 
Over the last week 
 
1 On how many days has your/your child’s skin been itchy because of their eczema? 
 No days 1-2 days 3-4 days 5-6 days Every day 
      
2 On how many nights has your/your child’s sleep been disturbed because of their eczema? 
 
 No days 1-2 days 3-4 days 5-6 days Every day 
      
3 On how many days has your/your child’s skin been bleeding because of their eczema? 
 No days 1-2 days 3-4 days 5-6 days Every day 
      
4 On how many days has your/your child’s skin been weeping or oozing clear fluid because 
of their eczema? 
 
 No days 1-2 days 3-4 days 5-6 days Every day 
      
5 On how many days has your/your child’s skin been cracked because of their eczema? 
 No days 1-2 days 3-4 days 5-6 days Every day 
      
6 On how many days has you/your child’s skin been flaking off because of their eczema? 
 
 No days 1-2 days 3-4 days 5-6 days Every day 
      
7 On how many days has you/your child’s skin felt dry or rough because of their eczema? 
 
 No days 1-2 days 3-4 days 5-6 days Every day 
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Participant ID:  Participant initials:                       Date of birth: 
 
CLOTHES 6 month on-line questionnaire –Final 2.0_05 Sept 2013    
Please select one response for each of the questions below. 
Over the last week: 
Has your child had any visits to a health care professional? 
Yes No  If yes please record 
details in the diary card 
 
Has your child had any prescriptions for eczema? 
Yes No If yes please record 
details in the diary card 
   
Have you bought anything specifically because of your child’s 
eczema? 
 
Yes No If yes please record 
details in the diary card 
   
Have you had any time off work and/or has your child had any 
time off school or nursery because of their eczema? 
 
Yes No If yes please record 
details in the diary card 
 
 
Please select one response for each of the questions below. 
Over the last week, on how many days have you/your child used the following: 
Topical Steroids 
0 1 2 3 4 5 6 7 
        
Emollients 
0 1 2 3 4 5 6 7 
        
Topical Calcineurin Inhibitors 
0 1 2 3 4 5 6 7 
        
Wet/Dry Wraps 
0 1 2 3 4 5 6 7 
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Participant ID:  Participant initials:                       Date of birth: 
 
CLOTHES 6 month on-line questionnaire –Final 2.0_05 Sept 2013    
Over the past week 
On how many nights has the clothing been worn for at least some of the night? 
 
0 1 2 3 4 5 6 7 Not 
Known 
         
On how many days has the clothing been worn for at least some of the day? 
 
0 1 2 3 4 5 6 7 
Not 
known 
         
 
 
 
How satisfied were you with the clothing overall? 
 
Very satisfied Satisfied Neither satisfied or dissatisfied Dissatisfied 
Very 
Dissatisfied 
 
 
 
    
 
 
Were you/your child happy to wear the clothing? 
 
Very happy Happy Neither happy nor unhappy Unhappy Very unhappy 
 
 
 
    
     
Comments 
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Participant ID:  Participant initials:                       Date of birth: 
 
CLOTHES 6 month on-line questionnaire –Final 2.0_05 Sept 2013    
Condition of trial clothing 
 Body suits / vests Leggings 
 
How many vests/bodysuits and 
leggings have you had since the 
start of the study (please include 
those you have returned)? 
 
  
 
How many can you still wear? 
 
 
  
How many can you not wear? 
 
 
  
Why can you not wear them? 
(please select all that apply) 
 
  
  
Too small 
  
  
Worn out/torn 
 
  
  
Lost 
 
  
  
Other 
 
Reason: 
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Participant ID:  Participant initials:                       Date of birth: 
 
CLOTHES 6 month on-line questionnaire –Final 2.0_05 Sept 2013    
Apart from the clothing received for the trial, over the last 6 months, did you/your 
child wear any of the following? 
 
 
Pure cotton clothing 
Yes No   
 
Silver impregnated clothing  
Yes No  
   
Silk clothing  
Yes No  
   
Stretchy garments eg tubifast, comfifast, skinnies  
Yes No  
  
 
Other   
 
Yes No  
Please name  _____________________________________________________ 
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Appendix 13 Participant week 32 (8-month)
questionnaire
Participant ID:  Participant initials:                       Date of birth: 
Date of completion: 
Suggested date of completion: 
 
 
 
Eight-month on-line questionnaire    Week 32 (8 months) 
We hope that you/your child has had a good week.  Please select one response for each 
of the seven questions below about your child’s eczema.  If your child is old enough to 
understand the questions then please fill in the questionnaire together.  Please leave 
blank any questions you feel unable to answer. 
 
Over the last week 
 
1 On how many days has your/your child’s skin been itchy because of their eczema? 
 No days 1-2 days 3-4 days 5-6 days Every day 
      
2 On how many nights has your/your child’s sleep been disturbed because of their eczema? 
 
 No days 1-2 days 3-4 days 5-6 days Every day 
      
3 On how many days has your/your child’s skin been bleeding because of their eczema? 
 No days 1-2 days 3-4 days 5-6 days Every day 
      
4 On how many days has your/your child’s skin been weeping or oozing clear fluid because 
of their eczema? 
 
 No days 1-2 days 3-4 days 5-6 days Every day 
      
5 On how many days has your/your child’s skin been cracked because of their eczema? 
 No days 1-2 days 3-4 days 5-6 days Every day 
      
6 On how many days has you/your child’s skin been flaking off because of their eczema? 
 
 No days 1-2 days 3-4 days 5-6 days Every day 
      
7 On how many days has you/your child’s skin felt dry or rough because of their eczema? 
 
 No days 1-2 days 3-4 days 5-6 days Every day 
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Participant ID:  Participant initials:                       Date of birth: 
 
CLOTHES 8 month on-line questionnaire_Final 3.0_21 Oct 2013    
Please select one response for each of the questions below. 
Over the last week: 
Has your child had any visits to a health care professional? 
Yes No   
 
Has your child had any prescriptions for eczema? 
Yes No  
   
Have you bought anything specifically because of your child’s 
eczema? 
 
Yes No  
   
Have you had any time off work and/or has your child had any 
time off school or nursery because of their eczema? 
 
Yes No  
 
Please select one response for each of the questions below. 
Over the last week, on how many days have you/your child used the following: 
Topical Steroids 
0 1 2 3 4 5 6 7 
        
Emollients 
0 1 2 3 4 5 6 7 
        
Topical Calcineurin Inhibitors 
0 1 2 3 4 5 6 7 
        
Wet/Dry Wraps 
0 1 2 3 4 5 6 7 
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Participant ID:  Participant initials:                       Date of birth: 
 
CLOTHES 8 month on-line questionnaire_Final 3.0_21 Oct 2013    
 
Over the past 2 months, how often has the trial clothing been worn? 
 
 
All/most of 
the time 
(days and 
nights) 
All/most of 
the time 
(days only) 
All/most of 
the time 
(nights only) 
Some of the 
time Rarely 
 
Never 
 
 
 
     
 
 
 
How satisfied were you with the clothing overall? 
 
Very satisfied Satisfied Neither satisfied or dissatisfied Dissatisfied 
Very 
Dissatisfied 
 
 
 
    
 
 
 
 
Were you/your child happy to wear the clothing? 
 
Very happy Happy Neither happy nor unhappy Unhappy Very unhappy 
 
 
 
    
     
Comments 
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Participant ID:  Participant initials:                       Date of birth: 
 
CLOTHES 8 month on-line questionnaire_Final 3.0_21 Oct 2013    
Condition of trial clothing 
 Body suits / vests Leggings 
 
How many vests/bodysuits and 
leggings have you had since the 
start of the study (please include 
those you have returned)? 
 
  
 
How many can you still wear? 
 
 
  
How many can you not wear? 
 
 
  
Why can you not wear them? 
(please select all that apply) 
 
  
  
Too small 
  
  
Worn out/torn 
 
  
  
Lost 
 
  
  
Other 
 
Reason: 
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Participant ID:  Participant initials:                       Date of birth: 
 
CLOTHES 8 month on-line questionnaire_Final 3.0_21 Oct 2013    
Your opinion of the trial clothing 
Do you feel that you/your child’s eczema has improved wearing the trial clothing? 
 
Yes No  Not sure 
 
Would you ask your GP to prescribe the clothing? 
Yes No Not sure 
   
Have you asked your GP to prescribe the clothing? 
 
 
Yes No  
 
 
  
If you have, did they prescribe the clothing?  
Yes No  
  
 
If your GP did prescribe the clothing, what did they prescribe? 
 
 
  
 
 
 
If your GP did not prescribe the clothing, what reason did s/he give  
(please tick all that apply) 
 
 
Too expensive No proof that 
they work 
No reason given Other  
 
    
   Please specify 
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Participant ID:  Participant initials:                       Date of birth: 
 
CLOTHES 8 month on-line questionnaire_Final 3.0_21 Oct 2013    
 
Have you purchased any silk clothing for eczema during the trial? 
 
Yes No 
 
If yes, select all types purchased. 
 
 
Vest 
 
  
Number purchased 
 
Total cost (£) 
 
 
Leggings 
 
  
Number purchased 
 
Total cost (£) 
 
 
Body suit 
 
  
Number purchased 
 
Total cost (£) 
 
 
 
Other 
 
Please specify  
Number purchased Total cost (£) 
 
 
 
 
 
 
 
 
 
 
THANK YOU FOR TAKING PART IN THE CLOTHES TRIAL 
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Appendix 14 Additional data on outcomes
collected at clinic visits to inform future sample
size calculations
TABLE 52 Arithmetic mean of EASI scores on original scale and log-transformed EASI scores
Allocated group Baseline 2 months 4 months 6 months
Standard care
n 151 137 133 139
Mean (SD) 9.6 (7.8) 7.8 (7.2) 7.7 (8.7) 6.5 (6.4)
Log-transformed mean (SD) 2.13 (0.68) 1.89 (0.77) 1.79 (0.86) 1.70 (0.80)
Intervention
n 149 139 135 133
Mean (SD) 11.4 (10.6) 8.8 (10.6) 7.7 (10.1) 7.3 (10)
Log-transformed mean (SD) 2.22 (0.76) 1.86 (0.88) 1.75 (0.86) 1.69 (0.87)
Note
One was added to the EASI scores before transformation because some EASI scores were 0 at follow-up.
TABLE 53 Correlation between outcomes assessed at clinic visits
Follow-up (months) Baseline 2 months 4 months
EASI
2 0.71 (n = 276) –
4 0.65 (n = 268) 0.79 (n= 265) –
6 0.62 (n = 272) 0.70 (n= 266) 0.77 (n= 261)
TIS
2 0.51 (n = 276) –
4 0.49 (n = 269) 0.51 (n= 265) –
6 0.42 (n = 273) 0.45 (n= 266) 0.62 (n= 262)
Note
Spearman’s correlation coefficients are presented for all outcomes.
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Appendix 15 Additional data on weekly Patient
Oriented Eczema Measure scores
TABLE 54 Weekly POEM scores
Week Standard care (N= 151) Intervention (N= 149)
Week 1
Mean (SD) 15.8 (5.6) 15 (6.0)
n 134 131
Week 2
Mean (SD) 15.7 (6.1) 13.2 (6.8)
n 127 125
Week 3
Mean (SD) 15.8 (6.4) 13 (6.1)
n 128 125
Week 4
Mean (SD) 16.1 (6.4) 11.8 (6.5)
n 129 122
Week 5
Mean (SD) 15.4 (6.5) 11.7 (7.1)
n 124 123
Week 6
Mean (SD) 15 (6.8) 11.7 (6.8)
n 122 120
Week 7
Mean (SD) 14.6 (6.4) 12.2 (7.1)
n 115 125
Week 8
Mean (SD) 15.1 (6.7) 12 (6.6)
n 117 121
Week 9
Mean (SD) 14.2 (6.7) 11.4 (6.5)
n 114 123
Week 10
Mean (SD) 14.6 (6.3) 10.9 (6.2)
n 123 116
continued
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TABLE 54 Weekly POEM scores (continued )
Week Standard care (N= 151) Intervention (N= 149)
Week 11
Mean (SD) 14.1 (6.9) 10.6 (6.7)
n 118 121
Week 12
Mean (SD) 13.4 (6.7) 11.5 (7)
n 113 122
Week 13
Mean (SD) 13.7 (6.7) 11.5 (7.1)
n 116 115
Week 14
Mean (SD) 13.8 (7) 11.7 (7.1)
n 116 119
Week 15
Mean (SD) 12.9 (6.8) 11.6 (6.8)
n 110 116
Week 16
Mean (SD) 13.3 (7.2) 10.9 (6.6)
n 114 111
Week 17
Mean (SD) 13.4 (7.2) 11.2 (6.6)
n 110 107
Week 18
Mean (SD) 13.4 (6.7) 11.4 (7.6)
n 114 112
Week 19
Mean (SD) 13.6 (6.6) 10.4 (6.8)
n 110 114
Week 20
Mean (SD) 12.4 (6.6) 10.8 (7)
n 107 114
Week 21
Mean (SD) 13.5 (6.5) 10.7 (6.5)
n 100 110
Week 22
Mean (SD) 12.6 (7) 11 (7.2)
n 108 109
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TABLE 54 Weekly POEM scores (continued )
Week Standard care (N= 151) Intervention (N= 149)
Week 23
Mean (SD) 13.6 (6.7) 10.3 (7)
n 90 104
Week 24
Mean (SD) 13.4 (6.5) 11.4 (7.4)
n 61a 71a
a A total of 242 (81%) participants completed the POEM scale at 24 weeks, but data from the online questionnaires were
included in the analysis only if they were completed on or before the 6-month clinic visit date to ensure that no
contamination occurred as a result of children in the standard care group receiving silk clothing after the 6-month
clinic visit.
TABLE 55 Correlation between weekly POEM scores at baseline, 8, 16 and 24 weeks
Follow-up (weeks) Baseline 8 weeks 16 weeks
8 0.47 (n = 238) –
16 0.39 (n = 225) 0.64 (n= 202) –
24 0.35 (n = 241) 0.55 (n= 208) 0.64 (n= 211)
Note
Spearman’s correlation coefficients are presented for all outcomes.
Baseline POEM was collected in clinic.
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Appendix 16 Eczema severity according to
coverage of garments
The EASI score is calculated based on the severity of AE on the head and neck, upper limbs, trunk andlower limbs. The trial garments, however, did not cover the head and neck. Therefore, an exploratory
analysis was conducted for the EASI scores for the head and neck only and the EASI scores for the other
body areas combined.
Figure 26 shows that EASI scores for the body areas covered by the garments were similar in the standard
care and intervention group at each follow-up visit, and EASI scores for the head and neck were similar in
each group at each follow-up visit.
Body areas covered by garments are upper limbs, trunk and lower limbs. All scores above range between
0 and 72. Scores for the body areas covered by the garments (upper limbs, trunk and lower limbs) are
combined and weighted based on the child’s age at randomisation (as for the calculation of the EASI total
score and rescaled in order that the sum of the weights for the covered body areas was 1).
Covered standard care
Covered intervention
Head/neck standard care
Head/neck intervention
Body area and group
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FIGURE 26 Eczema Area and Severity Index body region scores according to coverage of garments, by group.
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Appendix 17 Causal effect of adherence with
wearing trial garments
This section presents CACE estimates for all participants with EASI scores at 6 months, based on thesensitivity analysis for garment wear for periods when questionnaires were not completed (Table 56).
TABLE 56 Causal effect of adherence with wearing trial garments (all participants at 6 months)
Estimate n
Adjusted ratio of geometric
means (95% CI)
ITT at 6 monthsa 272 0.982 (0.844 to 1.144)
CACE: binary – garments worn for at least 50% of days or 50% of the
nightsb
272
Assuming that garments worn for the same proportion of time when
questionnaires not completed as when completed
0.978 (0.815 to 1.175)
Assuming that garments not worn when questionnaires not completed 0.973 (0.769 to 1.230)
CACE: each additional 10% of time garments wornb,c 272
Assuming that garments worn for the same proportion of time when
questionnaires not completed as when completed
0.997 (0.971 to 1.024)
Assuming that garments not worn when questionnaires not completed 0.996 (0.966 to 1.027)
ITT, intention to treat.
a Analysed using linear regression with log-transformed EASI score at 6 months as the outcome variable and adjusted for
randomisation stratification variables and baseline EASI score.
b Analysed using instrumental variable regression.
c Percentage of time worn calculated as (total number of days and nights clothing worn × 100)/(total number of
questionnaires completed × 14).
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Appendix 18 Further exploratory analysis
according to brand of garment
In addition to exploration of the primary outcome by brand (as summarised in the main report), we alsoexplored the impact of brand of garments on self-reported symptoms (POEM). For this analysis, we used
data from baseline and 2 months (for the intervention group), and 6 and 8 months (for the standard care
group), in order to maximise the available data.
Results are shown in Table 57. There was no difference in mean POEM scores 2 months after receiving the
clothing for DreamSkin compared with DermaSilk (difference in means –0.57, 95% CI –2.35 to 1.21;
n = 187), using a linear regression model adjusting for POEM score prior to receiving the clothing, site, age
and treatment group.
Adherence to and acceptability of the garments at 8 months by allocated group and allocated garment
brand are shown in Table 58.
TABLE 57 Self-reported AE symptoms using POEM scores collected on online/paper questionnaires by brand of
garment and allocated group
Self-reported symptoms
Standard care Intervention
DermaSilk
(N= 62)
DreamSkin
(N= 51)
DermaSilk
(N= 67)
DreamSkin
(N= 63)
Prior to receiving garmentsa
Mean (SD) 13.3 (7.2) 13.2 (6.2) 18.1 (6.1) 16.1 (5.6)
Median (25th, 75th centile) 12 (8, 19) 11.5 (9, 18) 18 (13, 23) 16 (12, 19)
n 53 42 67 63
2 months after receiving garmentsb
Mean (SD) 11.8 (7.6) 12.3 (7.2) 12.6 (6.2) 11.2 (6.5)
Median (25th, 75th centile) 11 (5.5, 18.5) 12 (7, 17) 13 (8, 18) 10 (6, 16)
n 48 39 58 49
a POEM scores from online/postal questionnaire at 6 months for standard care group and baseline clinic visit for
intervention group.
b POEM scores from online/postal questionnaire at 8 months for standard care group and week 8 for intervention group.
The intervention group received the trial garments at baseline. The standard group received the trial garments after their
6-month clinic visit.
DOI: 10.3310/hta21160 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 16
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Thomas et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
237
TABLE 58 Adherence to and acceptability of clothing during the open follow-up period (between 6 and 8 months)
by brand of clothing and allocated group
Adherence and acceptability
Standard care, n (%) Intervention, n (%)
DermaSilk
(N= 48)
DreamSkin
(N= 39)
DermaSilk
(N= 52)
DreamSkin
(N= 51)
Frequency clothing worn during the follow-up period
Never 2 (4) 2 (5) 6 (12) 11 (22)
Rarely 4 (8) 11 (28) 6 (12) 11 (22)
Some of the time 12 (25) 10 (26) 14 (27) 8 (16)
All/most of the time (days only) 1 (2) – 1 (2) 1 (2)
All/most of the time (nights only) 24 (50) 10 (26) 11 (21) 11 (22)
All/most of the time (days and nights) 2 (4) 5 (13) 12 (23) 8 (16)
Not answered 3 (6) 1 (3) 2 (4) 1 (2)
Satisfaction with the clothing overall
Very dissatisfied – 1 (3) 2 (4) 4 (8)
Dissatisfied 3 (6) 6 (15) 2 (4) 5 (10)
Neither 11 (23) 12 (31) 12 (23) 11 (22)
Satisfied 19 (40) 14 (36) 18 (35) 17 (33)
Very satisfied 12 (25) 4 (10) 16 (31) 13 (25)
Not answered 3 (6) 2 (5) 2 (4) 1 (2)
Child happy to wear clothing
Very unhappy – 2 (5) 2 (4) 6 (12)
Unhappy 7 (15) 6 (15) 2 (4) 2 (4)
Neither 10 (21) 9 (23) 10 (19) 9 (18)
Happy 16 (33) 12 (31) 18 (35) 14 (27)
Very happy 12 (25) 9 (23) 18 (35) 19 (37)
Not answered 3 (6) 1 (3) 2 (4) 1 (2)
Note
Table shows data for participants included in the exploratory analysis according to brand of clothing (see Figure 12) and
completing the questionnaire at 8 months.
APPENDIX 18
NIHR Journals Library www.journalslibrary.nihr.ac.uk
238
Appendix 19 Health economics analysis plan
 
CLOTHES Trial 
FINAL Health Economic Analysis Plan 
Authors: Tracey Sach 
CLOTHES trial team 
Version 1.0 – 13.01.16 
 
The following people have reviewed the Health Economic Analysis Plan and are in 
agreement with the contents 
Name Role Signature  Date 
Tracey Sach Author 
 
 
13.01.16 
    
Prof Alan 
Montgomery 
 
 
Trial Stascian 
 
19 Jan 2016 
    
Prof Kim Thomas  
 
 
Chief Invesgator 
 
 
13.01.16 
 
The HEAP has also been reviewed by Lisa Irvine, Senior Research Associate in 
Health Economics at the University of East Anglia. 
 
Objective 
This economic analysis plan aims to provide a detailed description of the economic 
evaluation to be conducted alongside the CLOTHES trial. It describes how the data 
will be collected, analysed and reported. 
Summary of clinical trial 
Eczema is a chronic skin condition that can have a large impact on the quality of life 
of patients and their families. Non-pharmacological therapies are often appealing to 
people suffering eczema, and so silk therapeutic garments represent an attractive 
therapy for many. Silk therapeutic garments are included in the British National 
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Formulary meaning that doctors can prescribe these items to patients should they 
deem it necessary. However, the effectiveness and cost-effectiveness of these 
garments in the management of eczema is as yet unproven. The CLOTHES trial will 
test the hypothesis that ‘silk therapeutic garments plus standard eczema care’ is 
superior to ‘standard care alone’ for children with moderate to severe eczema.  
It will be a parallel group, observer-blind, pragmatic, multi-centre randomised 
controlled trial of 6 months’ in length. Three hundred children aged 1 to 15 years with 
moderate to severe eczema will be randomised (1:1) to receive silk therapeutic 
garments plus standard eczema care, or standard eczema care alone. The primary 
outcome is eczema severity at 2, 4 and 6 months, using the validated Eczema Area 
and Severity Index (EASI) recommended by the HOME initiative. Secondary 
outcomes include: patient-reported eczema symptoms (collected weekly for 6 
months to capture long-term control); global assessment of severity; quality of life of 
the child, family and main carer; use of standard eczema treatments (emollients, 
topical corticosteroids, calcineurin inhibitors and wet wraps); frequency of infections; 
and cost-effectiveness. The acceptability and durability of the clothing will also be 
assessed, as will adherence in wearing the garments. A nested qualitative study will 
assess the views of children wearing the garments, and those of healthcare 
providers and commissioners. 
Recruitment started in November 2013, and the trial is expected to be completed by 
June 2016. The trial was funded as part of the NIHR HTA programme and 
sponsored by the University of Nottingham. Full details of results will be published in 
the National Institute for Health Research Journal series. 
 
Comparators to be included 
100% silk garments made from antimicrobially protected knitted sericin-free silk used 
in addition to standard eczema care 
The specific products being used are Dreamskin™ and Dermasilk™. Participants will 
be asked to wear the clothing as much as possible including at night, and when 
possible during the day. Participants will receive three sets of garments (long-
sleeved vest and leggings, or body suits and leggings depending on the age of the 
child). Replacement clothing is also available as required should the child grow or 
garments get spoiled. 
Participants allocated to the therapeutic clothing will continue to use their standard 
eczema care (including emollients, topical corticosteroids and topical calcineurin 
inhibitors), as described below. 
Standard care 
All participants (active and control groups) will continue with standard eczema care 
in line with NICE guidance (NICE, 2007). A child’s standard eczema care will not 
change unless the research nurse thinks that the skin may be infected. If an infection 
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is suspected the research nurse will recommend that the patient contact their normal 
medical team (GP, Nurse, dermatologist) as appropriate. 
Standard advice about what clothing to use for a child with eczema will be provided 
(avoid wool, and wear cool loose clothing – especially cotton and linen), but specific 
products will not be recommended. 
If a child is currently using “specialist” cotton clothing (e.g. special sleep suits with 
built-in mittens), the use of these garments will be recorded, but will not be grounds 
for exclusion. However, participants in the control group will be asked to refrain from 
using prescription clothing (including silk clothing and synthetic garments used for 
wet wrapping) during the trial.  
 
Study design – Economic evaluation 
Guidelines for economic evaluations` 
The economic evaluation will adhere to published and well accepted guidelines for 
the economic evaluation of health care interventions as appropriate. 1-3 
 
 
 
Study Question 
To estimate the within trial cost-effectiveness of silk therapeutic clothing with 
standard care compared to standard care alone from an NHS perspective in the 
base case and from an NHS and family perspective in secondary analyses.  
 
Blinding 
The health economics analysis will be undertaken blinded to intervention group as 
much as is possible. Thus the majority of resource use items can be valued and 
utility values scored along with estimation of QALYs without knowledge of 
intervention group. It will be possible to conduct some preliminary analysis to 
examine costs and outcomes in the two (unidentified) groups at this point. However 
the costs of the intervention, i.e. the silk clothing costs are specific to group. 
Assigning these costs would require knowledge of intervention group and the health 
economist would need to become unblinded at this point. Final analysis, including 
the cost of intervention, will therefore not be carried out blinded to intervention group. 
 
Form of economic analysis 
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Two types of economic evaluation will be conducted as part of this within trial 
economic evaluation: A cost-effectiveness analysis and Cost-utility analysis.  
 
Perspective 
The analysis will primarily take an NHS perspective, reflecting that Personal Social 
Services costs are unlikely to be relevant for childhood eczema. A secondary 
analysis will capture costs incurred by the family to assess whether the intervention 
makes a significant difference to these. 
 
 
Resource use: identification, measurement and valuation 
The range of resource use and costs captured will be in keeping with the chosen 
perspective. 
 
Intervention resource use 
The cost of the intervention will include the cost of silk clothing and replacement 
garments needed due to growth or wear and tear. The unit costs for this will be taken 
from the HSCIC Prescription Cost Analysis as the Net Ingredient Cost per Item (NIC) 
which does not include any discounts, costs/fees of dispensing nor adjust for income 
from prescription payments. An alternative method of costing the NHS cost of 
prescribed medications will be explored in sensitivity analyses. 
 
Resource use associated with wider health care contacts related to eczema 
The resource use is recorded on the diary card and entered by the research nurse at 
each of the study visits. To aid memory an online/paper questionnaire prompts 
participants to complete their diary if a health care professional is visited for eczema 
in the last week. Resource use will focus on those resources consumed as a result 
of the child’s eczema and will include health care visits (number of appointments to 
GP, practice nurse, outpatients, other and nights in inpatient care), prescriptions 
(topical corticosteroids, topical calcineurin inhibitors, emollients (including bath 
emollients), wet/dry wraps, antibiotics/antivirals for skin infections, other eczema-
related prescriptions). This resource use will be recorded at study visits at baseline, 
2, 4, 6, and 8 months. 
Resource use will be valued using published national sources of unit costs 
(UK£sterling for the most recent year available)(Curtis 2014, NHS reference costs 
2013-14, HSCIC 2014).  
 
Resource use incurred by the family related to their child’s eczema 
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The resource items recorded in this component reflect a family or more societal 
perspective. 
Figure 1 shows the types of resource use items families were asked about at study 
visits but families were not limited to these examples. Respondents were asked to 
place a monetary value on the additional cost incurred as a result of eczema, for 
instance if they bought a more expensive washing detergent because it is kinder on 
the persons with eczema skin they were asked to state the amount over and above 
that which they would have paid for a normal washing detergent. 
In addition families were asked to record time off work and school as a result of 
eczema. The time of parents will be valued using the mean gross hourly wage rate 
for all employee jobs in the UK as reported in the Annual Survey of Hours and 
Earnings (ASHE) in 2014 since we will not know the respondents personal earnings. 
[Accessed online on 5th January 2016: http://www.ons.gov.uk/ons/rel/ashe/annual-
survey-of-hours-and-earnings/index.html]  This approach is known as the human 
capital approach and assumes a person’s productivity is equal to their wage rate to 
place a maximum cost on the time off work. Time off school will be reported in hours 
and minutes and not valued due to a lack of evidence about the cost of lost 
schooling. 
 
Presentation of cost results 
To ensure transparency and reproducibility the unit costs used to attach monetary 
costs to resource use will be clearly displayed in tabular format with source of unit 
cost displayed in addition to the actual unit cost used. (see appendix 1 for an 
example) 
Resource use and costs will be presented clearly in tabular format to ensure 
transparency in the final figures reported. Mean and SD resource use and costs will 
be presented by intervention group and health sector (Primary care, secondary care, 
Family costs). (see appendix 2 for an example) 
 
Outcomes: effectiveness and utility 
The primary measure of effectiveness for the cost effectiveness analysis will be the 
difference in the number achieving treatment success at 6 months – defined as 
those with at least a 50% improvement compared to baseline on the primary 
outcome measure Eczema Area and Severity Index (EASI) (Barbier et al 2004). 
Secondary analyses will be conducted using continuous data from the Dermatitis 
Family Impact Scale. 
A cost utility analysis, where effectiveness is measured in terms of the Quality 
Adjusted Life Years (QALYs) for child and main carer, will be undertaken. Utility will 
be measured in all children using the disease specific Atopic Dermatitis Quality of 
Life scale (ADQoL), and in those aged 5 or over by the generic health-related quality 
of life instrument the Child Health Utility index (CHU-9D). The CHU-9D is being used 
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with children aged 7 and over self-completing and parental proxy completion for 5 
and 6 year olds. In addition, the main carer will record their own utility using the EQ-
5D-3L. All three utility instruments will be measured at baseline and 6 months and 
used to estimate QALYs for the trial period by using linear interpolation and area 
under the curve with and without baseline adjustment (Manca et al, 2007). The 
primary cost-utility analysis will report the incremental cost per QALY based on the 
ADQoL since we will have this completed for all children in the study. Secondary 
analyses will report the cost per QALY based on the CHU-9D for those aged 5 and 
over. Statistical modelling will explore the potential to impute values for those 
children too young to complete the instrument but some strong assumptions are 
made in such an analysis, including that the utility values of those aged under 5 in a 
similar disease state as the 5 and overs will be the same irrespective of the age 
difference. In addition, a cost per QALY for the main carers using their EQ-5D-3L 
values will be estimated separately. Previous work has not explored the ability of the 
EQ-5D to detect impacts on carers quality of life for this condition. (see appendix 3 
for example tables). 
 
Length of follow-up 
Since this is a within-trial analysis the trial period will be used (6 months) for both 
costs and outcomes in the base case. Therefore costs and benefits will not be 
discounted, reflecting the short time horizon.  
 
Statistical analysis and analysis of uncertainty 
In line with statistical analyses an intention to treat population will be used in primary 
analyses.  The economic evaluation will be a ‘within trial analysis’. This means that 
costs and benefits will only be evaluated for the trial follow-up period (6 months). 
Costs in both arms of the study will be estimated using the methods described 
above. We will calculate outcomes and QALYs again as described above. This 
information on costs and benefits will be used to conduct incremental economic 
analysis comparing the silk therapeutic clothing in addition to usual care to usual 
care alone. This will be done for both the cost-effectiveness and cost-utility analyses. 
Conclusions will be based on results achieved. If one arm is clearly dominant (less 
costly and more effective) a recommendation can be made on this basis. If non-
dominance occurs (that is if costs are greater and the intervention is more effective 
or if the intervention is cheaper and less effective), an incremental cost-effectiveness 
ratio (ICER) will be produced and a value judgement about value for money will need 
to be made. ICERs will be calculated using accepted methodology (Ramsey et al 
2015, Drummond et al 2005).  
Since costs and benefit data may be skewed we will use non-parametric 
bootstrapping to estimate mean costs, mean QALY estimates, and net benefit. 
Estimates of cost and benefits will be placed upon cost-effectiveness planes. 
Bootstrapping will also be used to estimate cost-effectiveness acceptability curves 
(CEACs)(Glick et al, 2007), these will show the probability that each of the 
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intervention groups is the most cost-effective option at different monetary valuations 
of the outcome variable. A range of ceiling ratio (or willingness to pay per QALY) 
values will be tested but this will include £20,000 and £30,000 per QALY given 
thresholds used by NICE in cost-utility calculations (NICE, 2013). 
The analysis will be undertaken unadjusted and adjusted to control for differences in 
baseline characteristics (e.g. costs, age, baseline EASI score) using regression 
methods to estimate differences in costs and QALYs between intervention groups. 
Assumptions will need to be made in the estimation of costs and QALYs in this 
analysis. There may also be cases where there is uncertainty over the best values to 
use in the analysis. These assumptions and sources of uncertainty will be recorded.  
Where these are likely to affect results we will carry out sensitivity analysis. 
Sensitivity analysis tests the robustness of results in the face of any uncertainties. It 
also improves the generalisability of results by indicating what could happen with 
different values of a parameter. The sensitivity analysis will include the following: 
 Imputing missing values – the base case will be a complete case analysis but 
if there is significant (>10%) missing data it may bias results. If there is 
missing data, the extent and nature of the missingness will be explored in 
order to choose an appropriate approach to deal with the missing data. If 
missing data is a significant issue multiple imputation will be used to impute 
missing values and presented as secondary analyses. 
 Run a per protocol economic analysis to estimate the cost-effectiveness of the 
intervention for those participants who complied with the protocol to wear the 
silk clothes as much as possible day and night. Participants will be classified 
as adherent if they wear the trial clothing for at least 50% of the days or nights 
where the diary had been completed, provided that at least 50% of the diary 
had been completed. 
 If the statistical analysis finds a significant difference in effectiveness on the 
primary outcome measure for those with mutations in the gene encoding for 
filaggrin FLG as defined on page 17 of the Statistical Analysis Plan, the 
economic evaluation will be re-run as part of a subgroup analysis for presence 
of the FLG genotype. 
 The cost of the silk therapeutic garments may be a major cost driver affecting 
the likely cost-effectiveness or not of the garments. To test this the unit cost of 
the garments will be varied to find the unit cost at which it would change the 
decision about cost-effectiveness. 
 We are also collecting utility information from the main carer. Since the 
evidence about how to analyse this in addition to the child’s utility is limited 
(Al-Janabi et al 2011) we will present cost per QALY for the child as the base 
case and cost per QALY per carer (since only one carer completed the EQ-5D 
an assumption that any change in utility might be double for two parents 
families could be tested) separately in sensitivity analyses. 
 Method of estimating prescription costs will be tested. The main analysis will 
rely on the HSCIC Prescription Cost Analysis as the Net Ingredient Cost per 
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Item (NIC). In sensitivity analysis an alternative based on the NHS Business 
Services Authority formula  to estimate the actual cost to the NHS: 
 
Actual Cost = (Net Ingredient Cost less the discount) + Payment for 
Consumables + Payment for Containers (10p for splitting packs) + Out of 
Pocket Expenses 
 
Source:www.nhsbsa.nhs.uk/documents/prescriptionservices/gp_faqsver4.doc. 
Accessed 5th January 2016. 
 
Will be used employing the methods outlined in a personal communication 
from Kirsty Garfield at the University of Bristol to cost eczema prescriptions in 
the NIHR RfPB funded “Choice Of Moisturiser in Eczema Treatment 
(COMET): A feasibility study of pragmatic, single blind, randomised clinical 
trial to compare the clinical and cost effectiveness of leave-on emollients in 
treat” study. 
 
 If feasible, a sensitivity analysis will consider the resource use data collected 
in the observational period (8 months) in order to assess the likely costs of the 
intervention over an 8-month period of time to reflect more fully the wear and 
tear of the garments and growth of children. However, health outcomes will 
not be measured at 8 months so it will not be possible to repeat the economic 
evaluation for an 8 months period. 
 
All statistical analysis will be undertaken in STATA 14 64-bit SE. 
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Appendix 1: Example of the “Unit costs in 2014/15 UK pounds sterling” table 
 
Table 1: Example of the “Unit costs in 2014/15 UK pounds sterling” table  
Resource  It em  Unit 
cost  
Source  
Intervent ion 
Silk therapeutic garments (Various) 
 
Primary heal th ca re 
GP (Per surgery consultation lasting 11.7 minutes) 
Practice nurse (per consultation) 
Pharmacist (per home visit) 
 
Second ary he alt h care 
A&E (per visit) 
Outpatients first visit (dermatology, non consultant led) 
Outpatients follow up visit (dermatology, non consultant led) 
Cost per bed day on a general medical ward 
 
Medications  
Various 
 
£ 
 
£ 
£ 
£ 
£ 
 
 
£ 
£ 
£ 
£ 
 
 
£ 
 
PCA 
 
PSSRU 
PSSRU 
PSSRU 
DH 
 
 
PSSRU 
DH 
DH 
DH 
 
 
PCA 
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Appendix 2: Examples of tables for mean resource use and costs 
 
Table 2: Example of the “Mean (Standard Deviaon) Resource Use and Mean Diﬀerence in 
Resource Use per Paent (95% Conﬁdence Interval)” table 
Resource use item 
Silk therapeutic 
clothing (n=)  
Number (SD) 
Usual care 
(n=) 
Number (SD) 
Mean diﬀerence 
(95% CI) 
Intervention 
Silk therapeutic garments 
(number) 
  
 
Primary health care 
GP (number of visits)    
Practice nurse (number of 
visits) 
   
Pharmacist (number of visits)    
NHS walk-in centre (number of 
visits) 
   
Secondary health care 
Inpatients (number of bed 
days) 
   
A&E (number of visits)    
Outpatients first and follow-up 
visit (number) 
   
Medications 
Prescription items (number)    
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Table 3: Example of the “Mean (Standard Deviaon) Cost and Cost Diﬀerence (95% Conﬁdence 
Interval) Per Paent over the 6 months Intervenon arm compared to usual care arm (in 2014/15 
UK pounds sterling)” table 
Resource use item 
Silk 
therapeuc 
clothing  (n=):  
mean (SD)  £’s 
Usual Care 
(n=):  
mean (SD)  £’s 
Mean diﬀerence  
(95% CI)  £’s 
Intervention resource use 
Silk therapeutic garments  
0.00 
(0.00) 
 
Primary health care 
GP     
Practice nurse 
 
   
District nurse    
NHS walk in centre    
Total Primary health care costs    
Secondary health care 
Cost of inpatients     
A&E     
Outpatients first and follow-up visit    
Day hospital visits 
 
   
Total prescription costs    
Total health care costs    
This table will include considerably more resource items than those illustrated here and will be 
presented for children and for adults with and without asthma as a co-morbidity. 
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Appendix 3: Examples of tables reporting outcomes 
 
Table 4: Mean (SD) utility values for intervention and control group at baseline and 
follow-up for the ADQoL, CHU-9D (both for childrens HRQL) and EQ-5D-3L for 
parental HRQL 
 Intervention Group Control Group 
 Baseline 6 Months Baseline 6 Months 
ADQoL all     
ADQoL under 5’s     
ADQoL 5 and overs     
CHU-9D 5 and overs     
EQ-5D-3L for 
parents HRQL 
    
 
 
Table 5: Quality-adjusted Life Years (SD) for intervention and control group at 
baseline and follow-up for the ADQoL, CHU-9D (both for children’s HRQL) and EQ-
5D-3L for parental HRQL 
 
 Intervention 
Group 
Control 
Group 
ADQoL all   
ADQoL under 5’s   
ADQoL 5 and overs   
CHU-9D 5 and overs   
EQ-5D-3L for 
parent’s HRQL 
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Appendix 20 Nested qualitative study: further
information
Children data analysis
TABLE 59 Demographic information of child participants
Child characteristics Site
Focus group
Girl, age (years)
5–6 Nottingham
5–6 Nottingham
5–6 Nottingham
7–8 London
7–8 Cambridge
Boy, age (years)
5–6 Nottingham
7–8 London
7–8 Cambridge
Face-to-face interview
Girl, age (years)
9 Isle of Wight
9 Isle of Wight
15 Isle of Wight
12 Cambridge
9 Isle of Wight
Boy, age (years)
11 Isle of Wight
9 Isle of Wight
10 Cambridge
Telephone interview
Girl, age (years)
9 Cambridge
10 Cambridge
Boy, age (years)
13 Cambridge
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Child interview and focus group topic guide
l Grand tour question:
¢ Tell me a bit about your eczema, what it’s like living with it?
l Mini tour questions:
¢ How have you got on with the special clothing?
¢ How much did you wear the clothing (day/night/away from home)?
¢ What was it like wearing the clothing (skin condition, comments from others)?
l Example questions:
¢ Can you tell me about any differences you have noticed (skin condition/well-being)?
l Experience questions:
¢ Were there particular things you liked or did not like about using the special garments?
Parent data analysis
TABLE 60 Demographic information of parent participants with reported usage
Sex of child (age, years) Parent Site Reported usage
Standard carea
Girl (14)b Father Nottingham Occasional nights
Girl (9) Mother Portsmouth Every day and night
Girl (6) Mother Isle of Wight Most nights
Girl (14) Mother Isle of Wight One night
Girl (12) Mother Isle of Wight Very occasional nights
Girl (2) Mother London Twice
Girl (4) Mother London Every night
Girl (8) Mother London Most nights and 1 or 2 days
Boy (11) Father London Most nights and occasional days
Boy (5) Mother London 1 or 2 nights
Boy (8) Father London Every night and weekend days
Girl (9) Mother Cambridge Top virtually every day and night, leggings some nights
Boy (2) Father Cambridge Every night
Boy (4) Mother Nottingham Every night
Boy (5) Mother Isle of Wight Every day and night except PE day
Girl (10) Mother Nottingham Every night
Girl (5) Mother Cambridge Every night
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TABLE 60 Demographic information of parent participants with reported usage (continued )
Sex of child (age, years) Parent Site Reported usage
Intervention
Boy (2) Mother Portsmouth Every night
Boy (2) Mother Isle of Wight Every day and night
Boy (2) Mother Isle of Wight Day and night, less over time
Boy (4) Motherc Isle of Wight Virtually every day and night
Boy (4) Fatherc Isle of Wight Virtually every day and night
Boy (11) Mother Isle of Wight Day and night, approximately 50%
Boy (2) Mother Isle of Wight Virtually every day and night
Girl (6) Mother London Every night
Boy (3) Mother London Every night and leggings only everyday
Boy (2) Mother Cambridge Every night
Boy (5) Mother Cambridge Every night and occasional daytime at the weekend
Girl (3) Mother Nottingham Every day and night
Boy (13) Mother Nottingham Every day and night except PE days
Boy (10) Mother Isle of Wight Every day and night, less in the day when hot
Boy (4) Mother London Every day and night
Boy (7) Mother London Every night
PE, physical education.
a Participants in the standard care group received the garments after their 6-month visit so all had some experience of
using them.
b Daughter attended focus group with father.
c Both parents of one boy took part in one focus group.
Parent interview and focus group topic guide
l Grand tour question:
¢ Tell me a bit about the eczema, what it’s like living with it?
l Mini tour questions:
¢ How have you got on with the special clothing?
¢ How much did you/your child wear the clothing (day/night/away from home)?
¢ What was it like wearing the clothing (skin condition, comments from others)?
¢ How did you get on with looking after the garments (washing, size)?
l Example questions:
¢ Can you tell me about any differences you have noticed (skin condition/behaviour/well-being)?
l Experience questions:
¢ Were there particular things you or your child liked or did not like about using the silk garments?
¢ How would you feel about continuing to use the special clothing (what things might make you
continue or make you stop, barriers to use)?
¢ What makes you think that the garments have worked or not worked?
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Stages 1–3 of parent data analysis
Stage 1
All transcripts were read in full to ensure immersion in the detail of the data as a whole. Transcripts were
annotated with key emergent themes.
Stage 2
The recurring key themes and subthemes from the initial readings of the transcripts are presented in Table 61.
Stage 3
The draft framework presented in stage 2 was applied to the transcripts and data were coded and
annotated, similarities and differences in data were identified and recurring themes and subthemes were
refined, combined and developed. A refined framework was developed in which repetition across themes
was removed and data clearly fitted with one theme only (Table 62).
TABLE 61 Initial themes and subthemes (stage 2)
Key themes Subthemes
Desperation Tried everything
Impact on quality of life
Allergies
Fear of some treatments
Hope for improvement
Trial garments Fit and look
Wear and tear
Washing
Effect of the garments Amount of wear
Difference to skin condition
Difference to well-being
Being in the trial Motivation
Inconvenience
TABLE 62 Refined themes and subthemes (stage 3)
Key themes Subthemes
Despair and hope Treatments
Adjustments
Quality of life
Hopes for the trial
Fit, durability and care Look, feel and fit
Durability
Laundry care
Perceived impact of the garments Patterns of use
Effect of garments
Continued use post trial
Engaging in the trial Experience of participation
Commitment
Important outcome measures
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Clinician and commissioner data analysis
Clinician and commissioner interview guide
l What is your experience of prescribing silk garments for children with eczema?
l What makes you select this line of treatment?
l Are there any barriers to you enabling children to use these garments?
¢ Perceived cost.
¢ Lack of evidence.
¢ Durability of the garments.
l Do you think it is a reasonable expectation that GPs should prescribe silk garments?
l If no, who do you think is the most appropriate person to prescribe these garments?
l Do you think they should be prescribed at all? Can you explain the reason for this?
TABLE 63 Demographic information of clinician and commissioner participants
Job role Region
Community dermatology specialist nurse Northwest
Consultant dermatologist Midlands
Consultant dermatologist Southeast
Commissioning pharmacist Midlands
GP with special interest Midlands
GP Central south
Dermatology clinical nurse specialist Northeast
Dermatology support nurse – primary care Northwest
Lead dermatology clinical nurse specialist – community Northwest
Paediatric dermatology specialist nurse – primary care Midlands
Paediatric dermatology clinical nurse specialist – secondary care Central south
Pharmacist Northwest
GP (specialist) Midlands
Clinical commissioning group prescribing lead (GP) Northeast
Consultant dermatologist Northeast
Community pharmacist Midlands
Clinical commissioning group prescribing lead (GP) Northeast
Paediatric dermatology clinical nurse specialist Central south
Dermatology clinical nurse specialist Midlands
Dermatology specialty doctor Northeast
Dermatology specialist nurse Central south
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Stages 1–3 of clinician and commissioner data analysis
Stage 1
All transcripts were read in full to ensure immersion in the detail of the data as a whole. Transcripts were
annotated with key emergent themes.
Stage 2
The recurring key themes and subthemes from the initial reading of transcripts are presented in Table 64.
Stage 3
The draft framework presented in stage 2 was applied to the transcripts and data were coded and annotated,
similarities and differences in data were identified and recurring themes and subthemes were refined,
combined and developed. A refined framework was developed in which repetition across themes was removed
and data clearly fitted with one theme only (Table 65).
TABLE 64 Initial themes and subthemes
Key themes Subthemes
Knowledge and evidence base Lack of knowledge
Lack of evidence base
Using silk garments Unclear indications for use
Top of ladder of treatment options
Quality of product
Prescription and expected outcomes Rarely prescribed
Who should prescribe
Subjective and objective outcome
measures
TABLE 65 Refined themes and subthemes
Key themes Subthemes
Knowledge base Lack of evidence base
Information from manufacturers
Treatments protocols
Reasons to use silk garments Failure of other treatment regimens
Greater concordance
Avoiding referral to secondary care
Cost-effectiveness
Reasons for not using silk garments Lack of familiarity/experience
Cost
Contentious prescription
Quality of product
Outcome measures Existing measures
Clinical improvement
Patient reports
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Appendix 21 Summary of amendments to report
after the funding body review stage
TABLE 66 Editorial amendments following NIHR HTA review
Summary of change Revised wording
Plain English summary amended Details of adherence in wearing the clothing added
Implication for practice amended Removed ‘Clinical commissioners can now be encouraged to
make informed decisions on the basis of these robust trial
findings’
Strengths and limitations amended Added further mention of the independent nature of the trial
and its pragmatic nature in reflecting normal patterns of
adherence
TABLE 67 Editorial amendments following review by clothing suppliers
Summary of change Revised wording
Health economic analysis updated to correct an error in
how the garments were costed
All figures updated throughout the report with revised
cost-effectiveness analysis. Clarification added that unit costs
refer to sets of garments, rather than individual items
Conclusion amended to remove reference to this being
the first independent trial
Revised wording in abstract: ‘This trial adds to the evidence
base to guide clinical decision-making’
Clarified that prescription data showing an increase in
silk prescribing by the NHS over the last 5 years is for all
indications, not just for eczema
‘All indications’ added where relevant
Potential confusion around our definition of adherence
was clarified. Clarification was added relating to the
CACE analysis demonstrating the likely impact of
adherence in wearing the garments on the trial results
Methods and Results amended to clarify our definition of
non-adherence, and CACE analysis expanded to aid
understanding of how to interpret these findings
Details of the amount of topical corticosteroid used have
been added (based on prescription data)
Added to Table 30
Removed potentially inflammatory statements Removed from Discussion: ‘Were the UK NHS to stop
prescribing such items, millions of pounds could be saved each
year, which could then be better invested into more effective
treatments’
Clarified that the nested qualitative study was conducted
by colleagues at the University of Hull and results were
not disclosed to the trial team until after data analysis
was complete
Details added to Chapter 5
Reference to previous small studies being sponsored by
the silk manufacturers removed
Chapter 7, Involvement of clothing suppliers after completion
of the trial section amended
Discussion updated to address concerns about
interpretation of study results with regard to inclusion of
participants with mild disease at baseline and the impact
of adherence in wearing the garments
Discussion updated to reiterate the relevant sensitivity and
subgroup analyses, and recognition that children with all
severities of AE (as assessed by EASI at baseline) were included
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